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Isthmin (ISM) is a recently discovered endogenous angiogenesis inhibitor, both in 
physiology and pathology. ISM exerts its biological effect by binding to its 
receptors αvβ5 and GRP78 on endothelial cells (ECs). Identification of 
endogenous angiogenesis inhibitors is an important area in biomedical research as 
anti-angiogenic therapy is a promising approach to treat cancers. Similar to other 
endogenous angiogenesis inhibitors identified so far, it is likely that ISM plays a 
role in a variety of physiological functions in addition to angiogenesis. An 
understanding of the full spectrum of ISMs endogenous roles is required in order 
to develop ISM-based drugs to treat angiogenesis-related disorders.  
I first analyzed the expression pattern of Ism in mouse. ISM was expressed by 
cells of epithelial and endothelial origin in skin, lung, brain, pancreas, spleen, 
stomach, kidney and liver. Based on the high level of Ism expression in lung and 
skin, I focused my studies in these two tissues.  
Integrin αvβ5, a cell-surface receptor for ISM, is expressed in pulmonary 
microvascular endothelial cells and has been implicated in regulating pulmonary 
vascular permeability.  I hypothesized that ISM may influence pulmonary vascular 
function through the αvβ5 integrin. The role of ISM in regulating vascular 
permeability was investigated in vitro and in vivo. ISM enhanced EC monolayer 
permeability in a dose-and time-dependent manner. It also potentiated 
permeability induced by rapid inducers of permeability such as VEGF. EC 
adherens junctions are disrupted by ISM, in particular the VE-cadherin complex. 
Disruption of cell-cell junctions correlated with potent activation of Src tyrosine 
kinase and enhanced permeability. Mechanistic investigation revealed that both 
ISM-induced apoptosis and Src activation played a role in ISM-induced 
permeability.  Hence both αvβ5 integrin and GRP78 can mediate ISM-induced 
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vascular permeability.  In vivo, ISM enhanced both dermal and systemic 
permeability. These data suggest that ISM is a novel permeability inducer, in 
addition to its role in inhibiting angiogenesis. 
I further demonstrated that systemically delivered ISM inhibits melanoma 
pulmonary metastasis in mice. Administration of ISM prior to tumor cell injection 
led to a transient increase in tumor cell homing to lung. Subsequent metastatic 
growth in lung was suppressed by continuous ISM application. In comparison, 
application of ISM after tumor cell inoculation did not affect the initial tumor cell 
homing to lung while continuous application subsequently suppressed the growth 
of the metastasized tumor nodule.. These results indicated that although ISM 
inhibits tumor progression at metastatic sites, it may aid in tumor cell 
extravasation into the target organs. 
Further, I demonstrated that ISM delays murine wound healing in a dose-
dependent manner. It does so by inhibiting granulation tissue formation, 
angiogenesis and cell proliferation. Enhanced macrophage infiltration is also 
observed in the healed wound tissue which may be due to a prolonged 
inflammatory phase during the wound healing process.  
Lastly, I have shown that ISM may have a potential role to play in inflammation. 
ISM is expressed in low levels in normal skin and this expression increases after 
wounding. During the wound healing process, ISM expression remains high 
during early time-points and reduces to basal levels only upon wound closure. 
Further, in bronchiolar asthma models of mice, ISM-expression in the bronchioles 
increases upon triggering of the asthmatic condition.  
Taken together, this thesis work identified ISM as a novel vascular permeability 
inducer by disrupting endothelial cell-cell-junctions and inducing apoptosis. ISM 
inhibited experimental tumor metastasis and delayed wound healing in mice 
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possibly through its anti-angiogenic function. Furthermore, ISM may play a role in 











Parts of this thesis has been published or presented in the following: 
 
Publications: 
 Zhang Y, Chen M, Venugopal S, Zhou Y, Xiang W, Li YH and Ge R. Isthmin 
exerts pro-survival and death-promoting effect on endothelial cells through 
alphavbeta5 integrin depending on its physical state. Cell death & disease. 
2011;2:e153. 
 Saran Kumar, Nithya Rao, Shruthi Venugopal, Ruowen Ge. Endogenous 
Angiogenesis Inhibitors: Is the list never ending?  pp 1-48 Advances in 
Medicine and Biology, Volume 38, 2012 Nova Science publishers, Inc 
 
Conference Presentations: 
 Mo Chen, Shruthi Venugopal and Ruowen Ge: The novel angiogenesis 
inhibitor Isthmin exerts dual functions on endothelial cells through αvβ5 
integrin depending on its physical state. Frontiers in Cancer Science, Oct 2011, 
National University of Singapore,  
 Shruthi Venugopal and Ruowen Ge: Isthmin, a novel secreted angiogenesis 
inhibitor, promotes vascular permeability through regulating adherens junction 










List of figures 
Figure 1.1 Origin and assembly of vasculature ...................................................................... 1 
Figure 1.2 Types of angiogenic processes ................................................................................ 2 
Figure 1.3 Phases of wound healing ........................................................................................ 4 
Figure 1.4 The metastatic process ......................................................................................... 10 
Figure 1.5 Schematic showing the interacting partners of TSP1 & 2 ................................ 20 
Figure 1.6 Pathways regulating EC barrier function .......................................................... 26 
Figure 1.7 Domain structure of ISM ..................................................................................... 37 
Figure 1.8 Receptors recognized by ISM and the signaling pathways ............................... 38 
Figure 1.9 Integrins are expressed on multiple cell types aiding in angiogenesis and 
pathogenesis of cancer .................................................................................................. 39 
Figure 1.10 Summary of GRP78 localization in different sub cellular compartments ..... 43 
Figure 3.1 Expression of ISM in different tissues ................................................................ 64 
Figure 3.2 Expression of ISM in various tissues .................................................................. 68 
Figure 3.3 Mammalian cell produced ISM inhibits in vitro angiogenesis and induces EC 
apoptosis ........................................................................................................................ 71 
Figure 3.4 ISM induces dose-dependent permeability of EC monolayers ......................... 72 
Figure 3.5 ISM induces time-dependent permeability of EC monolayers ......................... 73 
Figure 3.6 ISM potentiates permeability induced by rapid-inducers of permeability ..... 75 
Figure 3.7 ISM induces dose-dependent increase in dermal permeability ........................ 77 
Figure 3.8 ISM potentiates VEGF-induced dermal permeability ...................................... 78 
Figure 3.9 ISM has no effect on TGF-β1-induced dermal permeability ............................ 79 
Figure 3.10 ISM enhanced permeability of lung and stomach within 15 mins of ISM 
administration (Balb/c) ................................................................................................. 81 
Figure 3.11 ISM enhanced permeability of lung and stomach within 15 mins of ISM 
administration (C57/Bl6) .............................................................................................. 83 
Figure 3.12 ISM induces tyrosine phosphorylation of inter-cellular junctions ................. 85 
Figure 3.13 ISM treatment leads to changes in adherens junction molecules ................... 88 
Figure 3.14 ISM induces phosphorylation of VE-cadherin................................................. 90 
Figure 3.15 ISM induces phosphorylation of β-catenin and p120 catenin ......................... 91 
xiii 
 
Figure 3.16 ISM-induced apoptosis is evident 4 hours following ISM treatment ............. 93 
Figure 3.17 Inhibition of ISM-induced apoptosis partially attenuates ISM-induced 
permeability................................................................................................................... 95 
Figure 3.18 Effect of caspase inhibition on cell-cell junctions ............................................ 96 
Figure 3.19 ISM affects AJ molecules in vivo ....................................................................... 97 
Figure 3.20 ISM induces Src activation ................................................................................ 98 
Figure 3.21 Inhibition of Src activation attenuates ISM-induced permeability .............. 100 
Figure 3.22 ISM induces permeability through signaling via αvβ5 and GRP78 ............. 101 
Figure 3.23 ISM induces Src activation through GRP78 .................................................. 102 
Figure 3.24 ISM-induced Src activation and vascular permeability is mediated by 
GRP78-mediated internalization of ISM .................................................................. 105 
Figure 3.25 GRP78 potentially interacts with Src in vitro in response to ISM binding .. 106 
Figure 3.26 ISM injected prior to tumor cell injection causes a transient increase in 
bioluminescent signal .................................................................................................. 109 
Figure 3.27 ISM inhibits B16F10 melanoma metastasis ................................................... 111 
Figure 3.28 Systemically delivered ISM inhibits metastasis by inhibiting angiogenesis, 
proliferation and inducing apoptosis ......................................................................... 112 
Figure 3.29 ISM injected prior to tumor cell injection causes a transient increase in 
bioluminescent signal .................................................................................................. 114 
Figure 3.30 ISM inhibits 4T1 breast cancer metastasis ..................................................... 116 
Figure 3.31 ISM delayed HUVEC wound closure ............................................................. 117 
Figure 3.32 ISM delayed HaCat wound healing ................................................................ 118 
Figure 3.33 ISM delays murine wound healing ................................................................. 120 
Figure 3.34 ISM reduces the formation of granulation tissue .......................................... 120 
Figure 3.35 Histological analysis of wound sections .......................................................... 123 
Figure 3.36 ISM expression increases during initial phases of wound healing ............... 125 
Figure 3.37 ISM is upregulated in asthmatic lungs ........................................................... 126 





List of tables 
Table 1.1 List of angiogenesis regulators involved in wound healing ..................... 5 
Table 1.2 List of angiogenesis stimulators ............................................................... 11 







































List of abbreviations 
ADAMTS A disintegrin-like and metalloproteinase with 
thrombospondin motif 
AJ Adherens junction 
AMOP Adhesion-associated domain in MUC4 and 
other proteins  
Ang-1/2 Angiopoietin-1/2 
APS   Ammonium per sulfate 
ATCC  American type culture collection 
ATP Adenosine triphosphate 
α2M* Activated α2 macroglobulin 
BiP Binding immunoglobulin protein 
bPEI Branched polyethylenimine 
BSA  Bovine serum albumin 
CAM Chick chorioallantoic membrane 
CM  Conditioned medium 
COX-2 Cyclooxygenase-2 
DMEM  Dulbecco’s minimal essential medium 
DMSO  Dimethyl sulfoxide 
EC Endothelial cell 
ECM Extracellular matrix 
EDTA  Ethylene di-amine tetra acetic acid 
EGF Epidermal growth factor 
ER Endoplasmic reticulum 
FAK Focal adhesion kinase 
FBS  Fetal bovine serum 
FGF Fibroblast growth factor 
FGF-R Fibroblast growth factor receptor 
GRP78 Glucose-regulated protein of 78 kDa 
HPLC Reverse-phase high-performance liquid     
chromatography 
HRP  Horse radish peroxidase 
HSP70 70 kDa Heat shock protein  
HSPA5 Heat shock 70 kDa protein 5 
xvi 
 
HSPG Heparansulfate proteoglycan  
HMVEC Human microvascular endothelial cells 
HUVEC  Human umbilical vein endothelial cell 
IAP Integrin associated protein 
ICAM Intercellular adhesion molecule 
IHC  Immunohistochemistry 
IL-3 Interleukin-3 
IL-8 Interleukin-8 
IMD Integrin-mediated death 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
ISM Isthmin 
JAM Junctional adhesion molecules 
LB  Luria-bertani  
MAPK Mitogen-activated protein kinase 
MHB Midbrain-hindbrain boundary 
MLC Myosin light chain 
MMP Matrix metalloproteinase 
NFκB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
PAGE  Polyacrylamide gel electrophoresis 
PAR-1 Protease activated receptor-1 
PBS  Phosphate buffered saline 
PCNA  Proliferating cell nuclear antigen 
PDGF Platelet derived growth factor 
PECAM Platelet endothelial cell adhesion molecule 
PEDF Pigment epithelial derived factor 
PF4 Platelet factor 4 
PFA  Paraformaldehyde 
PI3K Phosphatidylinositol 3 kinase  
PKB Protein kinase B 
PLA Proximity ligation assay 
PlGF Placenta growth factor 
PS  Penicillin-streptomycin 
RT Room temperature 
SDS  Sodium dodecyl sulfate 
xvii 
 
SE Standard error 
SMC Smooth muscle cell 
SD Standard deviation 
TAF Tumor angiogenesis factor 
TBST  Tris buffered saline with 1% tween-20 
TGF-β Transforming growth factor-β 
TJ Tight junction 
TMB  3,3',5,5'-tetramethylbenzidine 
TNF-α Tumor necrosis factor-α 
TSP Thrombospondin 
TSR Thrombospondin-1/2 type 1 repeats 
TUNEL Terminal deoxynucleotidyl transferase 
UPR Unfolded protein response 
VASH1 Vasohibin-1 
VCAM Vascular cell adhesion molecule 
VE cadherin Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VPF Vascular permeability factor 










Chapter 1 Introduction 
1.1  Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing ones. It is an 
essential process in various physiological processes such as tissue repair, wound 
healing, organ development and reproduction, as well as in several pathological 
conditions such as cancer and rheumatoid arthritis (Folkman 1995). The blood 
vessel network is an essential source of gases, nutrients and other macromolecules 
that govern normal metabolism. Due to the limitation of gas diffusion, every tissue 
is located very close to a blood vessel and thus a well established network is 
essential (Fraisl, Mazzone et al. 2009).   
 
Figure 1.1 Origin and assembly of vasculature 
In vertebrates, blood islands fuse together to undergo vasculogenesis. Angiogenic 
remodeling then occurs to give rise to branches. Simultaneously, 
lymphangiogenesis gives rise to lymphatic vessels. Together, vasculogenesis, 
angiogenesis and lymphangiogenesis ensure efficient transport of gases, nutrients 
and signaling molecules [Adapted from (Adams and Alitalo 2007)]. 
 
The blood vessel network is formed by vasculogenesis and angiogenesis. 
Vasculogenesis is the process of de novo blood vessel formation from endothelial 
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progenitor cells (Heinke, Patterson et al. 2012).  During development, 
angiogenesis is responsible for most of the blood vessel formation. 
 
Figure 1.2 Types of angiogenic processes 
 A: Sprouting angiogenesis; B: Intusssusceptive angiogenesis [Adapted from 
(Adams and Alitalo 2007)]. 
 
Angiogenesis can be achieved by two distinct processes: i) Sprouting angiogenesis 
and ii) Intussusceptive angiogenesis. Sprouting angiogenesis is a well 
characterized process during embryogenesis, development and growth. Here there 
is proteolytic degradation of the extra-cellular matrix (ECM), which is followed 
by migration and proliferation of endothelial cells (ECs) in response to vasoactive 
factors. This leads to lumen formation and thus new capillary growth from the pre-
existing vessel (Risau 1997). Also known as non-sprouting angiogenesis, 
intussusceptive angiogenesis occurs by the formation of transcapillary pillars 
which gradually increase in size and thus split the network to form new ones 
(Burri and Djonov 2002) (Fig. 1.2). 
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1.1.1 Angiogenesis in physiology 
Angiogenesis predominantly occurs during embryonic development. In adults, it is 
sequestered to selected niches. While a major part of angiogenesis occurs during 
development, adult angiogenesis is limited to specific physiological processes and 
is tightly regulated (Hanahan and Folkman 1996; Carmeliet and Jain 2000). This 
tight regulation is a complex interplay between angiogenic and angiostatic factors 
which involve a large number of growth factors, chemokines and cytokines. 
Physiological angiogenesis mainly occurs during embryogenesis, wound healing 
and during ovulation.  
 
Wound healing is a delicately orchestrated physiological phenomenon that 
involves inflammation, granulation tissue formation and vascular remodeling. 
When a wound is created, the injury causes blood vessel constriction and the 
coagulation cascade is triggered. Inflammation is the body’s first reaction to 
injury. This happens immediately after injury and continues for more than 24 
hours following injury. Following blood clot formation and infiltration of 
neutrophils and monocytes, keratinocytes and fibroblasts are stimulated to 
proliferate and migrate over the wound site, thus helping granulation tissue 
formation. The granulation tissue is so called due to its granular appearance 
histologically. It is rich in macrophages and inflammatory cytokines which help in 
stimulating angiogenesis and fibroplasia. This phase can last anywhere from 5-20 
days following wounding. During the final phase, which can take months to years, 
angiogenesis ceases and vascular cells in the wound undergo remodeling and 
apoptosis (Tonnesen, Feng et al. 2000; Falanga 2005) (Fig 1.3). 
 
The skin is a multi-layer tissue which covers majority of the outer body. The 
topmost layer is the epidermis, which consists of cells which proliferate to renew 
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regularly. It consists mainly of stratified squamous epithelia which exist in layers 
of different differentiation phases. Below the epidermal layers lies the dermis, 
which acts as a supportive structure for the epidermis. It consists of connective 
tissue, capillaries, collagen fibers and elastic fibers. The deepest layer is the 
hypodermis, which cushions the layers of skin and consists mainly of adipose 
tissue. Hair follicles, sweat glands, sebaceous glands and nerve fibers penetrate all 
the layers, however, the epidermis is considered avascular, with the majority of 
blood vessels being in the dermal layer (Wheaters functional histology, 5
th
 edition, 
2006). Thus angiogenesis is an essential process involved in aiding proper wound 
healing, especially of the avascular epidermal layer. In the initial phases, the 
broken blood vessels at the injury site recruit immune cells required to clean the 
wound of foreign particles and prevent sepsis. In the later phases, fresh 
angiogenesis cascades repopulate the wound bed with new blood vessels to supply 
oxygen and nutrition to sustain metabolism. This mainly happens during the 
proliferative phase, where local factors lead to activation of ECs and thus 
stimulate angiogenesis.  
 
Figure 1.3 Phases of wound healing 
 A: Stages of wound healing; (A1-A4: Progression of wound healing); B: Time 





Vascular Endothelial Growth Factor (VEGF) has been found to be essential for the 
wound healing process, by aiding in the formation of granulation tissue, 
angiogenesis and promoting keratinocyte migration and proliferation 
(Howdieshell, Callaway et al. 2001; Dickens, Vermeulen et al. 2008). VEGF is 
pre-dominantly released by keratinocytes in the skin and affects both ECs and 
keratinocytes during the wound healing process. Other sources of VEGF are the 
in-coming platelets and macrophages that increase the local concentration of 
VEGF, thus aiding wound healing (Banks, Forbes et al. 1998; Ohtani, Mizuashi et 
al. 2007). Since angiogenesis plays an important role in regulating wound healing, 
several studies have been conducted to analyze the role of endogenous 
angiogenesis inhibitors in regulating wound healing. Multiple angiogenesis 
inducers and inhibitors have been implicated in the wound healing process 
(summarized in Table 1.1). 
 
Table 1.1 List of angiogenesis regulators involved in wound healing 







Angiogenesis (Dickens, Vermeulen et 
al. 2008) 
Fibroblast Growth 









      Fibroplasia, 
Angiogenesis 




Angiogenesis (Cho, Sung et al. 2006; 




Angiogenesis (Kampfer, Pfeilschifter 















(Schafer, Maier et al. 
1994; Providence and 
Higgins 2004) 
Angiogenesis inhibitors 
Endostatin Angiogenesis (Bloch, Huggel et al. 
2000; Seppinen, 
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As revealed by several studies, different angiogenesis inhibitors delay wound 
healing by affecting different phases of the wound healing process. Endostatin, an 
endogenous angiogenesis inhibitor known to inhibit tumor angiogenesis, is found 
to impair blood vessel maturation, while having no significant effect on blood 
vessel density (Bloch, Huggel et al. 2000). Angiostatin, the proteolytic fragment of 
plasminogen, is found to be expressed in wounded skin at day 1 and 3 following 
creation of the wound, with the peak expression at day 7 after which its expression 
almost disappears (Chavakis, Athanasopoulos et al. 2005). Angiostatin delays 
wound healing by affecting both the local inflammation and blood vessel density. 
Thrombospondin1 (TSP1)-overexpression mice show delayed wound healing by 
affecting granulation tissue formation and reducing angiogenesis (Streit, Velasco 
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et al. 2000). While the expression of TSP1 peaks during day 2 to day 7 post-
wounding and is almost negligible at day 10, the expression of TSP2 increases 
during the later phases and peaks at day 10 post-wounding (Kyriakides, Tam et al. 
1999).  
 
From the expression pattern of pro- and anti-angiogenic factors in wound healing, 
it is thus clear that under physiological conditions, a balance exists between levels 
of angiogenic and anti-angiogenic factors resulting in the initiation of 
angiogenesis when required and termination of angiogenesis when needed.  
1.1.2 Angiogenesis in pathology 
Both insufficient or excessive angiogenesis can cause pathological conditions such 
as stroke (Slevin, Kumar et al. 2006), chronic non-healing wounds (Tonnesen, 
Feng et al. 2000), cancer (Folkman 1995), rheumatoid arthritis (Marrelli, Cipriani 
et al. 2011), endometriosis (Taylor, Yu et al. 2009) etc. Much focus on 
angiogenesis in pathology these days deals with the role of angiogenesis in cancer. 
1.1.2.1 Angiogenesis in cancer 
In 1971, Judah Folkman proposed that angiogenesis was an important hallmark of 
tumor progression, and that a tumor cannot grow beyond a size of 2 mm without 
recruiting its own blood supply. This implies that tumor progression is dependent 
on angiogenesis, and angiogenesis inhibition can be used as a strategy for 
suppressing tumor growth (Folkman 1971).  
 
Cancer is a complicated condition driven by genetic alterations which cause 
malfunction of basic cellular metabolism (Futreal, Coin et al. 2004). These genetic 
alterations can be gene mutations, deletions, insertions, translocations and increase 
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in copy numbers. The changes occurring during cancer has now been 
characterized as ten hallmarks of cancer by Hanahan and Weinberg (Hanahan and 
Weinberg 2000; Hanahan and Weinberg 2011). These are self-stimulated growth, 
resistance to anti-growth signals, escape from apoptosis, uncontrolled and infinite 
proliferation, angiogenesis, ability to invade and metastasize, evasion of the 
immune system, abnormal metabolism, genome instability and mutations and 
lastly, prolonged inflammation. Out of the ten cancer hallmarks, angiogenesis has 
been identified as one of the most important. Excessive angiogenesis allows the 
growing tumor to receive oxygen and nutrients in order to support uncontrolled 
proliferation and abnormally high metabolism, as well as provide a channel to 
metastasize. On the other hand, hypoxic environment surrounding a growing 
tumor acts as a trigger for angiogenesis (Pugh and Ratcliffe 2003) thereby aiding 
further growth of the tumor. Judah Folkman coined the term ‘angiogenic switch’, 
which defines the event that leads to activation of the otherwise quiescent 
endothelium to make new blood vessels from pre-existing ones (Folkman and 
Hanahan 1991). This switch involves the shift of the balance favoring angiogenic 
factors leading to increased angiogenesis and thus enhanced tumorigenesis.  
 
Oncogenic genetic alterations help tumor cells to escape normal cell proliferation 
control and confer it infinite proliferation and growth properties. However, 
without angiogenesis to sustain tumor growth, tumor progression is restricted. The 
tumor microenvironment consists of both transformed tumor cells, as well as 
normal cells. Tumor cells in the tumor microenvironment secrete numerous 
cytokines and growth factors that activate other non-transformed cells to trigger 
responses that aid tumor progression.  
 
Tumor blood vessels are fragile and leaky. Due to the imbalance between pro- and 
anti-angiogenic factors, and the continuous stimulation of the endothelia, proper 
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maturation of the newly formed vessels does not take place and the vessels remain 
hyper-permeable (Nagy, Chang et al. 2010). Also, in a tumor microenvironment, 
various other cell types acquire EC-like properties and participate in the growing 
tumor vessel causing structural malformations leading to leakiness (Chang, di 
Tomaso et al. 2000). Functionally, these newly formed vessels are inefficient in 
filtering out macromolecules. Leakage of plasma proteins such as fibrin lead to 
fibrin deposition and ultimately a richer extracellular matrix for further tumor 
progression (Nagy, Benjamin et al. 2008). 
1.1.2.2  Angiogenesis in tumor metastasis 
As described above, tumors vessels are morphologically and functionally different 
from normal blood vessels. In addition to being extremely leaky, tumor vessels 
may have bidirectional flow of blood and have very irregular branching patterns 
(Chaplin, Olive et al. 1987). This feature, in addition to the ease at which these 
blood vessels can support intravasation and extravasation of macromolecules and 
even cells, can aid in metastasis. Metastasis is an event in tumor progression 
which ultimately kills the cancer patient. It is the process by which cells from a 
primary tumor enter the circulation and re-establish as a secondary tumor at a 
distant site, usually away from the site of the primary tumor. Certain cells in a 
primary tumor acquire new abilities such as enhanced motility and survival in 
circulation which allow them to invade and metastasize (Wyckoff, Jones et al. 
2000; Chambers, Groom et al. 2002). In the new organ, the cells then extravasate 





Figure 1.4 The metastatic process 
(A) Cancer cells escape the site of the primary tumor and get arrested in 
circulation; (B) When the microenvironment is suitable, arrested cells extravasate 
and a secondary tumor is established in the distant organ (Adapted from 
(Chambers, Groom et al. 2002)) 
 
To study metastasis experimentally, two models have been used. The spontaneous 
metastasis model (Fidler 1991) involves establishment of a primary tumor, and 
studying the spontaneous metastasis and homing of tumor cells into distant organs. 
The experimental model (Welch 1997) involves injection of tumor cells directly 
into the systemic circulation of the animal to model the phases of metastasis after 
intravasation of primary tumor cells into the circulation.  
 
Ever since angiogenesis has been implicated in tumor progression, efforts have 
been made to study the role of angiogenic and anti-angiogenic factors in 
regulating metastasis. In addition to the effects of angiogenesis on tumor 
expansion, it is now thought that high vascularization of tumors can facilitate 
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metastasis by providing a route for exit of tumor cells from the primary tumor site 
(Dvorak, Detmar et al. 1995).  Consequently, angiogenesis inhibition should 
decrease the amount of cells that go into circulation and thus reduce the amount of 
metastatic colonies that arise. However, in therapy that involves angiogenesis 
inhibition; one undesirable effect observed has been a more aggressive metastatic 
phenotype (Bergers and Hanahan 2008; Ebos, Lee et al. 2009).  
1.1.3 Angiogenesis regulators 
1.1.3.1 Angiogenic stimulators 
A number of molecules have been identified as stimulators of angiogenesis and the 
list is growing. Based on biological characteristics, they have been classified under 
different groups (Table 1.2).  
 
Table 1.2 List of angiogenesis stimulators 
Heparin binding peptide growth factors 
Vascular endothelial growth factor 
(VEGF) 
(Lohela, Bry et al. 2009) 
Fibroblast growth factor 1 and 2 (FGF-
1 and FGF-2) 
(Beenken and Mohammadi 
2009) 
Platelet derived growth factor (PDGF) (Andrae, Gallini et al. 
2008) 
Placenta growth factor (PlGF) (Ribatti 2008) 
Pleiotrophin (PTN) (Perez-Pinera, Berenson et 
al. 2008) 
Non-heparin binding peptide growth factors 
Transforming growth factor - α (TGF-
α) 
(Leker, Toth et al. 2009) 
Transforming growth factor - β (TGF-
β) 
(ten Dijke and Arthur 2007; 
Massague 2012) 





Tumor necrosis factor (TNF-α)  (Sainson, Johnston et al. 
2008) 
Interleukin 3 (IL-3) (Dentelli, Del Sorbo et al. 
1999) 
Interleukin 8 (IL-8)  (Li, Dubey et al. 2003) 
Cell adhesion molecules 
Integrins (Avraamides, Garmy-Susini 
et al. 2008) 
Vascular cell adhesion molecule 1 
(VCAM-1) 
(Dong, Shen et al. 2011) 
E-selectin (Koch, Halloran et al. 1995) 
Vascular endothelial cadherin (VE-
cadherin) 
(Carmeliet and Collen 
2000) 
Enzymes 
Cycloxygenase (COX-2) (Toomey, Murphy et al. 
2009) 
Angiogenin (ANG) (Gao and Xu 2008) 
Matrix metalloproteinases (MMPs) (van Hinsbergh and 
Koolwijk 2008) 
Oligosaccharides 
Hyaluronan Oligo’s (Savani, Cao et al. 2001) 
Other factors 
Nitric oxide (Donnini and Ziche 2002) 
MicroRNAs (miR-27b, -126, -130a, -
210, -296, -378 and -17~92 cluster)  
(Suarez and Sessa 2009) 






One of the most important regulators of angiogenesis is vascular endothelial 
growth factor (VEGF). VEGFs are homodimeric glycoproteins with a molecular 
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weight of approximate 45 kDa (Ferrara and Henzel 1989). VEGFs are secreted by 
multiple cell-types, the most important being endothelial, stromal and 
hematopoietic cells in response to hypoxia or stimulation of other growth factors, 
such as interleukins, transforming growth factors and platelet-derived growth 
factors (Cebe-Suarez, Zehnder-Fjallman et al. 2006). Currently, 7 members of 
VEGF family have been reported. They are VEGF-A, -B, -C, -D, -E, -F and 
placenta growth factor (PlGF) (Suto, Yamazaki et al. 2005; Shibuya 2008).  
 
The VEGF-receptors (VEGF-Rs) mediate the biological functions of VEGFs 
(Cebe-Suarez, Zehnder-Fjallman et al. 2006). Three VEGF-Rs have been 
identified, namely, VEGF-R1/Flt-1, VEGF-R2/Flk-1/KDR and VEGF-R3/Flt-4. 
Among them, VEGFR-2 is the most important receptor in VEGF-induced 
mitogenesis and permeability (Waltenberger, Claesson-Welsh et al. 1994). VEGF-
Rs have important kinase activities through which their biological functions are 
carried out (Ortega, Hutchings et al. 1999). Binding of VEGF to its receptor leads 
to dimerization of the receptors and subsequent transactivation via tyrosine 
phosphorylation in the cytoplasmic domain. The receptors of VEGFs have been 
found to be expressed on the cell surface of endothelial cells (Ferrara and Davis-
Smyth 1997), macrophages and hematopoietic cells (Kabrun, Buhring et al. 1997), 
on vascular smooth muscle cells (Ishida, Murray et al. 2001) and on some 
malignant cancer cells (Bellamy 2002). 
 
As mentioned earlier, VEGF exerts its biological functions via transactivation by 
tyrosine phosphorylation of its receptors. Phosphorylation of several residues on 
the cytoplasmic domain of the VEGF-Rs has been observed, which are responsible 
for multiple functions of VEGF (Dougher and Terman 1999; Takahashi, 
Yamaguchi et al. 2001). ECs in culture have been shown to be specifically 
responsive to VEGF-A via the receptor VEGF-R2. VEGF-R2 gets phosphorylated 
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at multiple residues upon VEGF-A stimulation which then transmit signals to 
downstream effectors responsible for VEGF-As effects on angiogenesis and 
vascular permeability (Claesson-Welsh 2003).  
 
Although VEGF is known to be upregulated in several angiogenesis-related 
pathological conditions, it plays an important role in physiological angiogenesis. 
Vegf gene knockout, even the heterozygous knockout in mice, leads to embryonic 
lethality due to severe developmental anomalies, the main being severe vascular 
defects (Carmeliet, Ferreira et al. 1996; Ferrara, Carver-Moore et al. 1996). To 
buttress the important of VEGF in normal vascular development, Vegf-r knockout 
mice were also embryonic lethal with severe vascular defects (Fong, Rossant et al. 
1995; Shalaby, Rossant et al. 1995). As mentioned earlier, VEGF plays an integral 
role in wound healing. VEGF-A enhances angiogenesis in healing wounds and 
also accelerates the formation of granulation tissue in wound edge (Dvorak, 
Detmar et al. 1995; Dai, Huang et al. 2004). VEGF also plays an important role in 
the female reproductive tract (Cullinan-Bove and Koos 1993). VEGF-mediated 
angiogenesis in the uterus has been found to be responsible for luteal function 
(Fraser and Lunn 2000). 
 
VEGF plays a prominent role in angiogenesis- and inflammation-related 
pathological conditions (Ferrara 2001). It is thus not surprising that VEGF has 
been shown to be a major factor in tumor angiogenesis (Carmeliet 2003). VEGF 
mRNA is significantly up-regulated in a variety of tumor types (Ferrara and 
Davis-Smyth 1997). VEGF is expressed by both stromal cells and tumor cells. In 
tumors, VEGF induces the disruption of interendothelial junctions, caveolae and 
fenestrations, which facilitate hyperpermeability and thus transport of 
macromolecules (Hobbs, Monsky et al. 1998; Monsky, Fukumura et al. 1999). 
Tumor cells constitutively produce VEGFs that makes tumors inflammation that 
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never ceases. Elevated levels of VEGF and hence enhanced vascular permeability, 
angiogenesis and inflammation have also been reported in other pathological 
conditions, such as diabetic retinopathy, psoriasis, edema, asthma and other kinds 
of inflammation (Aiello, Avery et al. 1994; Dvorak, Detmar et al. 1995; Lee, Ma et 
al. 2011). 
.  
VEGF inhibition has been identified as an effective strategy to treat tumors and 
neo-vascular diseases. Inhibitors approved by the US Food and Drug 
Administration (FDA) are in the form of antibodies or small molecules blocking 
the function of either VEGF/VEGFR2 or downstream events (Carmeliet and Jain 
2011). A humanized anti-VEGF-A monoclonal antibody, Avastin, also known as 
Bevacizumab, has been demonstrated as an anti-cancer agent (Presta, Chen et al. 
1997; Ferrara, Hillan et al. 2004).  It has been approved for treating multiple types 
of tumors (Hurwitz, Fehrenbacher et al. 2004; Sandler, Gray et al. 2006) as well as 
in combinatorial chemotherapy (Carmeliet and Jain 2011). Sunitinib and Sorafenib 
are small molecules designed against the VEGF-Rs. Sunitinib blocks the tyrosine 
phosphorylation of VEGFRs (Smith, Mamoon et al. 2004) and has shown 
therapeutic promise (Morgan, Demetri et al. 2005).  
 
Fibroblast growth factor (FGF)s  
 
Fibroblast growth factors (FGFs), initially identified as Tumor Angiogenesis 
Factor (TAF) in 1971 (Folkman, Merler et al. 1971) are heparin-binding growth 
factors. The proteins of this family possess a high binding affinity for heparan 
sulfate proteoglycans and require heparan sulfate to activate their cell-surface FGF 
receptors (Shing, Folkman et al. 1984). Currently, 23 members of FGF family 
have been reported in human (Itoh and Ornitz 2004; Beenken and Mohammadi 
2009). Only few members of this family have been implicated in angiogenesis, 
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with FGF-1 and FGF-2 being the most extensively studied members. 
 
The biological functions of FGFs are exerted by binding of FGFs to their cellular 
receptors FGF-Rs. The FGF-Rs are a family of tyrosine kinase receptors that bind 
the FGFs in a heparan sulfate glycosaminoglycans (HSGAGs)-dependent manner 
(Vlodavsky, Bar-Shavit et al. 1991). Four FGF-Rs (FGF-R1, -R2, -R3 and -R4) 
have been reported till date. Upon activation, FGF-Rs transmit signals through 
their cytoplasmic domains to downstream signaling pathways resulting in 
endothelial cell proliferation, differentiation, migration, protease production and 
angiogenesis (Liekens, De Clercq et al. 2001; Sorensen, Nilsen et al. 2006). 
 
FGFs, like VEGFs, play important roles in both physiological and pathological 
conditions (Bikfalvi, Klein et al. 1997; Liekens, De Clercq et al. 2001). Both Fg-f2 
and Fgf-r1 knockout mice are embryonic lethal (Deng, Wynshaw-Boris et al. 
1994; Yamaguchi, Harpal et al. 1994; Xu, Weinstein et al. 1998). During 
development, FGFs participate in brain patterning, branching morphogenesis and 
limb development (Beenken and Mohammadi 2009). In adult physiological 
conditions, FGFs participate in hematopoiesis (Bruno, Cooper et al. 1993; Harada, 
Saito et al. 1994) and wound healing (Ashton, Dawes et al. 1995; Ortega, Ittmann 
et al. 1998; Liekens, De Clercq et al. 2001). FGF-2 also plays a significant role in 
inflammation (Bosse, Pare et al. 2008; Keller, Ruegg et al. 2008). However, 
several pathological conditions are driven by malfunctioning FGF signaling, 
especially tumor growth and progression through the dysfunction of cell 
proliferation, differentiation and angiogenesis in numerous tumor types (Carmeliet 
and Jain 2000; Carmeliet 2005). Especially in anti-VEGF therapy resistance, FGF 
pathways may compensate for the inhibited VEGF-pathways. 
 
Recombinant FGFs have been used in pathological ischemia (Sellke, Laham et al. 
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1998) and small molecule FGF-R inhibitors are in various stages of development 
for use in cancer therapy. Sunitinib, the FDA proved receptor tyrosine inhibitor for 
the treatment of renal cell carcinoma and gastrointestinal stromal tumors functions 
through both VEGF-Rs and FGF-Rs inhibition (Chow and Eckhardt 2007). Small-
molecule FGF-R inhibitors-PD173074, Su5402 and nordihydroguaiaretic acid also 
show efficacy in several myeloma cell lines with aberrant FGF-R3 expression 
(Grand, Chase et al. 2004; Meyer, McAndrew et al. 2008). Besides small-molecule 
inhibitors, antibodies against FGF-Rs have been shown to be effect in certain 
tumor types (Trudel, Stewart et al. 2006; Martinez-Torrecuadrada, Cheung et al. 
2008). 
1.1.3.2 Angiogenic inhibitors 
To date, several angiogenesis inhibitors have been identified which can potentially 
neutralize the effects of angiogenic factors. The following table lists out some of 
the endogenous angiogenesis inhibitors characterized (Table 1.3) and a few 
selected inhibitors will be reviewed in the following sections. 
 





A Disintegrin and 
metalloproteinase with 
thrombospondin motifs -1, -2, -5, 
-8, -9 and -12 (ADAMTS-1, -2, -
5, -8, -9 and -12) 
(Kumar, Rao et al. 2009; Kumar, Rao et 
al. 2012) 
Chondromodulin (Hiraki, Inoue et al. 1997) 
Interferons (Sidky and Borden 1987) 
Interleukin-10 and -18 (Cao, Farnebo et al. 1999; Silvestre, 
Mallat et al. 2000) 




Maspin (Zhang, Volpert et al. 2000) 
Pigment epithelial derived factor (Dawson, Volpert et al. 1999) 
Platelet factor-4 (Hagedorn, Zilberberg et al. 2001) 
Thrombospondin-1 and -2 (Good, Polverini et al. 1990) 
Tissue inhibitors of 
metalloproteinases-1, -2 and -3 
(Ikenaka, Yoshiji et al. 2003; Qi, 
Ebrahem et al. 2003; Seo, Li et al. 2003) 
Troponin Ⅰ (Moses, Wiederschain et al. 1999) 
Vascular endothelial growth 
inhibitor 
(Zhai, Ni et al. 1999) 
Vasohibin-1 (Watanabe, Hasegawa et al. 2004) 
Natural proteolytic fragments: 
Angiostatin (Kringles 1~4) (O'Reilly, Holmgren et al. 1994) 
Arrestin (Colorado, Torre et al. 2000) 
Canstatin (Kamphaus, Colorado et al. 2000) 
Endostatin (O'Reilly, Boehm et al. 1997) 
Kringle 5 (Cao, Chen et al. 1997; Davidson, 
Haskell et al. 2005) 
Parstatin (Duncan and Kalluri 2009) 
Pex (Ribatti 2009) 
Prolactin fragment (Galfione, Luo et al. 2003) 
Tumstatin (Maeshima, Colorado et al. 2000) 
Vasostatin (Pike, Yao et al. 1998) 
Other factors: 
2-methoxyestradiol (Pribluda, Gubish et al. 2000) 
MicroRNAs (miR-15, -16, -221 
and -222) 
(Suarez and Sessa 2009) 
 
.1.3.2.1  Gene products 
 
Thrombospondins (TSPs): The term ‘thrombospondin’ was coined by Lawler 
(Lawler, Chao et al. 1977; Lawler, Slayter et al. 1978) based on the fact that the 
protein was released and purified from thrombin-treated platelets from blood 
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vessels. The first thrombospondin to be identified was TSP1, which has been 
found to be secreted by aortic, venous, capillary and corneal ECs, fibroblasts and 
smooth muscle cells (McPherson, Sage et al. 1981; Sage, Pritzl et al. 1981; 
Mosher, Doyle et al. 1982; Raugi, Mumby et al. 1982; Jaffe, Ruggiero et al. 1983). 
The TSP family consists of 5 members, but TSP1 and TSP2 are more extensively 
studied as they contain the type-1 repeats which give them anti-angiogenic 
properties. The TSR domain (Thrombospondin-type-1 repeat) was first identified 
in the thrombospondins and has hence been associated with anti-angiogenic 
properties.  
 
Mice deficient in Tsp1 and Tsp2 have been found to be embryonic lethal. In the 
case of Tsp1 null mice, increased retinal vascularity was observed, whereas 
increased vascularity in healing wounds was observed in Tsp2 null mice 
(Kyriakides, Tam et al. 1999; Wang, Wu et al. 2003). Aberrant inflammation was 
observed in both the cases. Interestingly, the Tsp1 and Tsp2 double-knockout mice 
have severe wound healing defects, which include delayed wound healing and 
decreased vascularity (Agah, Kyriakides et al. 2002). This implies that TSP1 and 
TSP2 are essential for the normal course of wound healing by affecting 
angiogenesis and inflammation. 
 
The TSPs have a broad range of biological functions which include effects on cell 
adhesion, migration, proliferation and mobilizing molecules present in the extra-
cellular matrix (ECM) (Rastinejad, Polverini et al. 1989; Chen, Herndon et al. 
2000). TSP1 both positively and negatively regulates cell adhesion, migration and 
proliferation, which is not surprising because different domains on TSP1 bind 
different receptors on the cell surface (Bornstein 2009). The domains and the 
receptors they bind to are represented in Fig 1.5. The receptors that TSP1 bind to 
are CD36, integrins (αvβ3, α3β1 and αIIbβ3), HSPG, and integrin-associated 
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protein (IAP or CD47). The anti-angiogenic function of TSP1 has been found to 
occur through binding CD36 (Asch, Liu et al. 1993; Dawson, Pearce et al. 1997), 
and does so by induction of EC apoptosis (Guo, Krutzsch et al. 1997).  
 
Figure 1.5 Schematic showing the interacting partners of TSP1 & 2 
(Adapted from (Bornstein 2009)) 
 
 
Upon activation, CD36 transmits the signal to cytoplasmic p59Fyn which in turn 
activates p38MAPK and Jun-N-terminal kinase (JNK). The activation of these 
requires the action of caspase 3 and 9. Apoptosis is triggered when the Fas ligand 
(FasL) on one cell interacts with a Fas receptor on another cell (Jimenez, Volpert 
et al. 2000).  
 
Due to the interaction of TSP with multiple receptors, which make the function of 
TSP1 and TSP2 both angiogenic and angio-inhibitory, several synthetic peptides 
containing the angio-inhibitory TSR domain have been designed which shown 
angio-inhibitory properties both in vitro and in vivo (Tolsma, Volpert et al. 1993; 
Iruela-Arispe, Lombardo et al. 1999). The efficacy of TSP1 and its derived 
peptides against several tumors have highlighted their potential uses as anti-
angiogenic and anti-tumorigenic agents (Bocci, Francia et al. 2003; Lawler and 
Detmar 2004).  
 
Pigment Epithelial Derived Factor (PEDF): PEDF is a 50 kDa non-inhibitory 
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member of the serine-protease inhibitor gene family, initially identified in fetal 
pigmented epithelial cells (Steele, Chader et al. 1993; Goliath, Tombran-Tink et al. 
1996; Tombran-Tink, Mazuruk et al. 1996). PEDF is expressed in a wide variety 
of tissues in the body and has been associated with anti-angiogenesis, anti-
tumorigenesis and neurotrophy. Especially in ocular compartments, presence of 
PEDF leads to avascularity (Stitt, Graham et al. 2004) and delays angiogenesis in 
retinal ischemia (Stellmach, Crawford et al. 2001). These findings have suggested 
that PEDF is a potent anti-angiogenic agent. PEDF has been found to inhibit 
VEGF and FGF-induced angiogenesis more potently than the TSPs, endostatin 
and angiostatin. PEDF selectively inhibits neoangiogenesis, while causing no 
harm to existing blood vessels, which makes cancer therapy using PEDF and its 
derivatives a promising strategy (Bouck 2002; Tombran-Tink and Barnstable 
2003).  
 
Vasohibin-1 (VASH1): Vasohibin is a 42 kDa protein preferentially expressed in 
ECs and was identified as a gene up regulated by VEGF and FGF-2 (Watanabe, 
Hasegawa et al. 2004; Kimura, Miyashita et al. 2009). The expression of VASH1 
was restricted to tumor ECs and was expressed during active angiogenesis 
(Hosaka, Kimura et al. 2009). Interestingly, although VASH1 was expressed along 
with angiogenic factors like VEGF and FGF-2, it potently inhibited VEGF and 
FGF-2 signaling and had anti-angiogenic properties both in vitro and in vivo. It 
thus functions as a negative feedback regulator of VEGF/ FGF-2 signaling.  
 
VASH1 also helps in the maturation of newly formed vessels, thus inhibiting 
sprouting angiogenesis induced by VEGF and FGF-2. Tumors implanted into 
Vash1
-/-
 mice showed decreased vascular maturation (Hosaka, Kimura et al. 2009), 
while exogenous administration of VASH1 led to disruption of angiogenesis in the 
sprouting region, but showed no effect in the termination region (Heishi, Hosaka 
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et al. 2010).  
Recent work has indicated that VASH1 can be used as a diagnostic marker for 
predicting prostate cancer prognosis as late stage tumors had higher density of 
VASH1-positive vessels (Kosaka, Miyazaki et al. 2013). This makes VASH1 a 
potential target for therapy in prostate cancers, especially for targeting tumor 
angiogenesis.  
1.1.3.2.2  Natural proteolytic fragments 
 
Several natural products of proteolytic cleavage have been identified to have 
angio-inhibitory functions (Nyberg, Xie et al. 2005). The parent proteins of these 
fragments themselves do not have anti-angiogenic activity.  A few examples of 
such inhibitors have been detailed below. 
 
Angiostatin: Angiostatin was identified as one of the circulating factors present in 
the serum of tumor bearing mice (O'Reilly, Holmgren et al. 1994). It is a cleaved 
fragment of plasminogen and contains the first three (K1-K3) or four (K1-K4) 
kringle domains that are known to be lysine-binding (Liu, Ahmad et al. 2000). 
 These fragments, as well as the individual kringle domains, inhibit EC migration, 
proliferation and tube formation in vitro (Moser, Stack et al. 1999). In vivo, 
angiostatin inhibits tumor growth and primary tumor metastasis in mice (O'Reilly, 
Holmgren et al. 1994; O'Reilly, Holmgren et al. 1994) and vascular proliferation 
in the chick chorioallantoic membrane (CAM) assay (Gately, Twardowski et al. 
1996). Angiostatin also potently induces EC apoptosis (Claesson-Welsh, Welsh et 
al. 1998; Lucas, Holmgren et al. 1998). 
 
To date, at least three cell surface receptors for angiostatin have been reported 
namely, adenosine triphosphate (ATP) synthase (Moser, Stack et al. 1999), 
angiomotin (Troyanovsky, Levchenko et al. 2001) and integrin αvβ3 (Tarui, Miles 
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et al. 2001). EC apoptosis induced by angiostatin has been found to be due to an 
integrin-independent activation of Focal Adhesion Kinase (FAK) resulting in 
reduced turn-over of focal adhesions and ultimately cell death (Claesson-Welsh, 
Welsh et al. 1998). A recent study has shown that angiostatin can be internalized 
into ECs through binding to ATP synthase and ultimately target mitochondrial 
compartment to induce EC apoptosis (Lee, Muschal et al. 2009). Through those 
specific ligand-receptor interactions, angiostatin functions as an anti-angiogenic 
and anti-tumorigenic factor both in vitro and in vivo. Since its activity is EC-
specific, the anti-tumor effects seen are a direct result of anti-angiogenesis. 
 
Endostatin: Endostatin was originally discovered in 1997. It is a 20 kDa cleaved 
product of the carboxyl-terminal domain of collagen XVIII.  It was first 
discovered in conditioned medium from a murine endothelial tumor cell line 
(O'Reilly, Boehm et al. 1997). Like other angio-inhibitory molecules, endostatin 
directly exerts its anti-angiogenic function by inhibiting EC proliferation, 
migration and inducing EC apoptosis (Yamaguchi, Anand-Apte et al. 1999). 
Endostatin recognizes multiple receptors on ECs including cell surface integrins 
containing α5 or αv subunit (Rehn, Veikkola et al. 2001), nucleolin (Shi, Huang et 
al. 2007), VE-cadherin (Nemoto and Kubota 2011) and glypican (Karumanchi, Jha 
et al. 2001). It plays an important role in EC adhesion and cytoskeletal 
organization (Dixelius, Cross et al. 2002). These functions have been reported to 
be involved in mediating biological functions of endostatin. 
 
In vivo, endostatin potently inhibits tumor growth in various cancers; in some, 
more than 99% inhibition has been observed (Boehm, Folkman et al. 1997; Sund, 
Hamano et al. 2005) As mentioned earlier, endostatin also impairs blood vessel 




Parstatin: Parstatin is the N-terminal cleavage product of Protease Activated 
Receptor-1 (PAR-1) which is a potent angiogenesis inhibitor (Zania, Gourni et al. 
2009). Parstatin is released from PAR-1 as a result of proteolytic cleavage at 
Arg41/Ser42 by many serine proteinases such as thrombin (Vu, Hung et al. 1991), 
Factor Xa (Riewald and Ruf 2001),  activated protein C (Riewald, Petrovan et al. 
2002),  matrix metalloproteinase 1 (MMP1) (Boire, Covic et al. 2005) etc. PAR-1 
is expressed in various cell types such as platelets in blood (Andersen, Greenberg 
et al. 1999), cardiomyocytes and vascular endothelium (Storck and Zimmermann 
1996), astrocytes and neurons of nervous system (Corvera, Dery et al. 1999) and 
osteoblasts of bone (Abraham and MacKie 1999) . It is also found to be expressed 
in various human cancers (Kaufmann, Junker et al. 2002) (Rudroff, Seibold et al. 
2002) (Tellez and Bar-Eli 2003) (Boire, Covic et al. 2005). 
The cleaved form of PAR-1 is released from the cell surface and binds back onto 
the PAR-1 receptor to carry out its biological function (Tsopanoglou and 
Maragoudakis 2007). Parstatin inhibits EC proliferation and EC tube-formation in 
vitro. It also potently induces EC apoptosis. It neutralizes the angiogenic signals of 
VEGF and FGF-2 (Zania, Gourni et al. 2009). Parstatin inhibits neoangiogenesis 
in the CAM assay, even in the presence of VEGF and FGF-2. Further, the anti-
angiogenic function of parstatin seems to be due to inhibition of the MAPK/ERK 
pathway.  
 
As a therapeutic agent, parstatin has been successfully used in the treatment of 
excessive retinal angiogenesis (Huang, Vasilakis et al. 2010). Also, parstatin has 
proven to be cardioprotective in models of cardiac ischemia and reperfusion injury 
(Strande, Widlansky et al. 2009) 
 
Kringle-5: The Kringle fragments of plasminogen K1-K4 are present in 
angiostatin, which is a potent angio-inhibitory molecule. K5, which is an internal 
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cleavage fragment of plasminogen, on its own, is an angiogenesis inhibitor (Cao, 
Chen et al. 1997; Cao, Wu et al. 1999). Similar to angiostatin, K5 suppresses EC 
proliferation and induces apoptosis (Lu, Dhanabal et al. 1999). In vivo, K5 was 
shown to inhibit tumorigenesis and angiogenesis in mouse models (Liu, Qiu et al. 
2005; Perri, Nalbantoglu et al. 2005). 
 
K5 has been shown to interact with cell surface glucose-regulated protein 78 
(GRP78) (Davidson, Haskell et al. 2005). This binding and subsequent biological 
function requires association of GRP78 with low-density lipoprotein receptor-
related protein 1 (LRP1) (McFarland, Stewart et al. 2009). GRP78 is found at the 
cell surface in a wide variety of cancer cells, which makes it a promising anti-
cancer target (Delie, Petignat et al. 2012). The binding of K5 to GRP78 activates 
caspase-7 and subsequent apoptosis and autophagy (Nguyen, Subramanian et al. 
2007). 
1.1.4 Anti-angiogenic cancer therapy 
Several endogenous angiogenesis inhibitors have been identified over the years, 
including TSP1, PF4 (platelet factor 4), PEDF, to name a few (Canfield and Schor 
1995; Dawson, Volpert et al. 1999; Bikfalvi 2004). It is increasingly clear that 
angiogenesis is a complex phenomenon; hence a large number of angiostatic 
regulators may be required to balanced excessive angiogenesis as seen in 
pathological conditions such as cancers. Currently, anti-angiogenic strategies have 
been developed that block the functional receptors of potent angiogenic molecules 
such as VEGF and bFGF (VEGF-R1, VEGF-R2, FGF-R1 etc.) or by delivering 
angiogenesis inhibitors and synthetic antagonists (Folkman 2002). The reason for 
the growing interest in endogenous angiogenesis inhibitors lies in the fact that 
anti-angiogenic therapy with endogenous inhibitors may be less toxic than 
conventional therapies available today. In several clinical studies, treatment with 
26 
 
endogenous angiogenesis inhibitors have been shown to block neovascularisation 
while keeping healthy vessels unaffected (Volpert, Zaichuk et al. 2002; Noh, 
Matsuda et al. 2003). 
1.2  The endothelial barrier   
The endothelium regulates the entry of circulating cells and plasma proteins in its 
function of supplying tissues with gases, nutrients and clearing waste products. 
The endothelium can be seen as a porous membrane which certain molecules can 
pass freely, whereas the passage of other molecules are tightly regulated (Malik, 
Lynch et al. 1989). Like angiogenesis, a balance between vascular 
permeabilization factors and inhibitors may exist to maintain tissue homeostasis, 
in pathological as well as physiological barrier function. 
 
The endothelial barrier allows the passage of molecules through 2 distinct routes; 
i) transcellular route and ii) paracellular route. The route of passage largely 
depends on the radii of the molecules transported (Mehta and Malik 2006). 
Molecules less that 3 nm mainly get transported across the cell through the 
transcellular route. Larger molecules and even cells require disruption of cell-cell 
junctions to be transported across the endothelial barrier; by the paracellular route 
(Fig 1.6).  
 
Figure 1.6 Pathways regulating EC barrier function 
The passage of cells and macromolecules through the endothelial barrier can occur 
27 
 
through transcellular (vesicular vacuolar organelles) or paracellular (tight and 
adherens junctions) pathways. Gap junctions ensure water and ion transport. 
Moreover, endothelial cells are anchored and connected to the extracellular matrix 
(ECM) through integrin-based adhesion complexes, namely focal adhesions 
(Adapted from (Azzi, Hebda et al. 2013) 
 
The barrier function of blood vessels is controlled by the integrity of the 
endothelial structure. The determinants of this integrity are cell-cell junction 
complexes and cell-matrix complexes. In endothelial cells, like epithelial cells, 
two types of cell-cell junctions are present, the adherens junctions (AJ) and the 
tight junctions (TJ). However, unlike epithelial cells, the AJ and TJ in endothelial 
cells are less defined and along the cleft, AJ merge into the TJ (Dejana 2004). 
While the TJ’s comprise mainly claudins and JAM’s (Junctional Adhesion 
Molecules) (Furuse 2006), the major players of the adherens junctions are the 
cadherins, in endothelial cells, specifically VE-cadherin (Dejana 2004; Gumbiner 
2005). In addition to the AJ and TJ proteins, endothelial junctions also express Ig-
like Cell Adhesion Molecules which function both in inter-endothelial cell-cell 
contact as well as leukocyte adhesion and subsequent transcellular migration 
across the endothelial boundary (Carlos and Harlan 1994). Members of this family 
include ICAM-1, -2, VCAM and PECAM-1.  
1.2.1 Regulation of vascular permeability 
The endothelial barrier regulates vascular permeability to circulating cells and 
plasma proteins by maintaining its semi-permeable nature. The formation of an 
intact adherens junction between endothelial cells is necessary for the tight control 
of vascular permeability. Under resting conditions, junctional proteins restrict cell 
migration, inhibit proliferation and apoptosis and selectively allow 
macromolecules and cells, especially inflammatory cells across the endothelial 
layer (Lampugnani and Dejana 2007; Lampugnani and Dejana 2007). All these 
functions require loosening of the cell-cell junctions, and in a resting state, the 
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junctions remain closed, keeping the endothelial layer intact.  
 
As mentioned earlier, the AJs and TJs contribute to cell-cell contacts in endothelial 
cells. The TJs are present only in endothelia that require extremely tight regulation 
of permeability, for e.g., endothelia of the blood brain barrier. The AJs are more 
ubiquitous and undergo transient changes more frequently (Liebner, Cavallaro et 
al. 2006). The AJs usually contain transmembrane molecules that form hemophilic 
adhesions with one-another and act as active signal hubs. These transmembrane 
adhesion molecules are linked to specific intracellular partners, by which they 
maintain junction integrity through interaction with the cytoskeleton. Thus these 
intercellular junctions are not merely sites of physical interaction, they are 
important signaling hotspots, helping in transferring signals that regulate contact-
inhibited growth, apoptosis, gene expression and angiogenesis. 
 
ECs express a specific cadherin called Vascular Endothelial (VE)-cadherin at the 
AJ (Lampugnani, Resnati et al. 1992). The extracellular domain of VE-cadherin 
contains five cadherin-like repeats (EC1-5) that form rigid rod-like structures 
stabilized by calcium binding at the boundaries of each repeat. Homophilic 
adhesions between the extracellular domains of VE-cadherin in endothelial cell 
function has been demonstrated be essential for maintenance of resting 
permeability as function-blocking antibodies to VE-cadherin EC1 blocks 
angiogenesis both in-vitro and in-vivo (Carmeliet, Lampugnani et al. 1999; Liao, 
Li et al. 2000).  
 
Like classic cadherins, VE-cadherin acts through its cytoplasmic tail which is 
anchored to the catenins (directly-β catenin and p120 catenin; indirectly-α 
catenin), which in turn modulate polymerization of actin microfilaments, either 







 causes loss of interaction with the actin cytoskeleton and 
loss of cell-cell adhesion through dissociation of p120 catenin and β catenin 
respectively (Potter, Barbero et al. 2005). Regulation of VE-cadherin at 
intercellular junctions has been found to be carried out by activation of tyrosine 
kinases such as Src or by activation of phosphatases such as VE-PTP, PTP1B, 
PTPμ, and SHP-2 (Burden-Gulley and Brady-Kalnay 1999; Ukropec, Hollinger et 
al. 2000; Nawroth, Poell et al. 2002; Young, Sui et al. 2003; Weis, Shintani et al. 
2004; Wallez, Cand et al. 2007). 
 
Vascular permeability is necessary for the health of normal tissues and is greatly 
enhanced in various pathological conditions such as cancer and acute and chronic 
inflammation (Nagy, Benjamin et al. 2008). In a passive state, i.e. in physiological 
conditions, the molecules exchanged are gases, water, small molecules such as 
sugars and bigger proteins. A large part occurs through passive diffusion, while 
larger molecules pass through the transcellular and paracellular route. During 
physiological inflammation, factors released by immune cells such as histamine, 
serotonin, VEGF cause small and transient increases in vascular permeability. 
During pathological conditions, there is up regulation of permeabilizing factors, 
and possible down regulation of anti-permeability factors and vascular 
permeability is constitutively activated, leading to influx of material that may 
cause damage. 
 
In chronic inflammation, an immediate response is the release of inflammatory 
cytokines, many of which are potent permeabilizing factors (Wilhelm 1973). The 
inflammatory cytokines are responsible for three main functions; vasodilation, 
increased vascular permeability and leukocytosis or influx of immune cells into 
the inflamed tissue. Increased vascular permeability aids in the entry of immune 
cells, as well as to remove cellular debris.  
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In cancer, which is also a case of continuing inflammation, the new blood vessels 
are very leaky due to factors secreted by tumor cells and infiltrating immune cells. 
Leakiness of the vessels leads to excessive fibrin deposition in the tumor stroma 
(Nagy, Brown et al. 1989). This deposition leads to further infiltration of other 
plasma proteins and cells, and this provides a framework for tumor establishment 
and progression.  
 
Cancer metastasis involves local invasion, intravasation, survival in circulation, 
adhesion to the vascular bed, extravasation and colonization (Nguyen, Bos et al. 
2009). Tumor metastasis has been associated with hyper permeability of blood 
vessels, as the loosening of cell-cell junctions is required to aid both the 
intravasation of cells from the primary tumor into circulation, as well as to aid 
extravasation of cells into the metastatic site (Garcia-Roman and Zentella-Dehesa 
2013).  
1.2.2 Permeability regulators 
1.2.2.1 Permeability inducers 
VEGF: VEGF was first identified as Vascular Permeability Factor (VPF), purified 
as a tumor secreted factor that enhanced dye leakage (Senger, Galli et al. 1983). It 
was later that VEGF was identified as an angiogenesis factor. VEGF is a potent 
vascular permeability factor and is also involved in vasodilation (Ku, Zaleski et al. 
1993; Glass, Harper et al. 2006). It is a rapid permeability inducer, which causes 
fast, transient increases in endothelial permeability without causing damage to 
cells. The peak of permeability induced by VEGF is at 20 mins, following which 
permeability returns to basal levels. 
 
VE-cadherin associates with VEGF-R2, the receptor responsible for VEGFs 
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effects (Gavard and Gutkind 2006). In the absence of VEGF, VEGF-R2 is 
dephosphorylated by phosphatases and maintained in its inactive state. When 
activated (in the presence of VEGF), active VEGF-R2 is a tyrosine kinase, which 
activates the Src-Vav2-Rac1-PAK pathway, ultimately causing the 
phosphorylation of VE-cadherin at Ser-665. β-arrestin-2 binds to serine-
phosphorylated VE-cadherin and causes its internalization, or, in another scenario, 
Src can directly phosphorylate VE-cadherin at Tyr-685 and directly cause its 
internalization (Wallez, Cand et al. 2007). In vivo, inhibition of Src kinase inhibits 
vascular permeability as investigated by Evans Blue dye extravasation (Eliceiri, 
Paul et al. 1999). Phosphorylated VE-cadherin no longer binds its cytoplasmic 
partners; the catenins and actin and the cell-cell junctions open up to induce 
paracellular permeability. 
 
In pathological conditions such as tumors and acute inflammation, a natural 
response is the upregulation of VEGF levels (Weis and Cheresh 2005). In tumor 
stroma, VEGF-A induces the disruption of intercellular junctions, caveolae and 
fenestrations, which facilitate hyperpermeability and transvascular transport of 
macromolecules (Hobbs, Monsky et al. 1998; Monsky, Fukumura et al. 1999). 
Elevated level of VEGF and hence enhanced vascular permeability has also been 
reported in other pathological conditions, such as diabetic retinopathy, psoriasis, 
edema and other kinds of inflammations (Aiello, Avery et al. 1994; Dvorak, 
Detmar et al. 1995). Although VEGF induces both angiogenesis and vascular 
permeability, the permeability function of VEGF is not required for angiogenesis 
induction (Weis and Cheresh 2005). 
 
Histamine: Histamine is an amine stored in cytoplasmic granules of mast cells 
(Riley 1966; Hill 1990). It is a potent inflammatory mediator and acts locally on 
ECs, smooth muscle cells and fibroblasts in vivo. It transiently increases 
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endothelial permeability both in vitro and in vivo (Brigham and Owen 1975) (Wu 
and Baldwin 1992). Both in vitro and in vivo, the effects of histamine were rapid, 
with monolayer permeability peaking within 15 minutes of exposure to Histamine 
(Buckley and Ryan 1969).  
 
The receptor responsible for the role of histamine on vascular permeability is H1 
(Rotrosen and Gallin 1986). Upon receptor activation, interendothelial junctions 
are disrupted which enhance vascular permeability (Moy, Winter et al. 2000; 
Shasby, Ries et al. 2002). The RhoGTPases have been found to be responsible for 
the disassembly of the AJ and TJ of ECs upon histamine activation (Wojciak-
Stothard, Potempa et al. 2001). Histamine has been studied extensively and two 
distinct and inter connected mechanisms have been identified for the regulation of 
junctions in response to histamine exposure. On one hand, histamine induces cell 
contractility, which is induced by myosin-light-chain (MLC) phosphorylation. 
This leads to an increase in vascular permeability. On the other hand, histamine 
down regulates ZO-1 expression (a TJ protein) (Gardner, Lesher et al. 1996), in 
addition to causing phosphorylation of both TJ and AJ molecules (Shasby, Ries et 
al. 2002). Both these processes together cause disassembly of the inter-endothelial 
junctions to enhance vascular permeability.  
 
TSP1: The well known angiogenesis inhibitor Thrombospodin1 (TSP1) was found 
to regulate vascular permeability in addition to inhibiting angiogenesis. As 
mentioned earlier, as an angiogenesis inhibitor, TSP1 induces EC actin 
reorganization and affects cell-matrix adhesion and causes focal adhesion 
disassembly. Based on previous studies, it is evident that a structure-function 
relationship exists between barrier integrity and EC actin organization (Goldblum, 
Ding et al. 1993; Goldblum, Ding et al. 1994). Thus actin-reorganization of actin 
by TSP1 affects adherens junction proteins and ultimately leads to enhanced 
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vascular permeability in vitro (Goldblum, Young et al. 1999).  
 
The receptor responsible for TSP1 induced EC apoptosis, CD36, has been shown 
to associate to Src tyrosine kinases (Bull, Brickell et al. 1994). Src kinases are 
important regulators of the AJs as mentioned earlier (Wallez, Cand et al. 2007). It 
has been shown that TSP1 opens up an endothelial paracellular pathway by 
phosphorylating junctional proteins VE-cadherin, β-catenin and p120 catenin and 
does so by activating the EGFR/ErbB2 pathway (Garg, Yang et al. 2011). 
 
Transforming growth factor-β1 (TGF-β1): TGF-β1 is a cytokine belonging to 
the TGF-β superfamily. It is involved in a variety of biological functions ranging 
from development to adult tissue homeostasis (Walshe, Saint-Geniez et al. 2009; 
Wu and Hill 2009). TGF-β1 is secreted by multiple cell types including ECs, 
epithelial cells and immune cells such as macrophages. It plays an important role 
in inflammation and has been shown to have differential functions based on the 
type of tissue it is expressed in, and the microenvironment (Han, Li et al. 2012). 
Similarly, TGF-β1 has been shown to act as both angiogenesis inhibitor as well as 
stimulator depending on experimental conditions (Goumans, Liu et al. 2009). 
 
TGF-β1 induces endothelial paracellular permeability in vitro, and unlike rapid 
inducers like histamine and VEGF, permeability induction is slow and significant 
permeability induction is evident 24-48 hours post treatment (Shen, Li et al. 2011). 
This increase in permeability is accompanied by enhanced tyrosine 
phosphorylation of AJ and TJ proteins, namely, VE-cadherin and claudin-5. 
Although enhanced phosphorylation of the junctional proteins is evident as early 
as 30 minutes, this increases over time to correspond with increasing permeability.   
 
TGF-β1 up regulation has been implicated in multiple pathological conditions 
34 
 
where enhanced permeability and edema has been observed, such as acute lung 
injury (ALI) (Pittet, Griffiths et al. 2001), chronic obstructive pulmonary disease 
(COPD) (de Boer, van Schadewijk et al. 1998; Kanazawa, Tsunoda et al. 2001)), 
chronic ulceritis (Kanazawa, Tsunoda et al. 2001) etc.  
1.2.2.2 Permeability inhibitors 
Endostatin: As mentioned earlier, endostatin is a proteolytic fragment of collagen 
XVIII and is an endogenous angiogenesis inhibitor. It has been found to inhibit 
tumor growth in a variety of tumor types and there has been significant 
suppression of ocular cancers (Mori, Ando et al. 2001). Since VEGF has been 
found to be up regulated in several pathologies related to the eye, endostatin 
treatment has proven to neutralize the angiogenic effects of VEGF in these 
conditions. In an attempt to study the mechanism by which endostatin brings about 
this effect, Brankin and group found that endostatin inhibits VEGF-induced hyper-
permeability on retinal endothelial cells in vitro (Brankin, Campbell et al. 2005). 
In vivo too, endostatin inhibits VEGF-induced vascular permeability.  
 
Endostatin causes a dose-dependent increase in the expression of the TJ protein 
occludin, with no significant effect on the expression of ZO-1. It further enhances 
the serine/threonine phosphorylation of occludin , with no significant effect on 
tyrosine phosphorylation. The increased expression of occludin, as well as the 
increased phosphorylation serves to strengthen the TJs in the blood vessels, thus 
reducing the effect of VEGF on these vessels.  
 
Angiopoietin-1 (Ang-1): Both angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) 
are important regulators of the developmental and adult angiogenesis (Fagiani and 
Christofori 2013). Ang-1 and Ang-2 are naturally occurring antagonists of each 
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other and have opposing functions. Ang-1 is the ligand for the Tie-2 receptor and 
binding of Ang-1 leads to receptor activation. Ang-1 is expressed by a variety of 
cell types, but is mainly expressed by ECs and pericytes. During the angiogenic 
process, Ang-1 functions during the later stages of VEGF-induced angiogenesis, 
and functions mainly during vessel maturation and stabilization (Suri, Jones et al. 
1996). 
 
In vivo, conditioned media from cells over expressing Ang-1 attenuates 
permeability induced by vascular permeabilizing factors secreted by tumor cells 
(Stoeltzing, Ahmad et al. 2003). Also, over expression of Ang-1 by adenoviral 
gene transfer in mice inhibits VEGF-induced dermal permeability, as measured by 
Miles assay (Thurston, Rudge et al. 2000). Co-expression of VEGF and Ang-1 
also leads to the formation of leakage-resistant vessels (Thurston, Suri et al. 1999).  
 
The expression of Ang-1 has been reported to be up regulated in several cancers 
and there are many contrasting reports of the role of Ang-1 in tumorigenesis 
(Shim, Ho et al. 2007; Thomas and Augustin 2009). In some tumors, forced 
expression of Ang-1 leads to increased tumor growth, while in some, tumor 
growth is inhibited (Machein, Knedla et al. 2004; Nakayama, Yao et al. 2004). 
However, in both situations, Ang-1 plays the role of vessel maturation, probably 
due to higher pericyte coverage. 
 
Angiostatin: Angiostatin, the proteolytic fragment of plasminogen, also protects 
blood vessels from vascular leak in addition to being a potent angiogenesis 
inhibitor (Sima, Zhang et al. 2004). Angiostatin is down regulated in diabetic 
retinopathy, a condition characterized by excessive angiogenesis in the retina 
(Spranger, Hammes et al. 2000). The excessive angiogenesis is accompanied by 
extreme leakiness of the newly formed vessels, and up regulation of VEGF is one 
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of the main contributing factors (Murata, Nakagawa et al. 1996).  
 
Angiostatin reduces retinal vascular leak in mouse models of diabetic retinopathy 
in a dose-dependent manner.  It also significantly reduces VEGF-levels in the 
same model, which is possibly the mechanism by which vascular leak is reduced 
in this condition.  
1.3  Isthmin (ISM) 
ISM, a 60 kDa secreted protein, was first identified as part of the fgf-8 
synexpression group in the Xenopus midbrain-hindbrain organizer (xIsm) (Pera, 
Kim et al. 2002). Isthmin exhibits a distinct and complex expression pattern and 
when identified, it was postulated to be involved in the same biological process as 
Fgf-8 and other members of this group. ISM has a centrally located 
thrombospondin type 1 repeat (TSR) domain and a C-terminal domain called 
adhesion-associated domain in MUC4 and other proteins (AMOP) (Fig 1.7). The 
presence of the TSR domain in ISM suggests that ISM may function in regulating 
angiogenesis, as well as EC behaviour. The AMOP domain is a predicted protein 
domain which contains eight cysteine residues and like TSR, is mainly found in 
secreted and transmembrane proteins. Although the precise function of the AMOP 
domain is unknown, it is speculated to be involved in cell adhesion due to its 
presence in cell-adhesion molecules (Ciccarelli, Doerks et al. 2002). The AMOP 
domain in ISM also contains a ‘KGD’ motif. This motif is commonly found in 
many antagonists of platelet aggregation and has been shown to be involved in 
integrin-dependent cell adhesion and tumor metastasis (Johansson 1999; Nykvist, 




Figure 1.7 Domain structure of ISM 
TSR: Thrombospondin type-1 Repeat 
AMOP: Adhesion-associated domain in Muc-4 and Other Proteins 
 
Sequence analysis has revealed mammalian orthologs of xIsm. Human ISM shares 
78% overall amino acid identity with xIsm, sharing strong sequence conservation 
in the TSR domain (88%) (Pera, Kim et al. 2002). During the neuronal stage, xIsm 
was found to be highly expressed in the isthmus organizer, with additional 
expression being observed in the paraxial mesoderm and neural folds in the tail 
bud stage as well as in notochord in the neuronal stage. Similar to Xenopus, ism is 
expressed at high levels in the developing midbrain-hindbrain boundary and 
notochord of zebrafish (Xiang, Ke et al. 2009). The notochord is known to play an 
important role in zebrafish development including vascular development. 
Morpholino knockdown of the ism gene in zebrafish embryos results in obvious 
patterning defects of the trunk intersegmental vessels (ISV). In contrast, 
vasculogenesis, such as formation of the dorsal aorta and axial vein are not 
affected, which implies that ism may specifically influence angiogenesis.  
 
Recombinant mouse ISM inhibits angiogenesis both in vitro and in vivo (Xiang, 
Ke et al. 2009). Full-length ISM suppresses EC vascular tube formation in vitro in 
a dose-dependent manner. The C-terminal AMOP domain alone is sufficient to 
inhibit tube formation in vitro, which suggests that the anti-tube formation activity 
of ISM is largely mediated by the AMOP domain (Xiang, Ke et al. 2009).  
 
ISM inhibits VEGF and bFGF EC proliferation in a dose-dependent manner, but 
has no significant effect on EC migration. Further, ISM induces caspase-
dependent EC apoptosis in the presence of pro-survival factors VEGF, bFGF or 
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serum. However, none of the ISM truncates designed can induce apoptosis which 
suggests that the full-length protein is required for this function (Xiang, Ke et al. 
2009). In vivo, recombinant ISM inhibits VEGF/bFGF-induced angiogenesis in a 
modified Matrigel plug assay. In a pathological setting, B16 melanoma cells stably 
over expressing ISM show significantly reduced xenograft tumor growth. The 
reduction in tumor growth is accompanied by reduction in tumor vessel density, 
reduced proliferation and increased apoptosis.  
EC receptors for ISM 
 
 
Figure 1.8 Receptors recognized by ISM and the signaling pathways 
ISM binds to αvβ5 and triggers apoptosis via activation of caspase 8. ISM binds to 
cell-surface GRP78 and is internalized via a clathrin-dependent pathway. It is 
targeted to the mitochondria and leads to apoptosis by depleting ATP. Adopted 
from (Chen, Zhang et al. 2014) 
 
αvβ5: The integrin αvβ5 has been identified as one of the receptors on EC cells 
that mediate the functions of ISM (Xiang, Ke et al. 2011; Zhang, Chen et al. 
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2011). Integrins are transmembrane receptors that aid cell-matrix adhesions 
(Takada, Ye et al. 2007). They are usually functional as heterodimers of α and β 
subunits (Shimaoka and Springer 2003). Both α and β subunits consist of a large 
extracellular region, a transmembrane domain and a small cytoplasmic tail 
(Nermut, Green et al. 1988). The cytoplasmic domains of the integrins tether the 
molecules and thus the cell to actin filaments, while the extracellular domains bind 
to ECM components such as collagen, vitronectin, fibronectin, laminin etc. The 
extracellular domains can also function as co receptors to other cell-surface 
receptors, thus mediating their function.  
 
Figure 1.9 Integrins are expressed on multiple cell types aiding in 
angiogenesis and pathogenesis of cancer  
1: In endothelial cells, integrins regulate the migration, proliferation and survival 
necessary for angiogenesis, 2: Binding of integrin α4β1 on endothelial cells to 
vascular cell adhesion molecule 1 (VCAM1) on pericytes plays an important part 
in pericyte recruitment to the neovasculature, 3: Myeloid cells and monocytes in 
primary tumours secrete cytokines and growth factors that initiate angiogenesis 
and tumour cell migration, 4: Fibroblast infiltration into the primary tumour, 
known as desmoplasia, also contributes to tumour progression through increased 
growth factor secretion, 5: The invading fibroblasts deposit large amounts of 
collagen that might result in resistance to therapy in some tumours, 6: Platelet 
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expression of aIIbβ3 may be important for interacting with tumour cells through a 
fibrinogen bridge, possibly aiding in metastatic dissemination. Adapted from 
(Desgrosellier and Cheresh 2010) 
 
αvβ5, along with αvβ3, α1β1, α2β1 and α4β1, are expressed on ECs and have been 
shown to function in regulating angiogenesis (Silva, D'Amico et al. 2008) (Fig 
1.9). Binding of the integrin heterodimers leads to survival signaling through 
several mechanisms, including focal adhesion kinase (FAK), phosphatidylinositol 
3 kinase (PI3K)/protein kinase B (PKB), rho-family GTPases, nuclear factor-κB 
(NF-κB) and ras-mitogen-activated protein kinase (MAPK) (Eliceiri 2001; Martin, 
Slack et al. 2002; Smyth and Patterson 2002; Alghisi and Ruegg 2006). These are 
considered agonist-induced pathways for the integrin. In addition to the pro-
survival effect of integrins, antagonists of integrins lead to integrin-mediated death 
(IMD) and anoikis. Unligated or antagonized integrins may initiate pro-apoptotic 
signals (Desgrosellier and Cheresh 2010). Here anoikis denotes the apoptosis that 
occurs in response to the detachment from ECM (Frisch and Screaton 2001). 
Different from anoikis, IMD is apoptotic cell death triggered by recruitment and 
activation of caspase 8 by unligated or antagonized integrins (Stupack, Puente et 
al. 2001). ISM has been found to induce EC apoptosis through the αvβ5 integrin 
by IMD.  
αvβ5 and αvβ3 are the major integrins expressed in tumor and are involved in 
tumor angiogenesis (Takada, Ye et al. 2007) (Mizejewski 1999). In addition to the 
involvement of integrins in tumor angiogenesis, recent studies have shown that 
integrins also influence the response of other host cells, including pericytes, 
inflammatory cells (such as neutrophil and leucocytes) and fibroblasts, to facilitate 
tumor progression and angiogenesis (Desgrosellier and Cheresh 2010; Weis and 
Cheresh 2011). Although the β5 knockout mice show no obvious angiogenesis 
defects and developed normally, they showed abnormal responses to VEGF-A 
signaling (Eliceiri, Puente et al. 2002; Reynolds, Wyder et al. 2002). VEGF-A, 
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also known as the Vascular Permeability Factor, causes dissociation of the 
adherens junctions between endothelial cells and thus allows movement of 
molecules across the endothelial barrier.  This effect has been found to be 
dependent on the presence and ligation of αvβ5, i.e., function blocking antibodies 
to this integrin inhibit VEGF-induced increases in vascular permeability, and 
VEGF fails to cause an increase in permeability in β5 null mice (Eliceiri, Puente et 
al. 2002). How this effect is mediated by αvβ5 is not yet characterized.  
With increasing evidence of the involvement of integrins in angiogenesis, 
interactions of ISM with EC surface integrins were studied. ISM binds exclusively 
to αvβ5 integrin (Yong Zhang 2011). From in vitro and in vivo studies, it is evident 
that ISM inhibits angiogenesis through its effects on EC survival. ISM has been 
identified as a matricellular molecule which has differential effects on EC 
survival, based on its immobilization state. ISM, when immobilized, promotes EC 
attachment, integrin clustering and EC survival, functioning as a αvβ5 agonist.  
However, the soluble, non-immobilized form of ISM induces EC apoptosis and 
suppresses EC proliferation through its membrane receptor αvβ5, thus functioning 
as an antagonist. 
 
GRP78: Glucose-regulated protein of 78 kDa (GRP78), also referred to as binding 
immunoglobulin protein (BiP) or heat shock 70 kDa protein 5 (HSPA5), is a 
member of heat shock protein 70 kDa (HSP70) family (Mehta and Malik 2006). 
GRP78, as the name suggests, can be up-regulated in response to glucose 
deprivation and other cellular stresses, such as hypoxia and acidosis (Lee 2007). 
Traditionally, it is regarded as a central endoplasmic reticulum (ER) chaperon. It 
facilitates protein folding and assembly, and associates with misfolded protein. It 
helps in degradation of these misfolded proteins and serves as an ER stress sensor 
(Hendershot 2004; Lee 2005).  
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Recent studies have shown that GRP78 can localize to multiple sub cellular 
locations including the cell surface, mitochondria, nucleus, cytoplasm and as a 
secreted protein to mediate distinct cellular functions (Ni, Zhang et al. 2011) (Fig 
1.10). Importantly, cell surface GRP78 has emerged as an important regulator in 
tumor cell growth, progression, metastasis, angiogenesis and resistance to cancer 
therapy (Lee 2007). Cell-surface GRP78 has been shown to increase during stress, 
glucose-starvation and certain pathological conditions such as cancer. Thus, to 
target tumor cells, GRP78 seems to be a promising target. 
 
Cell surface GRP78 has been characterized to bind several ligands, including 
activated α2-macroglobulin (α2M*) (Misra, Deedwania et al. 2006), Kringle 5 
(Davidson, Haskell et al. 2005), Par-4 (Burikhanov, Zhao et al. 2009), cell-surface 
anchored proteins-Cripto (Shani, Fischer et al. 2008) and T-cadherin (Philippova, 
Ivanov et al. 2008). Through interactions with GRP78, these ligands participate in 
cellular signal transduction, inducing both pro-survival and pro-apoptotic 
pathways. GRP78 is known to be autophosphorylated both in vitro and in vivo 
(Leustek, Toledo et al. 1991; Carlino, Toledo et al. 1992). GRP78 also undergoes 
tyrosine phosphorylation upon binding its ligand α2M
*






Figure 1.10 Summary of GRP78 localization in different sub cellular 
compartments 
GRP78 is traditionally regarded as a major ER chaperone facilitating protein 
maturation and degradation, calcium binding and regulating ER stress signalling. 
However, it also exists in other subcellular compartments and acts in multifaceted 
cellular processes. For example, ER stress induces cell-surface expression of 
GRP78 and generates a cytoplasmic isoform through alternative splicing. Cell 
surface GRP78 emerges as an important regulator in cell signal transduction, 
viability and cancer-specific therapy. The cytoplasmic GRP78 is a newly 
characterized regulator of the ER stress signalling pathway. Beyond the ER, the 
secreted, mitochondrial and nuclear forms of GRP78 are involved in cellular 
homoeostasis and therapeutic resistance. C, cytoplasm; M, mitochondrion; N, 
nucleus. (Adopted from (Ni et al, 2011)) 
 
 
α2M* is a proteinase inhibitor interacting with cell surface GRP78 to promote 
proliferation, progression and metastasis of prostate cancer cells through 
activation of downstream PI3K/AKT pathways (Misra, Deedwania et al. 2006). 
Cripto binding to GRP78 causes activation of Src (Kelber, Panopoulos et al. 
2009). Cripto also forms a complex with GRP78 to inhibit TGF-β signaling, and 
thus enhance tumor growth. Additionally, activation of Src leads to activation of 
the transcription factor TF-II which enhances GRP78 promoter activity, thus 
regulating GRP78 activity during stress (Hong, Lin et al. 2005). GRP78 is also 
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expressed on the surface of activated ECs and can thus play a role in regulating 
angiogenesis (Bhattacharjee, Ahamed et al. 2005; Davidson, Haskell et al. 2005). 
Kringle-5 binds to EC GRP78 and induces apoptosis by disrupting the GRP78-
procaspase 7 complex. Cell-surface GRP78 is also known to be elevated in 
response to VEGF, aiding in VEGF-induced proliferation (Katanasaka, Ishii et al. 
2010) 
 
GRP78 has been identified as a high affinity cell surface receptor on ECs by our 
lab (Chen, Zhang et al. 2014). GRP78 mediates the anti-angiogenic and anti-
tumorigenic function of ISM. Further, GRP78 mediates the internalization of ISM 
through clathrin-dependent endocytosis and GRP78, along with ISM is targeted to 
the mitochondria. In the mitochondria, ISM blocks ATP transport into the 
cytoplasm and thus induces apoptosis.  
1.4  Gaps of knowledge in the functions of ISM 
Previous studies have shown that ISM is a novel endogenous angiogenesis 
inhibitor, with a role in pathological as well as development angiogenesis. As an 
angiogenesis inhibitor, it is unknown how ISM affects tumor metastasis. Further, 
the whole spectrum of physiological functions is still at its infancy. It thus 
becomes important to analyse the tissue expression pattern of ISM, especially in 
adult tissues.    
 
Two important functions of activated endothelia in an adult are angiogenesis and 
barrier permeability. ISM has already been characterized in regulating 
angiogenesis. ISM is known to bind the integrin αvβ5. Since ISM is expressed by 
lung ECs, and αvβ5 has been implicated in regulating vascular permeability (Su, 
Hodnett et al. 2007), how ISM regulates vascular permeability is interesting to 
study. Also, angiogenesis inhibitors have been implicated in the regulation of 
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wound healing, which is one of the physiological processes involving active 
angiogenesis. The role of ISM in regulating wound healing still remains to be 
determined. 
1.5  Aim and objectives of this study 
The aim of this project is to characterize additional functions of ISM, a novel 
angiogenesis inhibitor with tremendous potential as an anti-cancer drug. 
Knowledge of the full spectrum of functions is required in order to develop ISM-
based therapeutics.  
Specific objectives are: 
1) To establish the role of ISM in regulating vascular permeability  
2)    To determine how systemically administered ISM regulates tumor metastasis  




Chapter 2 MATERIALS AND METHODS 
2.1  Cell lines and culture conditions 
2.1.1 Isolation of Human Umbilical Vein Endothelial Cells (HUVECs) 
 
HUVECs used in this work were isolated from the freshly obtained human 
umbilical cord (Jaffe, Nachman et al. 1973). Umbilical cords were provided by 
consented maternal ward patients at the National University Hospital of Singapore 
according to the protocol (DSRB C/00/553) issued by the Singapore National 
University Health care Group’s Domain Specific Review Board (DSRB) ethics 
approval committee. Umbilical cord was stored at 4ºC in 1 Phosphate buffered 
saline (PBS) (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, 
pH7.4) after being collected from the placenta soon after birth. HUVECs were 
immediately isolated within 24 h.  Briefly, inside a sterile biosafety cabinet, both 
ends of the cord were cut transversely in order to insert adaptors into the vein. The 
adaptors were then tightly sealed by sterile suture threads. One adaptor was linked 
to a 50 ml syringe (Terumo, Philippines) for the flushing the cord. The umbilical 
vein was washed 3 times with 50 ml PBS to remove blood clots. Filter-sterilized 20 
ml of 0.2% collagenase (Sigma-Aldrich, USA) in PBS was injected into the vein. 
Both ends were clamped using clamping scissors on the rubber portions of two 
adaptors. The whole umbilical cord was incubated for 15 min at room temperature 
(RT) for enzymatic digestion. During this time, the cord was massaged gently to 
accelerate cell detachment. The HUVECs along with the collagenase were 
collected into a sterile 50 ml falcon tube. The umbilical vein was rinsed by 20 ml of 
PBS once more to flush all the residual HUVECs. The cells were spun down at 500 
g for 3 min. The cells were resuspended in 5 ml of Endogro-LS complete media 
(Millipore, Singapore) or CSC complete medium (Cell System Corporation, USA) 
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supplemented with 1% Gentamicin (Sigma-Aldrich, USA) and transferred into a T-
25 culture flask (NUNC, Denmark) pre-coated with 0.2% gelatin (Sigma-Aldrich, 
USA) in PBS. HUVECs were cultured at 37ºC in an incubator with 5% CO2. After 
2 h, HUVECs were able to attach to the plastic surface of the culture flask. Then 
medium was replaced with fresh one and HUVECs were cultured for future use.  
2.1.2 EC culture  
 
The HUVECs were cultured in EndoGRO-LS complete media or CSC complete 
medium supplemented with 1% Gentamicin in a 0.2% gelatin  coated T-25/T-75 
culture flask (Corning, USA) or 10 cm dishes (NUNC, Denmark) pre-coated with 
0.2% gelatin in PBS at 37ºC in a humidified incubator (Thermo Scientific, 
Singapore) with 5% CO2. Human Microvascular Endothelial Cells (HMVECs) 
were cultured EGM-2 MV complete media supplemented with 1% gentamycin 
(Invitrogen) in a 0.1% fibronectin coated T-25/T-75 dish. Cell culture medium was 
changed once every other day. When they reached around 80-90% confluence, 
HUVECs/HMVECs were washed once with PBS and rinsed by Trypsin-EDTA 
solution (Sigma-Aldrich, USA). The dish/flask was incubated at 37ºC incubator for 
2-3 min till the cells detached from the plastic surface. The trypsin-EDTA was 
neutralized using complete media. The cells were split into new gelatin pre-coated 
dishes/flasks at the passage ratio of 1:2 and cultured at 37ºC in a humidified 
incubator with 5% CO2. HUVECs and HMVECs within passage 3 to passage 8 
were used for all the experiments after which they may differentiate.  
2.1.3 Culture of cell lines  
 
In this study, several mouse and human cancer cell lines were obtained from 
American type culture collection (ATCC) – B16F10-Luc2 (mouse melanoma), 
4T1-12B (mouse mammary carcinoma), NIH3T3 (mouse embryo fibroblast), 
48 
 
HaCat (Human keratinocyte immortalized), HEK293T (human embryonic kidney 
epithelial cells). These cell lines were incubated in Dulbecco’s minimal essential 
medium (DMEM) (Sigma-Aldrich, USA) with 10% Fetal bovine serum (FBS) 
(Biowest, France) and 1% Penicillin-Streptomycin (PS) antibiotic solution (Life 
technologies, USA). The cells were cultured at 37ºC in a humidified CO2 incubator 
with 5% CO2.  Once reaching around 80-90% confluence, cells were trypsinized as 
explained before with 0.25% Trypsin (Life technologies, USA) and passaged at the 
ratio of 1:4 for further maintenance. 
2.1.4 Cell number quantification 
 
HUVEC, HMVEC or cancer cell lines were trypsinized and resuspended in a 
minimum volume of 1-5 ml culture medium. The quantification of cell number was 
done by using Nucleocounter NC-100 (Chemometec, Denmark). The cell 
suspension was mixed with an equal volume of Reagent A (Cell lysis buffer) and 
Reagent B (Stabilization buffer) in a 1.7 ml microcentrifuge tube (Axygen, USA). 
The lysate solution was vortexed and loaded into a nucleocassette by immersing its 
tip into the solution and pressing the piston. The nucleocassette was later inserted 
into the instrument slot. Then the program was run to calculate the cell number in 
the nucleocassette. Later, the cell number displayed on the screen was multiplied 
by 3 to obtain the cell number per ml in cell suspension.  
2.1.5 Cryopreservation and recovery of cell lines 
 
HUVECs, HMVECs or the cancer cell lines at 80-90% confluence were trypsinized 
as mentioned before and were spun down at 200 g for 3 min. The cell pellets were 
resuspended in their culture medium containing 5-10% Dimethyl sulfoxide 
(DMSO) (Freshney 1994). Around 4105 cells were transferred into a 1 ml 
cryovial. Cryovials were sealed tightly and placed in Mr. Frosty (Thermo 
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Scientific, USA) which provides the critical -1ºC/min cooling rate required for 
successful cell cryopreservation and recovery. Then the Mr. Frosty was placed in -
80ºC freezer (Sanyo, Japan) for 24 h before transferring inside cryovials into liquid 
nitrogen tank (Thermo Scientific, USA). Cell thawing and recovery was performed 
with rapid thawing by submerging cryovials in a 37ºC water bath (Memmert, 
Germany). The cells were centrifuged at 200 g for 3 min to remove DMSO and 
resuspended in fresh culture medium. After that, the cells were seeded onto a T-25 
flask/10 cm dish for further incubation. 
2.2  Transient transfection of cells 
Branched polyethylenimine (bPEI) (Sigma-Aldrich, USA) was used to transient 
transfect cell types that are easy to reach high efficiency, such as HEK293T cells, 
with desired plasmids. The cells were seeded in a 10 cm dish or a 6-well plate 
(Greiner bio-one, Germany). Once reaching 70-80% confluence, the cells were 
washed with PBS once and changed into fresh complete medium. The transfection 
mix possesses 10% of the volume of the culture medium (1 ml for 10 cm dish and 
200 µl for 6-well plate). It was comprised of DNA: bPEI in a ratio of 3:4 in PBS. 
Endotoxin free plasmid DNA of 10 µg or 2 µg was used for transfection for 10 cm 
dish or 6-well plate respectively. The 1 mg/ml bPEI working solution in sterile 
MilliQ H2O was stored in -20ºC and thawed before use. This transfection mix was 
vortexed and incubated at 37ºC for 20 min before adding onto the cells drop wise.  
2.3  Concentration of conditioned medium 
The conditioned medium (CM) was harvested after transfection and incubation 
with serum free medium for 48 h. Two distinct methods were applied for the 
concentration of CM according to the downstream application. For functional tests, 
Amicon Ultra-15 Centrifugal Filter Units (Millipore, USA) with appropriate 
molecular weight cut off membrane was used for the CM concentration and buffer 
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exchange. CM in the filter unit was centrifuged at 4,500 rpm for 15 min (Beckman 
Coulter, USA) to obtain a 75 concentrated CM (200 µl). This filter unit can be re-
filled with MilliQ H2O and centrifuged for another three times to desalt the protein 
solution. The obtained protein was quantified and stored in -80ºC till further use.  
For assays that do not require intact protein such as western blotting (WB), the CM 
concentration was performed by acetone precipitation. -20ºC pre-cooled acetone 
with 4 times of the sample volume was added into the CM, mixed and kept at -
80ºC for 2 h to overnight. The precipitated total protein was spun down at 4,500 
rpm for 15 min. The protein pellet was air-dried to remove residual acetone at RT 
for 30 min and dissolved in 200 µl of 2 SDS-loading dye (100 mM Tris-Cl (pH 
6.8), 20% (v/v) glycerol, 4% (w/v) SDS (sodium dodecyl sulfate), 200 mM β-
mercaptoethanol and 0.2% (w/v) bromophenol blue). Then the sample was boiled 
at 100ºC on a heat block (Techne, Germany) for 5 min and analyzed by WB.    
2.4  Cell lysis 
Briefly, cells were rinsed twice with PBS. Then RIPA lysis buffer containing 50 
mM Tris-HCl pH7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 
0.1% sodium dodecyl sulfate, 5 mM EDTA, 1 protease inhibitor cocktail solution 
(Roche, Germany) and 2mM Sodium Orthovanadate  was added drop wise on the 
cells. The cells were immediately harvested by cell scraper (SPL Life Science, 
Korea), transferred into a 1.7 ml tube and incubated on a nutator (Labnet 
International, USA) at 4ºC for 30 min. The residual cell debris was removed by 
centrifugation at 13,000 rpm at 4ºC for 10 min. For WB analysis, the supernatant 
was quantified, mixed with SDS-loading dye and boiled as above described. 
2.5  Quantification of protein concentration 
Protein concentration was quantified by Bradford protein assay. BSA standard (10 
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mg/ml) was prepared prior to the assay. A serial of BSA standard dilutions were 
prepared between 0-500 µg/ml. Standard dilutions and protein sample (20 µl) were 
added into 96 well plate in triplicate (Nunc, Denmark) and mixed with 180 µl of 
the filtered 1Bradford reagent (Bio-Rad, USA). The absorbance at 595 nm was 
measured by a microplate reader (Bio-Rad, USA). Based on the standard curve, the 
protein concentration was automatically calculated.  
2.6  Western Blotting 
2.6.1 Sodium dodecyl sulfate - Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
6-15% polyacrylamide gel was used according to the molecular weight of the 
protein band and was manually casted in Mini-PROTEAN

 3 Cell (Bio-Rad, USA) 
SDS-PAGE apparatus following the manufacturer’s instruction. Briefly, the clean 
glass cassette with a 1.5 mm spacer was secured in a casting frame. Resolving gel 
was prepared by mixing 1.5 M Tris-Cl (pH 8.8) and 30% acrylamide/bisacrylamide 
solution (37.5:1, acrylamide/bis; Bio-Rad, USA) in different proportions based on 
the percentage of the gel, 150 µl of 10% (w/v) SDS solution and 150 µl of 10% 
(w/v) ammonium per sulfate (APS) and made upto 15 ml with MilliQ H2O. The 
mix was completed by adding 8 µl of TEMED and poured into the gel cassette. 
MilliQ H2O was added on the top of resolving gel to produce a smooth surface. 
Once the gel is solidified, the MilliQ H2O was decanted and 5% stacking gel was 
poured. 8 ml stacking gel contained 5.5 ml H2O, 1.3 ml of 30% 
acrylamide/bisacrylamide solution, 1 ml 0.5 M Tris.Cl (pH 6.8), 80 μl of 10% SDS, 
80 μl of 10% APS, and 8 μl TEMED. The comb was inserted into the stacking gel 
and allowed to solidify. The settled gel cassette was carefully removed from the 
casting frame and placed into the Mini-PROTEAN

 3 electrophoresis module 
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assembly. The SDS-running buffer (15 g/L Tris base, 72 g/L Glycine, pH 8.3, SDS 
5g) was filled into the inner and outer chamber of the tank. The comb in the gel 
was gently removed. The protein marker (Bio-Rad, USA) and samples were loaded 
into the wells. The electrical leads were connected to a power pack and run at 100 
V for 1.6 h. 
To visualize protein bands, the resolving gel was carefully transferred into a 20 cm 
culture dish and stained with filtered Coomassie blue staining solution (0.1% 
Coomassie R250, 10% acetic acid, 40% ethanol in 1L of H2O) for 1 h with 
vigorous shaking (GFL, Germany). The gel was immersed in destaining solution 
(10% acetic acid, 5% ethanol) with 2 knotted Kimwipes and shaken for 1 h. After 
that, the destining buffer was replaced with fresh one and the gel was destained 
overnight till the protein bands are clear. The gel was placed on a gel illuminator 
(Hoefer, USA) and its photo was taken by a digital camera (Cannon, Japan). 
2.6.2 Gel transfer 
 
Proteins separated by SDS-PAGE were transferred into the nitrocellulose 
membrane (Bio-Rad, USA) by wet electroblotting transfer system (Bio-Rad, USA). 
Briefly, the nitrocellulose membrane, 6 sheets of chromatography papers 
(Whatman, UK) and foam pads were pre-soaked in transfer buffer (48 mM Tris, 39 
mM glycine, 0.04% SDS, 20% methanol). Gel covered by the membrane was 
sandwiched between 3 chromatography papers on each side followed by a foam 
pad in the plastic holder. Care was taken to avoid any bubble in this step. Then the 
holder was inserted into the cassette placed inside the electrophoresis system. It 
was made sure that the membrane faced the positive electrode. A bio-ice cooling 
unit was placed into the tank. After that, the transfer buffer was poured into the 
tank. The protein transfer was performed at 100V for 1 h.  
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2.6.3 Immunoblotting  
 
The nitrocellulose membrane with transferred protein was placed in a plastic box 
and blocked by 10 ml of 1% BSA in 1 Tris buffered saline (50 mM Tris-Cl, 150 
mM NaCl, pH to 7.6) with 1% tween-20 (TBST) at RT with gentle shaking for 2 h. 
The blocking solution was replaced by the primary antibody with appropriate 
dilution prepared in 1% BSA in 1 TBST with 0.2% sodium azide and incubated 
overnight at 4ºC with shaking. After incubation, the primary antibody solution can 
be collected and reused for the next WB. The membrane was washed for three 
times with TBST for 10 min each on a shaker. The matching secondary antibody 
conjugated with horse radish peroxidase (HRP) in 1% BSA in TBST was added to 
the membrane and incubated at RT with shaking for 1 h. This was followed by 
three times washes with TBST for 10 min each on a shaker.  
2.6.4 Chemiluminescent detection 
 
After immunoblotting, the HRP activity was detected by enhanced 
chemiluminescent substrate (Thermo Scientific, USA). In a dark room equipped 
with red light, equal volumes of the luminol/enhancer and the peroxide buffer were 
mixed and added drop wise on the membrane. After 5 min incubation, the 
membrane was transferred into the developing cassette and covered with a plastic 
sheet. An X-ray film (Kodak, USA) was placed on the plastic sheet and exposed for 
appropriate time. The film was developed by an automated X-ray film processor 
(Kodak, USA).  
2.6.5 Stripping and re-probe 
 
The immunoblotting on the nitrocellulose membrane was removed by washing the 
membrane in the stripping buffer (1.5% glycine, 0.1% SDS, pH 2.2) with shaking 
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at RT for 15 min. The membrane was further washed thrice with 1TBST before 
blocking with 3% BSA in TBST (or) 5% milk, depending on the primary antibody 
to be used. The re-probing was done as above mentioned.  
2.7  Expression and purification of recombinant ISM protein in E. coli 
The recombinant ISM protein with C-terminal 6His tag was expressed by the 
pETm-ISM plasmid (Xiang, Ke et al. 2011) upon isopropyl-beta-D-thiogalactoside 
(IPTG) induction in E.coli BL21 (DE3). Then His-tagged recombinant ISM (rISM) 
was purified by Ni-NTA affinity chromatography in 6 M urea according to the 
manufacturers’ protocol (Promega, USA). After that, rISM was further purified by 
reverse-phase high-performance liquid chromatography (HPLC) using a 
Phenomenex Jupiter 300 C18 column. Protein purity was estimated by SDS-PAGE 
combined with Coomassie blue staining. Endotoxin content of rISM was measured 
using Limulus Amebocyte Lysate PYROGENT kit (Cambrex, USA) following the 
manufacturer’s instruction.  
 
2.8  Expression and purification of recombinant ISM protein in 
mammalian cells 
The recombinant ISM protein with C-terminal 6His tag was expressed by the 
pSecTag-2B plasmid (Xiang, Ke et al. 2011) that can be expressed in mammalian 
systems. HEK293T were transfected with the overexpression plasmid and the 
conditioned media containing the His-tagged protein was concentrated before 
being purified by Ni-NTA affinity chromatography according to the manufacturers’ 
protocol (Promega, USA). Buffer exchange into water was carried out by 
centrifugal filtration using Amicon®-centrifugal filters (Millipore, USA) with MW 
cutoff of 50000.   Protein purity was estimated by SDS-PAGE combined with 
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Coomassie blue staining. Endotoxin content of rISM was measured using Limulus 
Amebocyte Lysate PYROGENT kit (Cambrex, USA) following the manufacturer’s 
instruction.  
2.9 Immunofluorescent Staining 
HUVECs were grown on 0.2% gelatin coated coverslip and treated with 1μM his-
tagged ISM for different time points according to the experiment. Then cells were 
fixed with 4% PFA in PBS (pH 7.3) at RT for 30 min. After fixation, the cells were 
washed trice 10 min each by PBST (PBS with 0.1% Triton) and permeabilized with 
0.3% Triton in PBS at RT for 15 min. Then the cells were again washed and 
blocked with 1% BSA in PBST at RT for 1 h. After blocking, the cells were 
incubated with the appropriate primary antibody overnight at 4°C. This was 
followed by washing for 3 times 10 min each with PBST at RT. The cells were then 
incubated with the appropriate secondary antibody at RT for 1 h. After wash, the 
cells were counter stained by 1 µg/ml DAPI (Chemicon, USA) in PBS to label the 
nucleus. To mount the stained cells to a glass slide, a drop of mounting solution 
(50% glycerol and 50% PBS) was applied on the slide. The coverslip with cells 
facing the slide was adhered to the slide by the mounting solution. The edge of the 
coverslip was sealed by transparent nail polish. Fluorescent images were collected 
by Zeiss LSM 510 Meta confocal microscope (Zeiss, Germany).  
2.10  In vitro cell-based assays 
2.10.1 EC Tube formation assay 
 
EC tube formation assay was performed using ECMatrix
®
 in vitro angiogenesis 
assay kit (Chemicon, USA) according to the manufacturers’ instruction. The 
matrigel was prepared in a 4ºC room. The gel solution and diluent buffer were 
thawed on ice. Then 100 µl of diluent buffer was mixed with 900 µl of gel solution 
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in a sterile microcentrifuge tube and mixed well. The gel solution of 10 µl was 
plated into a µ-Slide Angiogenesis chamber (ibidi, Germany) and kept at 37ºC for 1 
h to solidify. Then cells were treated with 1μM rISM for additional 30 min before 
being plated onto the polymerized matrigel. The cells were incubated at 37°C 
incubator with 5% CO2 for 6–8 h before documenting the tubular structure 
formation using Axiovert 200 inverted light microscope (Zeiss, Germany). 
Capillary length from representative fields was quantified by NIH ImageJ. 




) were seeded in each well of a 96-well plate. After overnight 
incubation at 37°C, the cells were starved for 3 h in basal medium. Following 
starvation, cells were treated with 1 μM ISM for 24 hours. Apoptosis was detected 
by a Cell Death ELISA kit (Roche, Germany). Briefly, the 96-well plate was 
centrifuged at 200 g for 10 min and the media were discarded carefully. The cells 
were lysed by 200 µl of lysis buffer at RT for 30 min and again centrifuged. 20 µl 
of the supernatant was transferred into the streptavidin coated microplate and 80 µl 
of immunoreagent containing anti-histone-biotin and anti-DNA HRP-conjugated 
antibody for 2 h at RT with vigorous shaking. The microplate was washed trice 
with the incubation buffer. Then 100 µl of substrate solution was added into the 
microplate and incubated at RT with shaking for around 20 min till the color 
development was sufficient for a photometric analysis. The reaction was terminated 
by adding 100 µl of stop solution. The absorbance at 405 nm was measured in a 
microplate reader. 
2.10.3 In vitro vascular permeability assay 
Dextran flux across post-confluent HUVEC monolayers was used as a measure of 
endothelial permeability. FITC-labelled dextran (MW 2,000,000 – Sigma Aldrich, 
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St. Louis, MO) was used as the permeability tracer. 200,000 cells were seeded on 
0.2% Gelatin-coated 1.0 μ transwell inserts (BD Biosciences, CA, USA). The cells 
were cultured in complete media (EndoGro-LS) undisturbed for 48-72 hours 
following which they were starved in starvation media (EndoGro-LS without 
supplements + 2% FBS) for 3 hours (0.5 ml in the lower chamber and 0.2 ml in the 
upper chamber). The starvation media was then replaced with treatment solution 
which contained different doses of ISM, TGF-β1 (10 ng/ml) (Sino Biologicals Inc, 
China), Histamine (100 μM) (Sigma Aldrich, St. Louis, MO) (or) TNF-α (2 nM) 
(Sinobiologicals Inc, China) depending on the experiment. The doses of ISM used 
were 50 nM, 100 nM, 250 nM, 500 nM and 1 μM. For VEGF-stimulation of 
HUVEC monolayers, 50 ng/ml VEGF (Sino Biological Inc, China) was added 20 
mins prior to assessment of permeability.  
 
For assessment of permeability, following treatment, 150 μl of FITC-dextran 
solution was added to the upper chamber at a concentration of 0.4 mg/ml and the 
inserts were shifted to another well with 0.5 ml of fresh media. 5 mins later, 0.1 ml 
of solution from the lower chamber was transferred to a 96 well plate and 
fluorescence intensity at 485/530 nm was measured, which gave a measure of 
permeability. In some experiments, the monolayer was treated with the pan-caspase 
inhibitor Z-VAD-fmk (1, 5, 20 μM) (Millipore, Germany), the Src kinase inhibitor 
PP1 (2, 20 μM) (Sigma Aldrich, St. Louis, MO), neutralization antibodies to αvβ5 
(P1F76, Santa cruz Biotechnology, CA) or GRP78 (E-4, Santa cruz Biotechnology, 
CA) for 2 hours prior to ISM treatment, endocytosis inhibitors Nystatin (5, 10, 25 
μg/ml) (Sigma-Aldrich, USA) and chlorpromazine (1.5, 3, 6 μg/ml) (Sigma-
Aldrich, USA).  
2.11  Co-immunoprecipitation  
Antibodies of GRP78 or Src antibody of 1 μg were pre-immobilized on 20 μl 
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protein A/G agarose beads (Santa Cruz, USA) for 1 h at RT. Unbound antibodies 
were removed by 100 mM Tris-HCl (pH 8.0). Then 1 mg whole cell protein lysates 
were incubated with anti-GRP78 or anti-Src antibody mounted beads at 4°C 
overnight. Anti-GRP78 or anti-Src antibody mounted beads alone were used as the 
control. After removing the unbound proteins by 100 mM Tris-HCl (pH 8.0), 
precipitates were resolved and analyzed for the presence of GRP78 or Src by WB. 
2.12  ISM internalization assays 
HUVEC monolayers were treated with 1 μM ISM for increasing times. Then cells 
were washed by acidic PBS (pH 3.5) to remove cell surface binding ISM and 
examined for internalized ISM by WB using anti-his (C-term) antibody 
(Invitrogen, USA) (procedure adapted from (Xiao, Garner et al. 2005)). 
 






cells of B16F10-Luc2 (or) 4T1-12B lines were injected into 
the tail vein of C57Bl/6J or Balb/c mice respectively to analyse the effects of 
systemically administered ISM on experimental metastasis. 6-8 mice were 
randomized in each group. In one experimental set-up, 100 ul of rISM was injected 
into the lateral tail vein 15 minutes before tumor cell injection (10 mg/kg dose). 
100 μl (B16F10-Luc2) or 250 μl (4T1-12B) of uniform cell suspension were 
injected into the tail vein of restrained mice using a 27 gauge needle (Becton 
Dickinson, USA). Tail veins were dilated by hyperthermia using an infra-red lamp, 
for easy insertion of the needle. Immediately after injection, mice tails were 
compressed with cotton swab to prevent blood loss. 100 ul of recombinant ISM 
solution at a dose of 10 mg/kg was injected in the lateral tail vein every 3 days or 
every 2 days after the homing of tumor cells based on the experiment. Animals 
were monitored daily and body weight recorded weekly. The experiment was 
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terminated when the mice showed signs of sluggishness. Mice were sacrificed by 
CO2 asphyxiation and lungs excised. Tumor nodules on the surface of lungs were 
counted. Half the lungs were fixed in 4% paraformaldehyde and the rest were snap-
frozen in liquid nitrogen. 
2.14  IVIS live mice imaging  
Mice in the experimental tail vein metastasis assay were monitored by the IVIS® 
spectrum live imaging system. Mice received an intraperitoneal route (ip) injection 
of a luciferin solution (200 × stock solution 30 mg/ml in PBS, dose of 150 mg/kg) 
that is allowed to distribute in conscious animals for about 5-15 minutes. The mice 
were then placed into a clear plexiglass anesthesia box (supplied with 2.5-3.5% 
isofluorane) that allows unimpeded visual monitoring of the animals using IVIS® 
Spectrum Imaging System 3D Series to track and monitor the homing of tumor 
cells to the lung in vivo. Images were captured on the every 2 or 3 days till the end 
of the experiment. 
2.15  Immunohistochemistry (IHC) 
After fixation with 4% PFA in PBS overnight, tumors o) skin sections were 
dehydrated by an increasing series of ethanol and then infiltrated with the paraffin 
(Sigma-Aldrich, USA). Briefly, tumors cut in equal size were transferred from PFA 
to 50% ethanol with shaking for 6 h at RT. Then tumors were incubated with 70% 
ethanol at 4°C overnight. Next day, tumors were further dehydrated with 90% 
ethanol for 2 h and 100% ethanol for 1 h. The tumors were incubated in histoclear 
(Sigma-Aldrich, USA) at RT for 3 h with a fresh histoclear replacement every hour. 
Then tumors were incubated with fresh histoclear at 4°C overnight with shaking.  
Next day, the tumors were submerged in melted paraffin (65°C) for 6 h and 
incubated with fresh paraffin at 65°C overnight. The following day, tumors were 
allowed to solidify in freshly-changed paraffin at RT.  
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The embedded solid tumor or organ was stuck to a wooden block and mounted on a 
microtome (Riechert-Jung Inc., Germany). The tumor tissue was sectioned at 5 µM 
and its paraffin sheets were carefully transferred into a 42°C water bath and 
allowed to spread. The sections were adhered to a polysilane coated glass slide 
(Thermo-Scientific, USA) and dried on a 40°C glass slide drier (Riechert, 
Germany) overnight. The slides were stored in a slide box till further use at RT.  
 
Paraffin-embedded tissue sections were deparaffinized by heating at 60°C for 7 
minutes before deparaffinizing in histoclear followed by the rehydration in a 
decreasing series of alcohol (100%, 90%, 80%, and 70% ethanol in ddH2O) and 
finally 5 min incubation in PBS. Antigen was retrieved in a bench-top 2100-
Retriever following the instruction of the manufacturer (Electron Microscopy 
Sciences, PA). The sections were blocked with 1% BSA in PBS in a humidified 
chamber at RT for 2 h followed by overnight incubation with the anti–VE-cadherin 
(the marker for vasculature), anti-PCNA (the marker for proliferation), anti-GRP78 
(for lung sections), anti-ISM (for lung and skin sections) or anti-F4/80 (the marker 
for macrophages) (Santa Cruz Biotechnology, USA) (1:500 dilution) at 4°C. After 
removing the unbound antibody by 3 times wash with PBST, the sections were 
incubated with the appropriate Alexa Fluor 568 or 488 secondary antibodies (Life 
Technologies, USA) for 1.5 h at 37°C. Sections were washed again by PBST and 
counter stained by 1 μg/ml DAPI at RT for 10 min.  
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was 
performed on tumor sections for detecting apoptotic cells by an in situ cell death 
detection kit (Roche, Germany). The tumor sections were deparaffinized, antigen-
retrieved and blocked as described before. Each slide was treated with 50 µl of 
TUNEL reaction mixture containing 5 µl of enzyme solution (Terminal 
deoxynucleotidyl transferase) and 45 µl of label solution (nucleotide mixture) in a 
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dark humidified chamber at 37°C for 1 h. The sections were washed with PBST 
and counter stained with DAPI.  
 
The images of sections were acquired using Zeiss Axiovert 200 or Zeiss LSM 510 
Meta microscope and analyzed by NIH ImageJ. For quantification, three random 
fields were analyzed in each section, three sections were selected from each tumor 
and two tumors were chosen from each group.     
2.16  In vivo Miles Permeability Assay. 
In vivo permeability assays were performed on 8-10 week old Balb/c mice as 
described by Miles and Miles (Miles and Miles 1952). Animal care and 
experimentation was carried out following institutional guidelines approved by the 
local institutional animal care and use committee (IACUC; protocol 078/08). For 
the dermal permeability assay, 100 μl of 1% Evans Blue dye solution (Sigma 
Aldrich, St. Louis, MO) was injected intravenously into Balb/c mice. 10 minutes 
later, different doses of ISM (500 ng, 1 μg and 10 μg), VEGF (50 ng), TGF-β1 (50 
nM) (or) PBS control (50 μl) were injected intradermally on the shaved dorsum of 
the mice. 20 minutes later, the mice were sacrificed and injection sites were excised 
for evaluation of dye extravasation.  
 
To study systemic permeability, 100 μl of ISM was injected intravenously (10 
mg/kg) at different time points before Evans Blue dye injection. Following animal 
sacrifice, organs were harvested and extravasated dye was quantified. Dye was 
extracted from the skin (or) organ samples by immersion in formaldehyde at 50
0
C 
for 3 days, following which readings were taken at 620 nm.  
2.17  In vivo wound healing assay 
Wounds of 4 mm diameter were created on the shaved dorsum of 8-10 week old 
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Balb/c mice. Animal care and experimentation was carried out following 
institutional guidelines approved by the local institutional animal care and use 
committee (IACUC; protocol 066/12). Maximum of 3 wounds were created on 
each flank of the mouse. The left flank wounds were treated with saline control 
(PBS) while the right flank wounds were treated with different doses of ISM. The 
treatment solution was mixed with 20% w/v PF-127 solution (Pluronic F-127, 
Sigma Aldrich, St. Louis, MO) so that it formed a gel at temperature above 10°C. 
This gelling prevented treatment solution run off. Wounds were treated once daily 
till the end of the experiment and wound measurements were conducted once daily. 
The mice were sacrificed when control wounds closed and wounded skin was 
harvested for further analysis. Half the skin samples were fixed in 4% PFA for 
immunohistochemistry while the rest were snap frozen for protein analysis. 
2.18  Statistical analysis  
Data were expressed as standard errors of the mean (±SEM) for in vivo 
experiments and standard deviation (±SD) for in vitro experiments. Statistical 













Chapter 3 RESULTS 
               PART I-Expression pattern of ISM in adult tissues 
3.1  ISM is expressed in cells of epithelial and endothelial origin in adult 
mouse tissues 
To clarify the function of Ism, it is important to know where this gene is expressed. 
An initial characterization of the expression pattern of Ism mRNA in mouse tissues 
by RT-PCR revealed expression in various tissues including spleen, liver, brain, 
heart, kidney, muscle, lung and pancreas with the highest expression levels in the 
lung and brain (Zhang, Chen et al. 2011). To further analyze the relative protein 
levels of ISM in normal adult tissues, I first performed an ELISA (Enzyme-linked 
immunosorbent assay) using a rabbit polyclonal anti-ISM IgG that was purified 
using an antigen-coupled purification process. As shown in Fig. 3.1 A, ISM is 
expressed in relatively higher levels in the lung, stomach and pancreas compared to 
the other tissues tested. This expression pattern was confirmed using western 







Figure 3.1 Expression of ISM in different tissues 
A) ELISA using anti-ISM IgG; 3 repeats performed; B) Protein expression using 
anti-ISM IgG 
 
Once the protein levels in different mouse tissues were analysed, we wanted to 
determine the tissue localization of ISM. Immunohistochemistry (IHC) using rabbit 
polyclonal anti-ISM IgG was performed on paraffin-embedded mouse tissues. To 
test the specificity of the anti-ISM-IgG, the IHC results were confirmed using in-
situ hybridization (ISH) using DIG-labelled RNA probes (Fig. 3.2A). Both ISH and 
IHC confirmed the expression of ISM and distinct patterns of expression in the 
bronchiolar epithelium of the lung. Staining was also observed in the endothelial 
cells of the blood vessels in the lung. ISM’s receptor αvβ5 has been shown to be 
expressed by both epithelial cells and ECs in vivo (Knight and Holgate 2003) (Su, 
Hodnett et al. 2007). Later, when GRP78 was identified as a high affinity receptor 
for ISM, co- localization of ISM and GRP78 in the lung was studied. To analyse 
the localization of ISM and its receptor GRP78 in the normal lung, 
immunofluorescence was performed. ISM and GRP78 co localized to the bronchial 
epithelia and ECs (Fig. 3.2A). 
 
Using immunohistochemistry, the expression pattern of ISM in the mouse brain 
was analyzed. Though ISM’s expression in the brain was ubiquitous, specific 
expression was observed in the dentate gyrus of the hippocampus (Fig. 3.2 B). The 
staining found was cytoplasmic and granular. 
 
ISM was expressed mainly in the epithelial and endothelial basement membranes 
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along the renal tubules in the kidney (Fig 3.2 C). Expression was mainly observed 
in the proximal tubules and the collecting ducts. 
 
The spleen acts as a primary blood filter in the body. It is the major site for blood 
reserves and also aids in immune responses (Swirski, Nahrendorf et al. 2009). IHC 
of the spleen showed ISM expression in the germinal centers and in monocyte-like 
cells (Fig 3.2 D).  
 
ISM expression was observed in the crypts of the fundic vili, as well as along the 
vili in the glandular cells (Fig. 3.2 E). The glands at the base of the stomach are 
enteroendocrine cells which secrete and respond to various hormones and chemical 
mediators like histamine, gastrin, endorphins, serotonin etc (Krause, Yamada et al. 
1985). 
 
The skin is the primary barrier between the body and the environment and consists 
of an outer epidermal later and an underlying dermal layer rich in connective tissue 
and collagen. Strong staining was observed in the epithelial layer of the epidermis, 
as well as in the developing hair follicles in the dermal layer. Weak staining was 
observed in the endothelial cells of the dermal layer too (Fig 3.2 F) 
 
In the pancreas, ISM expression was observed in the basement membrane of the 
acinar cells (Fig 3.2 G). The acinar cells are the functional units of the pancreas. 
The islet of langerhans showed little or no expression of ISM.  
 
In the mouse testis, spermatocytes and developing spermatids showed significant 
expression of ISM (Fig 3.2 H). The sertoli cells and spermatogonia had relatively 

















Figure 3.2 Expression of ISM in various tissues 
A) ISM is expressed in the bronchial epithelia and ECs as determined by ISH and 
IHC; ISM and its receptor GRP78 expression colocalize in the bronchial epithelia 
and ECs of the lung; B) ISM is expressed in the dentate gyrus of the hippocampus 
in the brain; C) ISM is expressed in the collecting tubules and ducts of the kidney; 
D) ISM is expressed in the germinal centers and monocytes of the spleen; E) ISM 
is expressed in the crypts of the fundic vili, GC-glandular cells; F) ISM is 
expressed in the epidermis (E), hair follicles (HF) in the dermal (D) layers and 
endothelial cells (EC); G) ISM is expressed in the acinar cells (AC) of the 
pancreas; H) ISM is expressed by the sertoli cells (SC) and spermatocytes of the 
testis. Scale bars represent 50 μm. Negative controls included are tissue sections 
treated with only secondary antibody (no primary antibody). 
 
Summary: 
In most of the tissues tested, ISM was expressed in cells of endothelial or 
epithelial origin. ECs and epithelial cells are known to express angiogenesis 
regulators and it is possible that ISM may be secreted as part of this pool in these 
cells. Since EC staining was observed in the skin and lung tissues, these tissues 
were selected for further analysis of ISM’s functions.  
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   PART II – Role of ISM in regulating vascular permeability 
3.2  ISM is a novel vascular permeability inducer 
Previous work from our lab has identified integrin αvβ5 as an EC cell-surface 
receptor for ISM (Xiang, Ke et al. 2009) (Zhang, Chen et al. 2011). Integrin αvβ5 
was reported to play an important role in pulmonary hyper permeability after acute 
lung injury (Su, Hodnett et al. 2007). Since ISM is present at high level in lung, 
we hypothesized that ISM may be involved in regulation of vascular permeability.  
3.2.1 ISM induces endothelial monolayer permeability in vitro 
3.2.1.1 Validation of functionality of ISM using mammalian cell 
produced ISM 
It has been previously reported that recombinant ISM produced from E.coli 
functions as an angiogenesis inhibitor through inducing apoptosis of ECs, 
inhibiting EC proliferation and inhibiting tube-formation in vitro (Xiang, Ke et al. 
2009). To confirm that bacteria produced ISM faithfully maintained the function 
of mouse ISM, mammalian cell produced recombinant ISM was also generated 
and its activity in angiogenesis compared with bacteria produced ISM. Human 
embryonic kidney cell line HEK293T was transiently transfected with an ISM-
expression plasmid and recombinant ISM was purified from conditioned culture 
media. Purified ISM was run on an SDS-PAGE gel and stained with Coomassie 
Blue to assess purity (Fig 3.3 A). The recombinant proteins were also transferred 
to nitrocellulose membranes and probed with anti-ISM antibody (produced in 
rabbit) to identify recombinant ISM. The major band after purification of ISM 
from both E.coli and HEK293T was observed at 60 kDa and 68 kDa respectively. 
The observed molecular weight of ISM produced by mammalian cells was slightly 
higher possibly due to post-translational modifications. ISM (293T) was found to 
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induce EC apoptosis and inhibit tube-formation in a dose-dependent manner, with 
similar potency as E.coli produced ISM in the in vitro assays (Fig 3.3 B, C). It 
seems that bacteria produced ISM has retained the full anti-angiogenic activity of 
mammalian ISM protein. Thus, in this work bacteria-produced ISM has been used 










Figure 3.3 Mammalian cell produced ISM inhibits in vitro angiogenesis and 
induces EC apoptosis 
A) Coomassie stained SDS-PAGE gel and western blots using anti ISM Ab 
showing purity and MW of recombinant ISM produced in HEK293T and E.coli; 
B) Mammalian produced ISM induces EC apoptosis with similar potency of 
bacteria-produced ISM. Apoptosis is presented as relative level comparing to 
apoptosis under basal medium condition (2% FBS); C) ISM expressed and 
purified from HEK293T cells suppresses EC tube formation with similar potency 
as bacteria-produced ISM. * represents P<0.05 
 
3.2.1.2 ISM induces EC monolayer permeability in a dose-dependent 
manner 
To analyze whether ISM could regulate EC permeability in vitro, ECs were grown 
to confluence on multiwell inserts and treated with ISM. Confluent HUVEC 
monolayers exposed to various concentrations of ISM showed enhanced 
permeability, as measured by fluorescently labelled dextran (MW 200,000) flux 
across the post-confluent monolayers over a period of 16 hours (Fig 3.4 A). The 
experiment was also repeated using HMVECs. The lowest ISM concentration that 
significantly increased dextran flux in HUVEC monolayers was 250 nM, whereas 







A                            HUVEC 
 
B                              HMVEC 
 
Figure 3.4 ISM induces dose-dependent permeability of EC monolayers 
HUVEC monolayers were treated with different doses of ISM for 16 hours; B) 
HMVEC monolayers were treated with different doses of ISM for 16 hours * 
represents P<0.05 
3.2.1.3 ISM induces EC monolayer permeability in a time-dependent 
manner 
Vascular Permeability factors such as VEGF and histamine induce permeability 
rapidly over a short time period. On the other hand, cytokines such as TNF-α and 
TGF-β1 induce permeability slowly over a longer period of time. To analyze the 









permeability from 0 hr – 16 hrs post ISM treatment was investigated. ISM 
increased FITC-Dextran flux at time points >= 2 hrs following exposure, with 
further time-dependent increments up to 16 hours (Fig 3.5 A). The experiment was 
repeated on HMVEC cells, and a similar trend was obtained (Fig 3.5 B) 
A                            HUVEC 
 
B                              HMVEC 
 
Figure 3.5 ISM induces time-dependent permeability of EC monolayers 
A) HUVEC monolayers were treated with 1 μM ISM for time intervals from 0-
16 hrs; B) HMVEC monolayers were treated with 1 μM ISM for time intervals 










3.2.1.4 ISM potentiates permeability induced by rapid-inducers of 
permeability 
VEGF, also known as Vascular Permeability Factor (VPF) (Senger, Galli et al. 
1983), is a potent inducer of permeability and disrupts the EC monolayer barrier. 
Since ISM was initially described as an angiogenesis inhibitor which induced EC 
apoptosis in the presence of VEGF, we tested the effect of ISM on VEGF-induced 
permeability. The confluent monolayer was treated with ISM for 2 hrs prior to 
VEGF stimulation (50 ng/ml) for 20 minutes. As shown in Fig. 3.6A, ISM 
potentiated VEGF-induced permeability in a dose-dependent manner.  
 
To study how ISM influences permeability induction by other permeability 
inducers, confluent HUVEC monolayers were treated with ISM alone or together 
with permeability inducers Histamine (100 µM), TNF-α (2 nM) and TGF-β1 (10 
ng/ml) respectively.  
 
Histamine, being a rapid permeability inducer like VEGF, enhances EC monolayer 
permeability within 15 minutes of exposure (van Nieuw Amerongen, Draijer et al. 
1998),(Wu and Baldwin 1992). HUVEC monolayers were treated with ISM for 2 
hours prior to histamine stimulation (100 μM) for 15 mins. ISM potentiated 
histamine-stimulated EC permeability in a dose-dependent manner (Fig 3.6 B).  
 
TGF-β1 (Behzadian, Wang et al. 2001) and TNF-α (Oku, Araki et al. 1987), each 
enhance EC monolayer permeability over a longer period of time (24-48 hours), 
similar to the permeability induced by ISM. Since TGF-β1 and TNF-α induce 
permeability over 16 hours, confluent HUVEC monolayers we treated with ISM 
alone or ISM in the presence of TGF-β1 or TNF-α for 16 hours. The increase in 
permeability in ISM treated samples were not significantly higher than 
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permeability triggered by either TGF-β1 or TNF-α alone (Fig 3.6 C, D). These 
results suggest that ISM may enhance permeability through mechanisms similar to 
slow permeability inducers, and may potentiate the effect produced by rapid 
permeability inducers such as VEGF. 
 
Figure 3.6 ISM potentiates permeability induced by rapid-inducers of 
permeability 
A) ISM potentiates permeability induced by (A) VEGF (50 ng/ml) and B) 
Histamine (100 μM); ISM has no effect on C) TGF-β1 (2 nM) and D) TNF-α (10 
ng/ml) induced permeability. * represents P<0.05 
3.2.1.5 ISM induces dose-dependent increase in dermal permeability in 
vivo 
To test if ISM could also induce vascular permeability in vivo, Miles assay was 
performed (Miles and Miles 1952). Briefly, Evan’s blue dye was distributed 
systemically through tail vein injection of Balb/c mice. Subsequently, different 
doses of ISM were administered intradermally into the shaved back skin. Control 
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animals received an equal volume injection of PBS. The animals were sacrificed 
15 minutes later and the area of skin that included dye extravasations were 
removed and the dye was extracted using formamide. The amount of the extracted 
dye indicates the extent of vascular permeability.  Compared to the controls, ISM 
could induce localized dye leakage at sites of injection within 15 minutes, in a 
dose-dependent manner (Fig 3.7 A). Quantification of the dye per mg tissue was 
plotted and the lowest dose that significantly enhanced dermal permeability was 1 
μg (Fig 3.7 B). Also, in spite of slow induction of permeability in vitro, 
permeability induced in vivo was quick, comparable to VEGF induced 













Figure 3.7 ISM induces dose-dependent increase in dermal permeability 
ISM at different doses was injected intradermally on shaved back skin of Balb/c 
mice. A) Permeability was measured by injecting Evans Blue dye (0.1% solution) 
prior to ISM injection and then analyzing dye leakage at localized sites of ISM 
injection; B) The extravasated dye was measured at OD 620. N=4 animals per 
group, 3 spots of injections per flank. * represents P<0.05 
 
3.2.1.6 ISM potentiates VEGF-induced dermal permeability 
In vitro, ISM induced EC monolayer permeability gradually; however, in vivo, 
significant permeability was induced within 15 minutes of ISM injection. To test 
whether ISM can potentiate VEGF-stimulated permeability in vivo, ISM and 
VEGF were injected together after Evans blue dye injection. Consistent with the in 
vitro situation, ISM also potentiated VEGF-induced permeability in vivo (Fig 3.8 
A, B). However, since VEGF is a very potent permeability inducer in vivo, only 












Figure 3.8 ISM potentiates VEGF-induced dermal permeability 
ISM at different doses was mixed with 50 ng VEGF and injected intradermally on 
shaved back skin of Balb/c mice. (A) Permeability was measured by injecting 
Evans Blue dye (0.1% solution) prior to ISM injection and then analyzing dye 
leakage at localized sites of ISM/VEGF injection; (B) The extravasated dye was 
measured at OD 620. N=4 animals per group, 3 spots of injections per flank. * 
represents P<0.05 
3.2.1.7 ISM does not influence TGF-β1-induced dermal permeability 
TGF-β1 induces EC monolayer permeability in vitro only after extended periods, 
usually between 16-48 hours of EC exposure to TGF-β1. In vivo, TGF-β1 induced 
Evans Blue dye leakage within 15 mins of intradermal injection with high potency. 
However, addition of ISM along with TGF-β1 did not significantly potentiate TGF-
β1- induced permeability (Fig 3.9 A, B). This is consistent with the lack of 
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Figure 3.9 ISM has no effect on TGF-β1-induced dermal permeability 
 ISM at different doses was mixed with 50 nM TGF- β1 and injected intradermally 
on shaved back skin of Balb/c mice. A) Permeability was measured by injecting 
Evans Blue dye (0.1% solution) prior to ISM injection and then analyzing dye 
leakage at localized sites of ISM/TGF- β1 injection; B) The extravasated dye was 
measured at OD 620. N=4 animals per group, 3 spots of injections per flank. * 
represents P<0.05 
3.2.1.8 Systemically administered ISM enhances vascular permeability 
in lung and stomach of mice in a time-dependent manner 
To evaluate the vascular leakiness induced by ISM systemically, ISM was injected 
intravenously at a dose of 10 mg/kg and permeability was measured at different 
time points using MILES assay. PBS was injected in control animals. Different 
organs were harvested and dye extravasation from these organs was quantified at 
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OD 620 (Fig 3.10 C).  
 
Five organs were harvested to assess permeability; lung, kidney, liver, heart and 
stomach. In general, all the organs displayed a basal level of dye leakage. However, 
the lung and stomach showed the highest rate of dye leakage within 15 minutes 
(Fig 3.10 A, B). An increase was observed up to 1 hour following ISM 
administration, following which there was a decrease in observed permeability. At 
24 hours following ISM administration, the dye leakage had reached basal levels in 
all the organs tested.  
 
The potency of ISM in inducing systemic permeability was compared to VEGF-
induced permeability (Fig 3.10 D). While VEGF induced permeability in all of the 
organs tested at 15 minutes post treatment, ISM induced significant permeability 












Figure 3.10 ISM enhanced permeability of lung and stomach within 15 mins 
of ISM administration (Balb/c) 




Blue Dye was injected intravenously. 20 mins later the mice were sacrificied and 
organs were collected and weighed for dye extraction with formamide. A) 
Quantification of extravasated dye from the lungs at OD 620; B) Quantification of 
extravasated dye from stomach at OD 620; C) Representative pictures of organs 
after dye extraction in formamide; D) Comparison of potency of ISM (10 mg/kg) 
and VEGF (0.1 mg/kg) in inducing  systemic permeability at 15 mins. N=4 
animals per group, * represents P<0.05. 
 
To validate the activity of ISM in regulating systemic permeability, the same assay 
was performed in C57/Bl6 mice. As in the previous experiment, ISM was 
administered intravenously at a dose of 10 mg/kg and the MILES assay was 
performed.  
 
Dye extravasation was analysed at 15 minutes, 30 minutes, 1 hour and 24 hours 
following ISM treatment. PBS was injected into control animals. 20 minutes before 
animal sacrifice, 0.1% Evans blue was injected intravenously. Both in the lung and 
stomach, significant increase in dye leakage was observed 30 minutes and 1 hour 
following ISM treatment (Fig 3.11 A, B). This effect returned to basal levels 24 
hours following treatment.  
 
Taken together, these results revealed that ISM is a novel vascular permeability 
factor. It not only enhances EC monolayer permeability in vitro, but also potently 
triggers mouse dermal permeability following a localized increase in ISM 
















Figure 3.11 ISM enhanced permeability of lung and stomach within 15 mins 
of ISM administration (C57/Bl6) 
ISM was administered intravenously at various time points following which Evans 
Blue Dye was injected intravenously. 20 mins later the mice were sacrificied and 
organs were collected and weighed for dye extraction with formamide.  A) 
Quantification of extravasated dye from the lungs at OD 620; B) Quantification of 
extravasated dye from stomach at OD 620; C) Representative pictures of organs 





3.2.2 Mechanism of ISM-induced vascular permeability 
3.2.2.1 ISM induces tyrosine phosphorylation of inter-cellular junctions 
The paracellular permeability of the endothelial barrier is regulated by inter-
endothelial junctions. Two types of junctions are present at cell-cell boundries in 
confluent endothelial cells – AJ (adherens junctions) and TJ (tight junctions). AJs 
and TJs function to promote adhesion between cells of an endothelial barrier and 
thus restrict the passage of matter across the barrier (Mehta and Malik 2006). It is 
known that EC monolayers, undergo increased tyrosine phosphoryation of 
junctional proteins, especially AJ proteins upon stimulation by mitogenic growth 
factors such as VEGF/VPF. (Esser, Lampugnani et al. 1998). 
 
The tyrosine phosphorylation status of post-confluent EC monolayers after ISM 
exposure was analyzed. Following serum starvation, ECs showed minimal 
tyrosine phosphorylation of junctional molecules, which implied intact 
boundaries. Stimulation with VEGF/VPF for 20 mins increased the tyrosine 
phosphorylation at boundaries. Exposure to ISM alone for 2 hrs showed a 
considerable increase in tyrosine phosphorylation. However, this effect was not as 
potent as VEGF/VPF. Interestingly, exposure to ISM for 2 hrs before VEGF 
stimulation potentiated VEGF-induced tyrosine phosphorylation, compared to 
VEGF-alone stimulated control (Fig 3.12 A). The intensity at the inter-cellular 
junctions was quantified and plotted (Fig 3.12 B). Western blot analysis of lysates 
for phospho-tyrosine (pY99) revealed increased tyrosine phosphorylation in the 
ISM treated samples (Fig 3.12 C). However, there was no significant potentiation 
of VEGF-stimulation of tyrosine phosphorylation, probably since VEGF is a very 
potent inducer. These results warranted a study of molecules that undergo tyrosine 










Figure 3.12 ISM induces tyrosine phosphorylation of inter-cellular junctions 
A) Post-confluent HUVEC were exposed to ISM for 2 hrs following 4 hours 
starvation. They were then stimulated with 1 nM VEGF/VPF for 20 mins. Cells 
were fixed, permeabilized and stained for phospho-tyrosine (pY99). White 
arrows indicate cell-cell junctions; B) Inter-cellular junction intensities were 




3.2.2.2 ISM causes loss of VE-cadherin and β-catenin from inter-cellular 
junctions 
The AJs of adherent cells are predominantly composed of vascular endothelial 
cadherins (VE-cadherin) (Dejana 2004). The integrity of the AJs is very critical 
for maintaining the endothelial barrier, which in turn is important in regulating 
vascular permeability. Disruption of VE-cadherin homophilic adhesions leads to 
loosening of cell-cell adhesions, thus leading to an increase in paracellular 
permeability. VEGF/VPF is known to cause loss of VE-cadherin from cell 
junctions (Kevil, Payne et al. 1998). Therefore, it was analyzed whether exposure 
of the monolayers to ISM, in the presence and absence of VEGF/VPF had an 
effect on the localization of VE-cadherin at cell junctions (Fig 3.13 A, B). In post-
confluent HUVEC monolayers, VE-cadherin localized to cellular junctions with 
the formation of strong hemophilic adhesions. In the presence of VEGF 
stimulation, VE-cadherin at cellular junctions was greatly reduced with the 
appearance of thinner boundaries between cells. Exposure to ISM alone also 
reduced VE-cadherin staining at cellular junctions; however, this effect was more 
pronounced in the samples stimulated with VEGF following exposure to ISM. In 
these samples, VE-cadherin staining became discontinuous and occasionally 
disappeared from cellular boundaries. In addition to loss of VE-cadherin, ‘gaps’ 
appeared in the monolayer upon ISM exposure. A time-course analysis of VE-
cadherin was performed to analyze its localization with time as ISM-induced 
permeability was time-dependent. VE-cadherin staining at cell-cell junctions 
reduced over time and was almost completely disrupted at 16 hours following ISM 
treatment (Fig 3.13 C). This was also the time-point at which there was maximum 
ISM-induced permeability in the in vitro assay. 
 
The localization of the cytoplasmic partner of VE-cadherin, β-catenin, was also 
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analyzed. ISM-treated samples showed reduced junctional β-catenin staining and 
this reduction were further potentiated in the samples treated with ISM and VEGF 
together (Fig 3.13 D, E).  
 
The observation that tyrosine phosphorylation was evident at cell-cell junctions, 
and consequently VE-cadherin and β-catenin were lost from cell-contacts 


















Figure 3.13 ISM treatment leads to changes in adherens junction molecules 
Post-confluent HUVEC were exposed to ISM for 2 hrs following 4 hours 
starvation. They were then stimulated with 1 nM VEGF/VPF for 20 mins. A) Cell 
were fixed and stained for VE-cadherin. White arrows indicate gaps in the 
monolayer; B) Inter-cellular junction intensities were quantified using Image-J; C) 
Time-course analysis of ISMs effect on VE-cadherin localization; D) Cells were 
stained for β-catenin; E) Quantification of inter-cellular junctions using Image-J.  
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 of VE-cadherin at 
time-points corresponding to increased monolayer permeability 




 by the 
tyrosine kinase Src upon VEGF stimulation. It is known that phosphorylation of 
either one of these residues is sufficient to disengage VE-cadherin at the inter-
cellular junctions and cause paracellular permeability. Thus, confluent HUVEC 
monolayers were treated with ISM for 6 hours (a time point at which significant 
permeability was induced) and the phosphorylation status of VE-cadherin was 
analysed. ISM induced phosphorylation of VE-cadherin at Y
658
 in a dose-and time-
dependent manner (Fig 3.14 A, B).  It also induced phosphorylation at Y
731 
in a 





 was more pronounced when the cells were pre-treated with ISM (Fig 




Figure 3.14 ISM induces phosphorylation of VE-cadherin 
A) ISM induces time-dependent phosphorylation of VE-cadherin at Y
658
; B) ISM 
induces dose-dependent phosphorylation of VE-cadherin at Y
658
; C) ISM induces 
dose-dependent phosphorylation of VE-cadherin at Y
731 
3.2.2.4 ISM increases phosphorylation of adherens junction molecules β-
catenin and p120 catenin 
The stability of the junctions and the actin-cytoskeleton tethering the junctions 
through VE-cadherin depends on the binding of β-catenin and p120 catenin to Y731 
and Y
658 
respectively (Dejana 2004). Based on the observation that ISM causes 
changes in localization of VE-cadherin and β-catenin at inter-cellular junctions and 
that ISM changes the phosphorylation pattern of these sites of VE-cadherin, the 
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phosphorylation of β-catenin and p120 catenin were analyzed. 
 
Confluent monolayers of HUVEC were treated with ISM for 6 hours with and 
without VEGF stimulation for 20 minutes and the cells were lysed with RIPA 
buffer containing protease and phosphatase inhibitors. The lysates were 
immunoprecipitated with anti-phosphotyrosine antibody (pY99) and 
immunoblotted for β-catenin and p120 catenin. Untreated cells had minimal 
phosphorylated β-catenin and p120 catenin while VEGF stimulated cells had an 
increase in phosphorylated forms of these proteins (Fig 3.15 A, B). ISM treatment 
increased phosphorylation in a dose-dependent manner, while VEGF-stimulation of 
cells after ISM treatment led to potentiation of VEGF-induced phosphorylation of 






Figure 3.15 ISM induces phosphorylation of β-catenin and p120 catenin 
ISM causes dose-dependent increase in tyrosine phosphorylation of β-catenin and 
(B) p120 catenin 
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3.2.2.5 ISM-induced permeability is partially dependent on ISM-
induced apoptosis 
3.3.2.5.1 Signs of ISM-induced apoptosis occur as early as 4 hours 
following ISM treatment 
 
Previously, treatment of HUVECs with ISM was found to induce apoptosis, as 
detected by DNA fragmentation, within 24 hours. This is the latest stage of 
apoptosis that can be detected. ISM-induced permeability was observed as early as 
2 hours following ISM treatment. To study whether ISM-induced apoptosis had a 
role to play in ISM-induced permeability, it was important to analyze how early 
ISM-induced apoptosis was triggered.  
 
Morphological changes of HUVECs upon ISM treatment were observed by 
imaging. Morphological changes occur once apoptosis has been initiated in a cell. 
Morphological changes of apoptosis were observed as early as 6 hours following 
Isthmin treatment. Cells became more rounded and fragmentation of cells into 
apoptotic bodies was initiated (Fig 3.16 A) 
 
The exposure of Phosphatidyl-Serine (PS) residues on the outer surface of the cell 
membrane is the earliest event of apoptosis that can be recorded (Martin, 
Reutelingsperger et al. 1995). Annexin V (which recognizes PS residues) 
immunocytochemistry was performed on HUVEC treated with Isthmin, 2, 4 and 6 
hours following treatment. Annexin V staining was first observed after 4 hours of 









Figure 3.16 ISM-induced apoptosis is evident 4 hours following ISM 
treatment 
HUVEC were treated with ISM following 4 hours of starvation; A) Cells were 
observed for morphological changes with ISM treatment, floating cells, cells that 
have undergone fragmentation into apoptotic bodies, and cells that have rounded 
up were observed; VEGF concentration: 50 ng/ml; B) Cells were fixed and stained 
with Annexin V 2 hours and 4 hours following ISM treatment.  
3.2.2.5.2 Inhibition of ISM-induced apoptosis partially attenuates ISM-
induced permeability 
As shown above, HUVEC treated with ISM start to show signs of apoptosis as 
early as 4 hours following ISM exposure. Since ISM-induced permeability is 
significant by 6 hours following ISM-exposure, I hypothesized that ISM-induced 
permeability could be a result of ISM-induced apoptosis. While the pan-caspase 
inhibitor Z-vad-fmk at 20 μM almost completely inhibited ISM-induced apoptosis 
(96% reduction), permeability-induction was only partially attenuated (75% 
reduction) over a period of 16 hours (Fig 3.17 A, B). Caspase inhibition for 6 hours 
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attenuated ISM-induced permeability only by 40% (Fig 3.17 C), suggesting that 















Figure 3.17 Inhibition of ISM-induced apoptosis partially attenuates ISM-
induced permeability 
Confluent monolayers were treated with Z-VAD-fmk for 30 mins prior to ISM-
treatment for A, B) 16 hours; C) 6 hours. FITC-dextran-flux across the monolayers 
were measured after 16 hours and 6 hours respectively. 
 
3.2.2.5.3 Caspase-inhibition leads to retention of adherens junction 
molecules at inter-cellular junctions 
 
To analyze the effect of inhibition of ISM-induced apoptosis on junctional 
molecules, HUVEC were treated with ISM in the presence or absence of Z-VAD-
fmk for 6 hours. The cells were fixed and analyzed for VE-cadherin and β-catenin 
localization. Untreated HUVEC showed strong VE-cadherin and β-catenin staining 
at cell-cell junctions consistent with intact barrier function. ISM-treatment caused 
loss of VE-cadherin and β-catenin staining from cell-cell junctions. The pre-
treatment of monolayers with Z-VAD-fmk prior to ISM-exposure attenuated the 
loss of these molecules from the junctions; however, disruption of contacts was still 
observed, consistent with the partial inhibition of permeability with inhibition of 
apoptosis (Fig 3.18). 
 
These results suggest that ISM-induced permeability is, in part, dependent on ISM-
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induced apoptosis. Since ISM induces permeability over a longer period of time 
(16 hours post treatment), apoptosis may be contributing to disruption of inter-




Figure 3.18 Effect of caspase inhibition on cell-cell junctions 
Following caspase inhibitor treatment, cells were fixed and stained for VE-
cadherin and β-catenin to analyse junction changes. VE-cadherin and β-catenin 
were retained at junctions following caspase inhibition; however junctional 
disturbances were still seen. 
3.2.2.6 ISM affects adherens junctions in vivo 
To analyze the effect of ISM on vascular permeability in vivo, skin samples 
receiving localized injection of ISM were collected for protein expression 
analysis. Different spots with injections of 500 ng and 10 μg ISM were analyzed 
for changes in activation states of molecules involved in AJ formation. Although 
no significant increase in general tyrosine phosphorylation was observed upon 
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ISM injection, ISM significantly enhanced activation states VE-cadherin and β-
catenin and interestingly, there was also an increase in Src activation in vivo (Fig 
3.19). 
 
These results show that ISM affects AJ molecules in vitro and in vivo, leading to 




Figure 3.19 ISM affects AJ molecules in vivo 
Protein lysates from skin collected after 15 minutes of ISM injection were probed 
for phospho-tyrosine (pY99) and the phosphorylated forms of VE-cadherin and β-





3.2.2.7 ISM activates Src kinase at time-points corresponding to 
increased permeability 
Since ISM-induced the disassembly of the adherens junction, we analysed the 
activation status of the Src tyrosine kinase. Src is responsible for the 




. Also, both the 
receptors of ISM; αvβ5 and GRP78; have been to known to be associated with Src 
activity. At 6 hours following ISM treatment, Src was found to be activated (as 
detected by levels of pY
416
). Activation of Src seems to be ISM dose-dependent. 
ISM-induced Src activation was potentiated after VEGF stimulation (Fig 3.20 A). 
Since Src activation also influences FAK activation upon integrin ligation 
(Eliceiri, Puente et al. 2002) (Shen, Park et al. 2005), ISMs effect on FAK was 
analyzed. No significant effect of ISM treatment on FAK activation was observed 
(Fig 3.20 B). This suggested that an alternative pathway may be involved in Src 





Figure 3.20 ISM induces Src activation 
Confluent monolayers were treated with ISM for 6 hours following which lysates 
were probed with (A) pSrc Y
416 





3.2.2.8 Inhibition of Src activation leads to attenuation of ISM-induced 
permeability 
Using a chemical inhibitor of Src activation, PP1, the effect of Src activation on 
ISM-induced permeability was attentuated. HUVEC monolayers were treated with 
different doses of PP1 for half an hour before treatment with 1 μM ISM for 6 
hours. At lower doses of PP1, ISM still induced monolayer permeability, however 
at a higher dose of Src inhibition, ISM-induced permeability was reduced to basal 
levels (93% reduction) (Fig 3.21 A). However, 16 hours following ISM treatment, 
a time-point at which ISM potently induces apoptosis, blocking Src activation 
reduced ISM-induced permeability only by 62% (Fig 3.21 B).  
 
This implies that at 16 hours following ISM-exposure, ISM enhances EC 









Figure 3.21 Inhibition of Src activation attenuates ISM-induced permeability 
A) Treatment of HUVEC monolayers with PP1, followed by ISM treatment for 
6 hours leads to complete attenuation of ISM-induced permeability; B) 
Treatment of HUVEC monolayers with PP1, followed by ISM treatment for 16 
hours leads to partial attenuation of ISM-induced permeability. * represents 
P<0.05 
3.2.2.9 ISM induces permeability via signaling through its receptors 
αvβ5 and GRP78 
αvβ5 and GRP78 are 2 known ISM receptors on ECs. GRP78 was a recently 
identified high affinity receptor for ISM with nM affinity (Chen, Zhang et al. 
2014).Neutralization of both these receptors led to attenuation of ISMs role in 
inducing EC apoptosis (Zhang, Chen et al. 2011). To identify the receptor 
responsible for ISM-induced permeability, antibodies were used to block these 
receptors sequentially.  
 
αvβ5 blocking using Anti-αv/β5 (P1F76) had no significant effect on basal 
permeability, however, VEGF-induced permeability was reduced in a dose-
dependent manner. Partial reduction of ISM-induced permeability was also 
observed, both on its own and in the presence of VEGF (Fig 3.22 A). Interestingly, 
blocking GRP78 with Anti-GRP78 (A-10) on HUVEC monolayers led to a more 
pronounced effect on ISM-induced permeability. Although no effect on VEGF-
induced permeability was observed, blocking GRP78 attenuated ISM-induced 
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permeability in a dose-dependent manner (Fig 3.22 B). Thus ISM induces 





Figure 3.22 ISM induces permeability through signaling via αvβ5 and GRP78 
HUVEC monolayers were pre-treated with blocking antibodies to A) αvβ5 
(Anti-αv/β5 P1F76) or B) GRP78 (Anti-GRP78 A-10) 1 hour prior to 
treatment with 1 μM ISM for 6 hours. FITC-dextran flux was analysed, * 





3.2.2.10 ISM induces Src activation through GRP78 
It is known that GRP78 can function as a cell-surface receptor in addition to its 
role in the endoplasmic reticulum (Shani, Fischer et al. 2008). Since GRP78 was 
identified as a cell-surface receptor for ISM on ECs (Chen, Zhang et al. 2014), 
whether it mediates ISM-induced Src activation was investigated. Src activation 
was analysed after neutralizing GRP78 on the cell surface. Since Src is also 
downstream of αvβ5 signaling, function blocking antibodies to this receptor was 
also used and Src activation in response to ISM was also analysed. Blocking 
GRP78 attenuated ISM-induced Src activation in a dose-dependent manner (Fig 
3.23 A). Although there was partial inhibition of ISM-induced permeability with 
αvβ5 blockage, no effect was seen on ISM-induced Src activation (Fig 3.23 B). 
These results show that although ISM-induced permeability is mediated by both 
αvβ5 and GRP78, ISM-induced Src activation was solely mediated by ligation of 





Figure 3.23 ISM induces Src activation through GRP78 
Antibodies against GRP78 lead to reduction of ISM-induced Src activation after 6 
hours of ISM-exposure; B) Neutralization of αvβ5 does not affect ISM-induced 
Src activation after 6 hours of ISM-exposure 
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3.2.2.11 ISM internalization is important for ISM-induced Src 
activation and permeability 
ISM has been shown to be internalized through clathrin-dependent 
endocytosis via its cell-surface receptor GRP78 (Chen, Zhang et al. 2014). 
Since blocking GRP78 led to attenuation of ISM-induced Src activation, 
the effect of blocking internalization on ISM-induced Src activation was 
analysed. Nystatin (inhibitor of lipid-raft mediated endocytosis) and 
Chlorpromazine (inhibitor of clathrin-mediated endocytosis) (Ivanov 2008) 
were used at different doses for pre-treatment of confluent monolayers for 
30 minutes following which the cells were treated with 1 μM ISM for 6 
hours. Cells pre-treated with Chlorpromazine failed to undergo Src 
activation following ISM treatment in a dose-dependent manner (Fig 3.24 
B), whereas the Nystatin treated samples showed no effect on ISM-induced 
Src activation during similar conditions (Fig 3.24 D). Only inhibition of 
clathrin-dependent endocytosis could attenuate ISM-induced permeability 
(Fig 3.24 A, C). Additionally, Src inhibition using the Src kinase inhibitor 
PP1 did not affect internalization of ISM, which implies that Src activation 
occurs after ISM internalization (Fig 3.24 E). These results showed that 
ISM-induced Src activation was mediated by GRP78, and GRP78-mediated 




















Figure 3.24 ISM-induced Src activation and vascular permeability is mediated 
by GRP78-mediated internalization of ISM 
HUVEC monolayers were pre-treated with different doses of A, B) 
Chlorpromazine or C, D) Nystatin  for 30 minutes prior to 6 hours of 1 μM ISM 
treatment. The lysates were then probed for activated Src (pY416); E) HUVEC 
monolayers were pretreated with 20 μM PPI for 30 mins prior to ISM treatment for 
different time points. Internalized ISM was analysed by probing for c-His-tag.  
3.2.2.12 GRP78 potentially interacts with Src in vitro in response to ISM 
binding 
Although GRP78 has been implicated to function as a receptor kinase    (Carlino, 
Toledo et al. 1994; Misra, Sharma et al. 2005; Kelber, Panopoulos et al. 2009), 
interaction of cell surface GRP78 with intracellular partners have not been 
reported. From the above results, ISM induced Src activation is dependent on ISM 
binding to GRP78. To analyze whether ISM binding to GRP78 induced interaction 
between GRP78 and Src, a co-IP was done using rGRP78 and rSrc (pure proteins). 
1 μg of rSrc protein was allowed to bind to anti-Src IgG bound protein A/G beads 
and 1 μg of rGRP78 protein was added to the mixture. However, no interaction 
was observed between rSrc and rGRP78 in this experimental set up. When ISM 
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was added to this mixture, interaction between Src and GRP78 was observed (Fig 
3.25). In an alternative experimental set up, control and ISM-treated HUVEC 
protein lysates were allowed to bind to either anti-Src IgG bound protein A/G 
beads (or) anti-GRP78 IgG bound protein A/G beads. Interestingly, even without 
ISM treatment, binding of GRP78 with Src was observed. However, there was an 
increase in interaction upon ISM treatment. For loading control, the supernatant 
after binding of whole cell lysate was analysed for β-actin (Fig 3.25). From these 
results, it seems that GRP78 potentially binds Src and this binding is enhanced 




Figure 3.25 GRP78 potentially interacts with Src in vitro in response to ISM 
binding 
Pure GRP78 and Src interact in the presence of ISM in the reaction mixture. 
GRP78 and Src from whole cell lysates potentially interact, and this interaction 







From Part II of my work, it is evident that ISM is a novel regulator of vascular 
permeability. Regulation of permeability is mediated by ISM-induced apoptosis as 

























                      PART III-Role of ISM in tumor metastasis 
3.3  ISM inhibits tumor metastasis in mice 
Both enhanced vascular permeability and angiogenesis inhibition can affect tumor 
metastasis. Since ISM regulates both vascular permeability and angiogenesis, in 
this part of my work, I studied how ISM influences metastasis using an 
experimental melanoma lung metastasis model in mice. 
3.3.1 Systemically delivered ISM causes transient increase in tumor cell 
homing, while also suppressing B16F10 melanoma metastasis in vivo  
3.3.1.1 Administration of ISM prior to B16F10 tumor cell injection 
causes transient increase in tumor cell homing to the lung 
Our lab has previously demonstrated that B16F10 melanoma cells stably 
expressing ISM can inhibit tumor growth and progression by inhibiting 
angiogenesis in mice (Xiang, Ke et al. 2011). Since angiogenesis inhibitors have 
been implicated in regulating tumor metastasis too, we used an experimental 
metastasis model to study the effect of ISM on regulating metastasis.  
 
Since it was demonstrated that systemically delivered ISM could enhance 
pulmonary permeability within 15 mins, in our first set of experiments, we 
administered rISM at a dose of 10 mg/kg systemically through the lateral tail vein 
10-15 minutes prior to tumor cell injection. 5 X 10
5 
Luciferase-expressing B16F10-
Luc2 cells were then injected into the animals through the lateral tail vein. ISM 
was administered at the same dose every 3 days during the course of the 
experiment (Fig 3.26 A). The control mice received PBS injections in the same 
volume 15 mins prior to tumor cell injection, as well as every 3 days during the 




Tumor cell homing to the lungs was monitored every 3 days by live imaging to 
record the bioluminescent signal up to day 6 (Fig 3.26 A). Interestingly, an increase 
in bioluminescent signal in ISM treated animals was observed at day 3 and day 6 
compared to the control (Fig 3.26 B).  These results suggest that ISM may aid in 






Figure 3.26 ISM injected prior to tumor cell injection causes a transient 
increase in bioluminescent signal 
A) Experimental setup. ISM was injected intravenously every 3 days at a dose of 
10 mg/kg up to 6 days; B) Representative images of bioluminescent signal taken at 
day 3 and day 6. Threshold on Day 3 was set lower than day 6 in order to observe 
early metastatic homing. Measured bioluminescence reported as average photon 
counts. Bars represent mean +/- SD. *P<0.05. n=6  
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3.3.1.2 Administration of ISM after B16F10 tumor cell has homed to 
target tissue inhibits lung metastasis and tumor growth 
To analyse the role of ISM on pre-formed metastases, 3X10
5
 luciferase-expressing 
B16F10-Luc2 cells were injected via tail vein at day 0 and ISM was administered 
after tumor cell homing. Analysis of the lungs for tumor cell homing revealed 
bioluminescent signal on Day 6. At this point, ISM was administered via tail vein 
injections every 2 days at a dose of 10 mg/kg. Tumor progression in the lung was 
monitored every 2 days until the end of the experiment at day 18 (Fig 3.27 A).  
 
Tumor-bearing animals treated with ISM showed slower growth of lung metastasis 
as well as significant reduction in size and number of tumor nodules at the end 
point (Fig 3.27 B, C). This finding reveals that in an experimental model of 















Figure 3.27 ISM inhibits B16F10 melanoma metastasis 
A) Experimental setup. ISM was injected intravenously every 3 days at a dose of 
10 mg/kg; B) Representative images of bioluminescent signal taken every 3 days 
up to the end of the experiment; C) Measured bioluminescence reported as average 
photon counts. Bars represent mean +/- SD. *P<0.05. n=6 
3.2.1.3 ISM suppresses lung metastatic tumor progression by inhibiting 
tumor angiogenesis, tumor proliferation and inducing cell apoptosis 
 
To investigate the potential mechanism by which there was a reduction in 
bioluminescent signal, end-point lungs were paraffin embedded and analysed for 
histopathological features (Fig 3.28 A). A simple H & E staining of lung sections 
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revealed larger foci in the PBS treated control lungs. Also, there was a reduction in 
Micro Vascular Density (MVD) as analysed by VE-cadherin staining. Reduced 
proliferation and increased apoptosis was also observed in the tumor areas of the 
lung. These results show that when ISM is administered after tumor cell homing, 
characteristics consistent with ISM’s role as an angiogenesis inhibitor are observed. 
The increase in tumor cell homing seen when ISM is already present in circulation 
suggests that ISM may aid in tumor cell extravasations by regulating vessel 




Figure 3.28 Systemically delivered ISM inhibits metastasis by inhibiting 
angiogenesis, proliferation and inducing apoptosis 
A) Histological analysis of lungs (end point) from animals in which rISM was 
delivered after tumor cell homing. In both experiments, ISM was administered 
regularly till the end of the experiment. H & E staining showed smaller metastatic 
foci. Angiogenesis was analysed by staining for VE-cadherin, proliferation was 
analysed by antibodies against PCNA and apoptosis was anaysed by TUNEL 
staining. ISM-treated lungs showed metastatic foci with reduced angiogenesis, 




3.3.2 Prior systemic delivery of ISM causes transient increase in breast 
cancer cell homing to lung, while long term treatment suppresses 4T1 
metastasis in mice 
3.3.2.1 Administration of ISM prior to 4T1 tumor cell injection causes 
transient increase in tumor cell homing to the lung 
To confirm the observation made in the B16F10 melanoma model, the experiments 
were repeated using 4T1-breast cancer cells in Balb/c mice. As mentioned above, 
in our first set of experiments, ISM was administered at a dose of 10 mg/kg 
systemically through the lateral tail vein 10-15 minutes prior to tumor cell 
injection. 5 X 10
5 
Luciferase-expressing 4T1-12B cells were then injected into the 
animals through the lateral tail vein. ISM was administered at the same dose every 
3 days during the course of the experiment (Fig 3.26 A). The control mice received 
PBS injections in the same volume 10-15 mins prior to tumor cell injection, as well 
as every 3 days during the course of the experiment. This time, the experiment was 
continued till the end point. 
 
Tumor progression at metastasis homing sites was monitored every 3 days by live 
imaging to record the bioluminescent signal. Interestingly, an initial increase in 
bioluminescent signal in ISM treated animals was observed at day 5 compared to 
the control. Towards the end of the experiment, this increase was no longer evident 
and in most of the animals (n=5/7), the ISM tumors had lower bioluminescent 
signal than the control tumors (Fig 3.29 A, B).  These results suggest that ISM may 
aid in the invasion on cells into metastatic sites, however, inhibit tumor progression 









Figure 3.29 ISM injected prior to tumor cell injection causes a transient 
increase in bioluminescent signal 
rISM was injected intravenously every 3 days at a dose of 10 mg/kg; A) 
Representative images of bioluminescent signal taken every 3 days up to the end 
of the experiment; B) Measured bioluminescence reported as average photon 
counts. Bars represent mean +/- SD. *P<0.05. n=7 
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3.3.2.2 Administration of ISM after 4T1 tumor cell homing inhibits lung 
metastasis and tumor growth 
To analyse the role of ISM on pre-formed metastases, 3 X 10
5
 luciferase-expressing 
4T1-12B cells were injected via tail vein at day 0 and ISM was administered after 
tumor cell homing.  Analysis of the lungs for tumor cell homing revealed 
bioluminescent signal on Day 6. At this point, ISM was administered via tail vein 
injections every 2 days at a dose of 10 mg/kg. Tumor progression in the lung was 
monitored every 2 days until the end of the experiment at day 18 (Fig 3.27 A).  
 
Tumor-bearing animals treated with ISM showed slower growth of lung metastasis 
as well as significant reduction in size and number of tumor nodules at the end 
point (Fig 3.30 A, B). This finding reveals that in an experimental model of 








Figure 3.30 ISM inhibits 4T1 breast cancer metastasis 
 ISM was injected intravenously every 2 days at a dose of 10 mg/kg; A) 
Representative images of bioluminescent signal taken every 3 days up to the end 
of the experiment; B) Measured bioluminescence reported as average photon 
counts. Bars represent mean +/- SD. *P<0.05. n=6 
 
Summary 
In summary, part III of my work demonstrates that ISM inhibits pulmonary 
metastasis as an angiogenesis inhibitor. However, as a novel permeability inducer, 
it may also aid in tumor cell extravasation at metastatic sites. Interestingly, 
although tumor cell extravasation is enhanced upon ISM treatment, tumor growth 






                      PART IV: Role of ISM in wound healing 
3.4  ISM delays wound healing 
Since ISM is found in the mouse blood circulation (Zhang, Chen et al. 2011), as 
well as in the ECs of the skin, it may be possible that ISM, like other endogenous 
angiogenesis inhibitors, plays a role in wound healing. 
3.4.1 ISM delays HUVEC wound closure over a period of 20 hours 
The effect of wound healing on ECs in culture was tested using an in vitro scratch 
assay. Briefly, scratches of equal width were made with a pipette tip and 
photographed immediately after wounding. The controls were treated with 2% 
FBS media with 15 ng/ml VEGF after a starvation period of 3 hours, while the 
experimental samples were treated with different doses of ISM in 2% FBS media 
with 15 ng/ml VEGF. The cells were then photographed at different time points. 
ISM was found to delay in vitro wound closure over 20 hours (Fig 3.31).  
 
 
Figure 3.31 ISM delayed HUVEC wound closure 
Scratches of equal width were made in confluent HUVEC monolayers and 
following a 4-hour starvation period, were treated with 1 μM ISM. The control 
wells were treated with 15 ng/ml VEGF to stimulate wound closure, while the 
ISM treated samples contained 15 ng/ml VEGF and 1 μM ISM. 
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3.4.2 ISM delays HaCat (keratinocyte) wound closure over a period of 
44 hours 
Keratinocytes are a major cell type in the epidermis of skin and have critical roles 
in the wound healing process (Pastar, Stojadinovic et al. 2008). Human 
immortalized keratinocytes (HaCaT) were used to study the role of ISM in wound 
healing in vitro. These cells are known to respond to VEGF (Yang, Man et al. 
2006) which is interesting because VEGF is an angiogenesis factor. It was thus 
studied whether in addition to delaying HUVEC wound closure, whether ISM 
affected HaCat wound closure. HaCat cells proliferate slower than HUVEC cells in 
culture. The control wounds closed to a greater extent than the ISM-treated wounds 
after 44 hours. At this point, ISM delayed wound closure in a dose-dependent 
manner (Fig 3.32). 
 
Figure 3.32 ISM delayed HaCat wound healing 
Scratches of equal width were made in confluent HaCat monolayers and 
following a 4-hour starvation period, were treated with 1 μM ISM. The control 
wells were treated with full growth media to stimulate wound closure, while the 




3.4.3 ISM delays mouse skin wound healing in a dose-dependent 
manner  
To study if ISM also suppress would healing in vivo, a mouse skin wound healing 
model was adopted. Briefly, full thickness wounds were created on the shaved 
back skin of Balb/c mice and the wounds were subjected to control (PBS) or ISM 
at different doses till the control wounds closed. Recombinant ISM at doses 5 
μg/wound and 10 μg/wound was applied topically daily and the wounds were 
measured daily. ISM wounds closed slower than PBS treated wounds from day 2 












Figure 3.33 ISM delays murine wound healing 
A) Photographs of wounds treated with control (PBS) and ISM (5 μg/ml and 10 
μg/ml per wound); B) Plots of percentage of wound closure compared to wound 
size on day 0. N=4 mice/group; 3 wounds per flank; * represents P<0.05 
3.4.4 ISM inhibits granulation tissue formation 
Wounds section histology was analysed at the end point of the wound healing 
assays. Granulation tissue formation is an important determinant of wound healing 
as it consists of ECs, fibroblasts and immune cells which help in the process. A 
healthy granulation tissue will have good perfusion of blood vessels and 
connective tissue. ISM-treated wounds showed reduced area of granulation tissue 
compared to the control treated wounds (Fig 3.34). 
 
Figure 3.34 ISM reduces the formation of granulation tissue 
Skin tissue was fixed and stained with H & E. GT: Granulation tissue 
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3.4.5 ISM suppression of wound healing is associated with decreased 
angiogenesis, decreased proliferation and increased macrophage infiltration 
In order to analyse the mechanism of wound healing delay induced by ISM, fixed 
wound skin sections were analysed for multiple characteristics of the granulation 
tissue (Fig 3.35 A, B). In the control wounds, the granulation tissue was rich in 
blood vessels, as determined by CD-31 staining, an EC marker. The ISM treated 
wounds showed a reduction in blood vessels, which was typical of ISMs role as an 
endogenous angiogenesis inhibitor. To study whether the vessel wall thickness 
differed between control and ISM treated wounds, sections were probed for α-
smooth muscle actin (α-SMA). No difference was observed between control and 
ISM treated wounds, although ISM-treated wounds had smaller blood vessels.  
 
Since inflammation is an important phase contributing to wound healing, the 
wound sections were analysed for presence of macrophages at the end point of the 
assay. Macrophage infiltration occurs during the early phases of wound healing 
and ceases by the time the wound closes. Interestingly, ISM-treated wounds had 
significantly higher number of macrophages as compared to the PBS treated 
controls. Proliferation, another hallmark of healing wounds, was analysed by 
probing for proliferating cell nuclear antigen (PCNA). ISM treated wounds had 
lower staining compared to control wounds. The wound area was also analysed for 
apoptotic cells. Apoptosis is a normal phenomenon during the course of wound 
healing; however, ISM-treated wounds had a significantly higher number of 


















Figure 3.35 Histological analysis of wound sections 
A) Fixed sections were probed for blood vessels (CD-31 and α-SMA), 
macrophages (F4/80), proliferation (PCNA) and apoptosis (TUNEL); B) 
Quantification of parameters, * represents P<0.05 
 
Summary: 
In this part, it has been shown that ISM affects physiological angiogenesis during 
wound healing. Exogenously applied rISM delays wound healing by inhibiting 
angiogenesis, cell proliferation and inducing cell apoptosis. ISM also increases 








               PART V – ISM is potentially involved in inflammation 
3.5  Expression profile of ISM in wounded skin and in models of 
inflammation 
3.5.1 ISM expression increases during the initial stages of wound 
healing 
Wound healing is a physiological condition which requires an orchestrated 
interplay of multiple processes such as inflammation, angiogenesis, proliferation 
and apoptosis. Since ISM has been identified as an endogenous angiogenesis 
inhibitor, the expression of ISM during the process of wound healing was analysed. 
Briefly, Balb/c mice were wounded using 4 mm biopsy punches and wounded skin 
was collected before wounding, at days 3, 7, 9 and 11 after wounding. Tissue 
lysates were prepared and probed for ISM using ELISA and western blotting (Fig 
3.36 A, B).  
 
ISM expression significantly increased after wounding (up to day 7 of the wound 
healing process) after which ISM protein levels came down to basal levels (similar 










Figure 3.36 ISM expression increases during initial phases of wound healing 
5 μg of total protein was probed for ISM expression using (A) western blotting; 
(B) ELISA 
3.5.2 ISM expression increases during the development of Asthma in a 
mouse model 
The expression of ISM in Asthma, another model of inflammation where 
endogenous angiogenesis and permeability regulators play a role, was studied. 
Fixed lung tissue and lung samples for lysate preparation were obtained from 
Ovalbumin (OVA)-sensitized mouse models of Asthma (Bao, Lim et al. 2007). 
This method of sensitization is a common method used to mimic asthmatic 
conditions in mice as it is highly reproducible. Sensitization by OVA elevates anti-
OVA IgE levels, activating mast cells leading to airway hyper-reactivity. Binding 
of OVA to anti-OVA IgE during allergen re-exposure leads to degranulation of 
immune cells, releasing inflammatory mediators, and further exacerbating 
inflammation. (Tatler, John et al. 2011). Re-exposure to OVA following 
sensitization makes the animal asthmatic and typical features of asthma are present 
in these mice. 
 
ISM levels in sensitized (OVA-sensitized) and asthmatic (OVA-sensitized-OVA-
challenged) mice was analysed by probing lung lysates with anti-ISM IgG. A 
significant increase in ISM levels were observed in asthmatic mouse compared to 
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sensitized animals (Fig 3.37 A). Immunohistochemistry was performed on lungs 
from these mice and the expression pattern during diseased conditions was 
studied. The naïve group consisted of mice that underwent no sensitization or 
challenge (healthy mice). These mice showed a basal level of ISM expression 
found in normal mouse lungs; significantly in the bronchial epithelium. 
Interestingly, sensitization of mice caused an increase in ISM levels in the 
bronchial epithelia but asthmatic lungs showed the highest ISM upregulation (Fig 






Figure 3.37 ISM is upregulated in asthmatic lungs 
Western blotting shows a significant increase in ISM expression in lungs of 
asthmatic mice compared to sensitized mice SI-S3: lungs from sensitized animals, 
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A1-A4: lungs from asthmatic animals; (B) Lung sections probed for ISM shows 





These results show that ISM is up regulated during inflammatory conditions such 
as wound healing and asthma. Although wound healing is a process undergoing 



























Chapter 4 Discussion 
4.1  ISM as a novel endogenous permeability inducer 
Endogenous vascular permeability factors have been identified that help maintain 
the endothelium function. During resting conditions, it is the capillaries that do the 
molecular exchange (Nagy, Benjamin et al. 2008; Nagy, Dvorak et al. 2012). 
Acute vascular permeability is the situation when the microvasculature is exposed 
to cytokines such as VEGF, histamine, serotonin etc. These permeability inducers 
are produced in short bursts and cause a rapid but self-limited permeability 
increase, whereby the inter-endothelial junctions open up to allow plasma proteins 
and immune cells into the tissue. Agents such as VEGF and histamine have to 
found to cause contraction of ECs that pull apart the junctions to cause enhanced 
vascular permeability (Majno, Shea et al. 1969). The main agents that protect the 
vasculature from enhanced vascular permeability include Ang-1, Sphingosine-1-
Phosphate (S1P), and FGF etc. These proteins, through various signaling 
pathways, keep the inter-endothelial junctions intact thus stabilizing the 
vasculature.  
 
A common factor among all permeability regulators is the ultimate alteration of 
the EC junctions. The mechanism and receptors that mediate this alteration may 
vary. VEGF phosphorylates VE-cadherin and the catenins in a Src kinase-
dependent manner (Eliceiri, Paul et al. 1999). VE-cadherin also inhibits VEGF-R2 
internalization, resulting in activation of Src, and increased permeability 
(Lampugnani, Orsenigo et al. 2006). Activation of VEGF-R2 also leads to myosin 
light chain phosphorylation (MLC), which leads to actin-myosin contraction and 
tension causing disruption of the AJs (Stockton, Schaefer et al. 2004). TGF-β1 
induced permeability involves p38/MAPK induced Rho/Rho-kinase dependent 
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stress fiber formation and actin-myosin contractility via MLC phosphorylation, 
leading to disassembly of cell-cell junctions (Birukova, Birukov et al. 2005). TGF-
β1 has also been shown to activate Src kinases and FAK, however this signaling 
does not involve its receptor ALK5, nor does it affect TGF-β1- induced 
p38/MAPK activation (Lee, Kayyali et al. 2007). In contrast, Ang-1 sequesters Src 
through mammalian diaphanous (mDia) and thus inhibits VE-cadherin 
phosphorylation. This strengthens the membrane junctions leading to intact barrier 
integrity (Gavard, Patel et al. 2008). S1P, an angiogenesis inducer that inhibits 
vascular permeability, does so by rearranging actin fibers to the cortical ring and 
stabilizing cell-cell junctions (Garcia, Liu et al. 2001; Xu, Waters et al. 2007). 
 
Since ISM plays a role in regulating vascular permeability, it may aid in 
extravasation of tumor cells during metastasis. Physiological levels of ISM in the 
blood plasma have been found to be ~100 nM (Zhang, Chen et al. 2011). Thus 
there is a possibility that at physiological levels, ISM aids in regulation of vascular 
permeability. The ISM dose used in the tumor metastases experiments conducted 
in this work was much higher (~1 μM) and may represent situations of increased 
circulating ISM. 
 
In vitro, ISM enhanced HUVEC monolayer permeability in a dose- and time-
dependent manner. Permeability of the monolayers increased over time and was 
the maximum at time-points corresponding to evidence of ISM-induced apoptosis. 
This effect was also observed on HMVEC, which are microvascular cells. 
Interestingly, ISM was more potent in inducing monolayers permeability on these 
cells compared to the large vessel HUVECs. Indeed, most of neoangiogenesis 
occurs in the microvasculature and it is known that microvascular cells are more 
responsive to mitogenic and angiogenic signals (Zetter 1981; Brindle 1993).  
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ISM also potentiated VEGF and histamine-induced permeability, both fast 
inducers of permeability. However, no significant effect was observed on slow 
inducers of permeability, in the presence of ISM. Fast inducers of permeability 
cause rapid changes in signaling and the effects return to basal levels within 30 
minutes. These results suggest that ISM induces permeability through mechanisms 
similar to those of slow inducers of permeability. Treatment of ISM along with 
fast inducers of permeability may already trigger the signaling for permeability 
induction by ISM, and thus potentiate the response.  
 
The cell-cell junctions of cells that had been treated with ISM for 6 hours, a time-
point at which significant permeability was induced, showed increased tyrosine 
phosphorylation. The cell-cell junctions are hot spots for intensive tyrosine 
phosphorylation (Dejana, Orsenigo et al. 2008). ISM treatment caused the 
adherens junction complex including VE-cadherin, β-catenin and p120 catenin to 
undergo phosphorylation and move away from the junctions. This implied 
disassembly of the junctions resulting in loosening of cell-cell contacts. This 
phenomenon could explain the increased dextran-flux across the EC monolayers 
as larger molecules could now pass through the monolayer. 
 
Having seen that ISM loosened the inter-cellular contacts, the next question was 
whether ISM-induced apoptosis was responsible for the effects seen on the 
junction, and thus permeability. Morphologically, ISM-induced apoptosis was 
evident as early as 4 hours following ISM-exposure. However, at 6 or 16 hours, 
attenuation of apoptosis did not completely attenuate ISM-induced permeability. 
Inhibition of ISM-induced apoptosis still caused membrane disruptions. Both 
these observations implied that an additional mechanism was responsible for ISM-
induced permeability.  
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4.2  ISM induces permeability through signaling via both αvβ5 and 
GRP78 
It has been reported that the integrin αvβ5 plays a role in regulating permeability 
of vessels (Su, Hodnett et al. 2007) (Ma, Rong et al. 2008) by regulating Src and 
opening up the VE-cadherin-catenin barrier. As mentioned earlier, growth factors 
and integrin ligation are known to activate non-receptor tyrosine kinases such as 
Src and FAK. Unlike other integrins, integrin αvβ5 requires pre-stimulation with 
growth factors to activate Src/FAK and thus carry out activation of these 
molecules (Eliceiri, Puente et al. 2002). ISM, on its own could activate Src, with 
no significant activation of FAK. Also, Src activation was not affected upon 
neutralizing αvβ5 on ECs. This could suggest that ISM may be inducing 
permeability through an alternate pathway to the integrin pathway. The partial 
attenuation of ISM-induced permeability by neutralizing αvβ5 could be due to the 
attenuation of apoptosis induced by ISM as reported by Zhang et al (Xiang, Ke et 
al. 2011) (Zhang, Chen et al. 2011).  
 
GRP78, the high affinity receptor of ISM identified recently, has been shown to 
bind to Cripto and activate an angiogenic cascade triggered by Src activation 
(Kelber, Panopoulos et al. 2009). As mentioned earlier, work done in our lab has 
identified a mechanism by which ISM binding to GRP78 leads to EC apoptosis 
and is responsible for its angio-inhibitory function. Binding of ISM to GRP78 
leads to endocytic internalization of ISM, and the complex is co targeted to the 
mitochondria, where dysfunction leads to apoptosis. 
 
In the present work, blocking GRP78 on ECs led to complete attenuation of ISM-
induced permeability. Src activation was also attenuated which implies that ISM-
induced Src activation was induced by ISM binding to GRP78. Blocking of 
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GRP78-induced endocytosis also led to attenuated of ISM-induced Src activation. 
Interestingly, inhibition of Src activation prior to 6 hours ISM treatment led to 
complete attenuation of ISM-induced permeability, however, after 16 hours of 
ISM treatment, only partial attenuation was observed. Thus both ISM-induced 
apoptosis and ISM-induced Src activation were responsible for ISM-induced 
permeability. 
4.3  ISM as a potential therapeutic agent in cancer and metastasis 
Ever since the discovery of endogenous angiogenesis inhibitors, anti-angiogenic 
therapy has been considered very promising. Endogenous angiogenesis inhibitors 
are naturally occurring proteins and thus show reduced toxicity when compared to 
traditional chemotherapy drugs and radiation therapy. Also, these inhibitors 
specifically target pathological activated vessels and have no impact on 
established quiescent vessels (Volpert, Zaichuk et al. 2002). As mentioned earlier, 
cancer metastasis is a serious condition and patients that have progressed to this 
stage seldom live on. There have been contrasting reports on the contribution of 
angiogenesis to metastasis. Several studies conducted with angiogenesis inhibitors 
have shown that after a short period of tumor shrinkage due to angiogenesis 
inhibition, metastasis is observed (Ebos, Lee et al. 2009) (Paez-Ribes, Allen et al. 
2009).  
 
Our lab has previously shown that ISM inhibits tumorigenesis by inducing both 
tumor-cell and EC apoptosis and by inhibiting angiogenesis (Xiang, Ke et al. 
2011; Chen, Zhang et al. 2014). In my work, I tested the effect of systemically 
administered ISM on regulating metastasis. The results were indeed interesting. 
When ISM was administered prior to tumor cells injection; i.e., ISM was already 
in the mouse circulation, at early time-points, tumor cell homing to the lungs was 
enhanced. At the end point of the experiment however, inhibition of metastasis 
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was observed, which was in corroboration of the role of ISM as an anti-
tumor/anti-angiogenic molecule. Inhibition of metastasis was also observed when 
ISM was administered after tumor cell homing.  
 
The experimental metastasis assay used in this case is actually an assay in which 
the tumor cells are shot directly into circulation. This simulates a situation where 
cells have dissociated from the primary tumor and entered circulation. When 
primary tumors are treated with endogenous angiogenesis inhibitors, the situation 
may be quite different. Vascular density will be reduced and the number of cells 
entering circulation may not be sufficient to establish metastasis.   
 
From my results, it looks like ISM may be aiding in the extravasation of tumor 
cells in the metastatic organ, but inhibiting tumorigenesis once the cells establish 
into tumors. In other words, ISM may enhance vascular permeability of the 
vessels enabling tumor cells to extravasate.  
 
In cancer therapy, this permeability induced by ISM may be advantageous in terms 
of efficient drug delivery through the Enhanced Permeability Retention effect 
(EPR) (Maeda, Wu et al. 2000). The EPR effect is more relevant in the context of 
macromolecules being used in cancer therapy today, as opposed to small molecule 
inhibitors. The small molecules can diffuse through the cells via transcellular 
routes. However, larger molecules remain specifically in tumors due to high 
permeability of tumors and exert their effect. Although angiogenesis is reduced in 
ISM-treated tumors, increased permeability of existing vessels may lead to 
increased amounts of ISM entering the tumor site, especially in tumors with high 
VEGF levels. Also, by affecting intercellular contacts, endothelial cells may be 
unable to reconnect to form mature blood vessels and thus may be a means by 
which ISM inhibits new blood vessels growth in cancers. Enhanced permeability 
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may also increase bioavailability of chemotherapeutic drugs into the tumor due to 
enhanced leakiness of the vessels, if used in combination therapies. This is a 
rapidly growing strategy which is being tested and used to treat pathological 
conditions such as cancer (Provenzale, Mukundan et al. 2005; Stieger, Caskey et 
al. 2007).  
4.4  The role of ISM in regulating wound healing 
It is widely accepted that angiogenesis is an essential process in wound healing. 
Angiogenic stimulators present in the wound microenvironment help repair, while 
angiogenic inhibitors inhibit repair (Nissen, Polverini et al. 1998; Tonnesen, Feng 
et al. 2000). VEGF in particular is very important in regulating wound healing and 
it affects multiple cells types in the healing wound in addition to ECs.  
 
Impaired wound healing is a serious condition and occurs mainly in diabetics 
patients (Falanga 2005; Brem and Tomic-Canic 2007). Due to the importance of 
angiogenesis in chronic non-healing wounds, it becomes necessary to study the 
effect of angiogenesis inhibitors on the process. More importantly, endogenous 
angiogenesis inhibitors are being increasingly used in clinical trials to treat 
pathological conditions like cancer and diabetic retinopathy.  
 
A recent study was conducted to study the role of ISM on mouse models of glioma 
(Yuan, Xian et al. 2012). Adenovirus expressing ISM (Ad-ISM) injected cerebrally 
into the glioma site caused inhibition of glioma tumorigenesis through 
angiogenesis inhibition. In this study, as part of assessing for side-effects, wound 
healing was analysed. ISM showed no significant effect on wound healing. A 
major factor to be consider in this study is that Ad-ISM was administered locally, 
i.e., intra-cerebrally. Due to the very strong blood-brain barrier, how much ISM 
entered the circulation is an important factor to be considered. Also, wound 
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healing is a process where local factors, at the site of wounding, contribute to the 
process.  
 
In the current work, ISM was applied topically on fresh wounds and the effect of 
ISM on wound healing was studied. ISM delayed wound healing in a dose-
dependent manner and the inhibition was evident throughout the wound healing 
process. Contraction of the wounds was not affected, however, angiogenesis was 
inhibited and granulation tissue was reduced. Consistent with being an 
angiogenesis inhibitor, ISM induced apoptosis in the wounds. Interestingly, at the 
end point, ISM-treated wounds had more macrophages than the control wounds. 
This work represents a situation where ISM is up regulated in the wound 
microenvironment. Thus, at physiological levels, ISM may be playing a role to 
regulate the normal process of wound healing by being part of the pool of factors 
induced during the process.  
4.5  The potential role of ISM in regulating inflammation 
Inflammation is an important physiological function which helps the body fight 
infection and damaged cells. Sustained inflammation is also a pathological 
indicator and can cause vascular dysfunction (Sprague and Khalil 2009). In blood 
vessels, inflammatory cytokines leads to vasodilation and increased vascular 
permeability. These processes allow further entry of cytokines and immune cells 
and also allow clearance of cell debris. The vascular permeability induced during 
inflammation is also associated with disrupted cell-cell junctions and 
reorganization of the actin cytoskeleton (Weber, Fraemohs et al. 2007). 
Macrophages are important sources of most inflammatory cytokines and direct a 
variety of functions including release of angiogenesis regulators. In addition to 
producing angiogenic stimulators like VEGF and TGF-β1, macrophages also 
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produce angioinhibitory molecules like TSP1 and endostatin (DiPietro, Nissen et 
al. 1996). 
 
Like TSP1, ISM is expressed at low levels in normal skin, and its expression goes 
up in wounded skin, especially in the early stages of wound healing. The 
expression goes back to basal levels upon wound healing. ISM is expressed by the 
epithelial cells and developing hair follicles.  
 
Macrophages play a very important role in the wound healing process (Koh and 
DiPietro 2011). Macrophages mediate the inflammatory phase of the process and 
proceed to influence the later stages too. The healed wound is clear of 
macrophages because by this phase, inflammation is over and other events take 
over. Since ISM-treated wounds had a significantly higher amount of 
macrophages, it is possible that ISM causes this effect in two ways. Firstly, ISM 
may enhance the infiltration of macrophages into the wound due to its increase in 
vascular permeability. Secondly, ISM may act as a chemo attractant to attract 
macrophages into the wound bed, leading to a prolonged inflammatory phase.  
 
As a preliminary study to analyze the significance of ISM in inflammation, we 
also analyzed lungs from an asthmatic mouse model to study the expression of 
ISM in this model of inflammation. In a stage-dependent manner, ISM expression 
was up regulated in the lungs of these animals. We have shown that the high 
affinity receptor for ISM, GRP78, co localizes with ISM in the normal mouse 
lung; in the bronchial epithelia. Studies have shown that receptors which play a 
role in inducing asthma are expressed along the airway epithelium (S. T. Holgate 
1999; Lambrecht and Hammad 2012). In addition, inflammatory cytokines are 
often found to be co localized and bound to their receptors along the airway 
epithelium (Vincent H.J. van der Velden 1998; Temann, Laouar et al. 2007). It has 
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also been shown that GRP78 expression tends to increase during inflammation and 
diseased states (Wang, He et al. 2005; Kelsen, Duan et al. 2008; Ni, Zhang et al. 
2011; Quesada Calvo, Fillet et al. 2011; Baek, Kim do et al. 2012). Also, the 
angiogenesis inhibitor TSP1 has been shown to be up regulated in models of 
asthma (Huang, Kao et al. 1996). These preliminary studies point towards a role of 
ISM in regulating inflammation at a physiological level, and may have functions 
similar to TSP1 in regulating inflammation.  
4.6  The potential role of ISM in tissues where it is expressed 
There have been several reports of the dentate gyrus being active centers for both 
angiogenesis and neurogenesis (Palmer, Willhoite et al. 2000; Louissaint, Rao et 
al. 2002). Both processes involve similar stimuli and VEGF is an important player 
in this region (Welberg 2011). It is interesting that ISM is expressed in this region. 
This suggests that while expressed during development, ISM may also play an 
uncharacterized role in regulating adult neurogenesis and angiogenesis in the 
brain.  
 
Angiogenesis is an important determinant of kidney health and several 
angiogenesis regulators have been implicated in kidney function (Maeshima and 
Makino 2010). The angiogenesis inhibitors Endostatin and TSP1 are also 
expressed in normal adult kidneys, possibly as part of the pool of factors 
regulating angiogenesis, along with VEGF (Schrijvers, Flyvbjerg et al. 2004; 
Thakar, Zahedi et al. 2005; Bellini, Coutinho et al. 2007). These results suggest 
that ISM maybe functioning as part of this regulation, or may play a previously 
uncharacterized function in the adult kidney. 
 
The germinal centers of the spleen are important factories of antibodies and 
monocytes. It also mediates lymphatic clearance. Secretions from spleen cells are 
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rich in angiogenesis regulators and have significant effects on tumorigenesis 
(Shaked, Cervi et al. 2005). It is possible that ISM, present in the pool of splenic 
secretion, has a role to play in angiogenesis and inflammation in the spleen.  
 
Vascular permeability changes in the stomach are mediated by the secretions of 
the glandular cells (Solligard, Juel et al. 2008) and several angiogenesis regulators 
have been implicated in gastric cancers (Kitadai 2010). From this work, it is 
evident that systemic administration of ISM increased gastric permeability. 
However, at physiological levels, the role of ISM in the stomach remains 
uncharacterized. 
 
The acinar cells are surrounded by pancreatic stellar cells, which have important 
roles to play in inflammation and other pancreatic diseases (Masamune and 
Shimosegawa 2009). Interestingly, in addition to be involved in exocrine 
pancreatic secretions, the stellar cells have been implicated in secretion of 
angiogenic factors in pancreatic cancers (Masamune, Kikuta et al. 2008). ISM 
may be involved in maintaining homeostasis in the normal pancreas by being part 
of the pool of angiogenesis/permeability regulators secreted. 
 
In the adult mouse testis, ISM is expressed by both sertoli cells and the developing 
spermatids. The sertoli cells are important for differentiation of the early 
spermatocytes into mature spermatids and they secrete several hormones 
important for nourishment of the sperms. These include inhibins and activins, 
androgen binding protein, anti-mullerian hormone, glial cell-line derived 
neurotrophic factor etc (Griswold 1988). A recent study has also shown that sertoli 
cells can influence co-cultured ECs in vitro (Fan, He et al. 2011). VEGF also 
functions in both physiological and pathological testis angiogenesis (Samson, 
Peale et al. 2004). Thus ISM may be an important molecule that helps maintain 
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the blood testes barrier and angiogenesis at physiological levels.  
 
From the expression pattern of ISM in adult tissues, it is possible that ISM is 
involved in the regulation of hemostasis in the organs where it is expressed. Its 
functions in these organs may be related to the characterized functions of 
angiogenesis and permeability regulation, or could open up previously 
uncharacterized functions in an organ-specific manner.  
4.7  Conclusions 
 In summary, this work characterizes the role of ISM in regulating three major 
aspects of vascular biology; vascular permeability, metastasis and wound 
healing. 
 
 ISM, as an angiogenesis inhibitor, inhibits tumor cell metastasis. However, in 
the earlier stages of experimental metastasis, ISM aids in tumor cell 
extravasation into the lung. At the end point, ISM suppresses tumor growth at 
the metastatic site by reduction of tumor angiogenesis, inhibition of 
proliferation and induction of apoptosis. 
 
 In vitro, ISM induces HUVEC and HMVEC monolayer permeability in a 
dose- and time-dependent manner. It also potentiates VEGF and histamine-
induced permeability, however, does not significantly affect TGF-β1 and 
TNF-α-induced permeability. 
 
 In vivo, ISM enhances dermal permeability within 15 minutes, in a dose-
dependent manner. Systemic delivery of ISM also enhances vascular 
permeability of the lung and to a lesser extent, of the stomach. This happens 
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in a time-dependent manner and permeability returns to basal levels 24 hours 
after systemic ISM administration. 
 
 ISM directly or indirectly binds to GRP78 and αvβ5 on the EC cell surface 
and induces apoptosis. Simultaneously, it induces Src activation which leads 
to β-catenin and p120 catenin phosphorylation, dissociation of VE-cadherin 
at the adherens junction and consequent barrier disruption. Both ISM-induced 
Src activation and ISM-induced apoptosis are responsible for ISM-induced 
permeability (Fig 4.1). ISM induces Src activation, VE-cadherin and β-
catenin phosphorylation in vivo too. 
 
 ISM delays wound healing in a dose-dependent manner both in vitro and in 
vivo. In vitro, ISM delays both EC and keratinocyte wound closure in a 
scratch assay. In vivo, ISM delays wound closure from early time-points 
itself. The delay is associated with reduced angiogenesis, increased apoptosis, 
decreased granulation tissue formation and increased macrophage infiltration.  
 
 In normal skin, ISM is expressed by the epidermal cells and developing skin 
follicles. In normal skin, ISM is expressed at basal levels and its expression 
goes up during wounding and remains during the early phases (possibly 
during the inflammatory phase). In the healed wound, ISM levels fall back to 
basal levels. In asthmatic lungs, ISM expression is up regulated in a stage-
dependent manner. Thus ISM may play a role in regulating inflammation, 





Figure 4.1 Proposed model of ISM effects on EC permeability. 
As a secreted protein, ISM interacts with its receptor GRP78 and αvβ5 on ECs. 
Through both the receptors, ISM induces apoptotic signaling which will ultimately 
lead to apoptosis of the ECs and disassembly of the junctions. Simultaneously, 
ISM binds to GRP78 and activates Src, which leads to phosphorylation of the AJ 
molecules p120 catenin, β-catenin and VE-cadherin. This causes junction 
disassembly and paracellular permeability is induced by ISM. 
 
4.8  Future directions 
This work has identified ISM as a novel endogenous permeability inducer, in 
addition to being an angiogenesis inhibitor. Some unresolved issues which require 
further studies are outlined below.  
4.8.1 Exploring the role of ISM in regulating spontaneous metastasis 
The potential of ISM in regulating tumor cell metastasis was examined for the first 
time in my work. However, the method used for determining this was the 
experimental metastasis model, where tumor cells are shot directly into circulation 
and are allowed to home to metastatic organs (Khanna and Hunter 2005). Since 
ISM behaves both as an angiogenesis inhibitor and a permeability inducer, how 
both the functions co relates in regulating spontaneous metastasis is unclear. In 
spontaneous metastasis, the primary tumor microenvironment dictates the start of 
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the metastatic process and this is a more realistic situation mimicking clinical 
reality. It will be interesting to study the effect of ISM over expression in the 
primary tumor.  
 
The cell lines tested in this study are B16 melanoma cells and 4T1 breast 
carcinoma cells. In the case of melanoma metastasis, metastatic foci were present 
mainly in the lungs, while 4T1 cells showed metastasis to multiple organs. Only 
the lungs were quantified because at the end point of the experiment, visible foci 
were present only on the lungs. Also, a lot of variation existed in metastasis to 
other organs. It would thus be interesting to see whether ISM had an effect on 
metastasis to organs other than the lung in a spontaneous metastasis assay. The 
spontaneous metastasis model will also answer whether ISM aids in the 
intravasation process, in addition to aiding the extravasation process during 
metastatic dissemination.  
 
Due to the results found in this study, it will also be interesting to co relate ISM up 
regulation in tumors versus normal tissue to invasiveness of cancers. Currently, the 
expression pattern of ISM in tumors follows no particular trend and ISM is down 
regulated only in a few cancers (Xiang, Ke et al. 2011).  
4.8.2 Exploring the physiological role of ISM in regulating permeability 
in ISM-knockout mice 
Knockout mice are important models to study protein function in vivo. Previously, 
knockdown of ISM in zebrafish showed abnormal formation of intersegmental 
vessels (ISV)s in development. How ISM affects the endothelia in mouse 
physiology is unknown.  
 
This work demonstrates that when administered locally or systemically, ISM 
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enhances vascular permeability in vivo. The conditions tested here represent a 
situation where there is up regulation of ISM either in the local environment, or in 
circulation. From these results, we can safely conclude that exogenously applied 
ISM induces vascular permeability. However the role of ISM at physiological 
levels is still unclear. 
  
To clarify this, vascular permeability in ISM knockout mice have to be studied. 
Also, blood vessel leakiness and formation of the junctions in response to 
permeability factors need to be studied.    
4.8.3 How does ISM binding to GRP78 activate Src? 
This work demonstrates the downstream events of receptor ligation responsible for 
ISM-induced permeability. However, further studies are required to deduce the 
mechanism of how ISM binding to GRP78 leads to activation of Src. Preliminary 
data outlined in this work suggests that GRP78 interacts with Src in cells. 
However, even without ISM treatment, GRP78 interacts with Src. Since ISM-
induced Src activation occurs at later time points and after ISM-induced 
endocytosis has occurred, it is possible that the ISM-GRP78 complex interacts with 
Src at the level of the endosome.  
 
GRP78 is known to be autophosphorylated both in vitro and in vivo (Leustek, 
Toledo et al. 1991; Carlino, Toledo et al. 1992). Autophosphorylation of GRP78 
has been shown to yield threonine phosphorylation. A study in 1994 reported that 
GRP78 was tyrosine-phosphorylated in vitro by Src-kinase (Carlino, Toledo et al. 
1994). A recent study has shown that GRP78 undergoes tyrosine phopshorylation 
upon binding its ligand α2M
*
 (Misra, Sharma et al. 2005). Another ligand of 
GRP78 on the cell surface is Cripto. Cripto binding to GRP78 causes activation of 
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Src (Kelber, Panopoulos et al. 2009). Additionally, Src activates the transcription 
factor TF-II which enhances GRP78 promoter activity, thus regulating GRP78 
activity during stress (Hong, Lin et al. 2005).  
 
With so many reported correlations between GRP78 and Src signaling, it is 
possible that at some point within the cell, these two proteins interact and exist in 
the same complex. As both proteins are regulated by 
phosphorylation/dephosphorylation events, how these events affect their 
interactions is unclear. Additionally, how ISM affects this interaction is also an 
interesting area to be pursued. 
4.8.4 Clarifying the role of ISM in regulating inflammation 
In this work, ISM has been shown to be expressed by the airway epithelial and the 
epidermis of the skin. Both these sites are well known to express cytokines and 
mediators of lung and skin inflammation (Bellini, Yoshimura et al. 1993; Becker, 
Quay et al. 1994; DiCosmo, Geba et al. 1994; Sousa, Lane et al. 1994). Also, 
inflammatory mediators such as TGF-β1 and TNF-α have also been known to 
regulate angiogenesis and permeability; both functions in which ISM also acts as a 
regulator.  
 
ISM-treated wounds show a higher macrophage count than the control treated 
wounds, which lead us to speculate that ISM must be causing higher infiltration of 
macrophages, or indirectly leading to a prolonged inflammatory phase. However, 
the role of ISM in this area is currently unclear and requires further substantiation. 
In the future, ISM-treated wounds at various stages of the wound healing process 
can be collected and compared to control wounds at the same stage to analyze the 
inflammatory phase. It would be interesting to know whether ISM delays the 
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inflammatory process, or whether it prolongs the inflammatory phase. Also, to 
study whether the effect of ISM is a direct or indirect effect, lysates from ISM-
treated wounds at different phases can be assayed for the levels different 
inflammatory cytokines. 
 
As part of this work, the level of ISM protein in lungs of mice in various stages of 
asthma was examined. In a stage-dependent manner, ISM was up regulated in these 
lungs. As mentioned earlier, in normal lungs, ISM is expressed in the bronchial 
epithelial cells. In asthma, severe hyperplasia of the epithelial wall is observed, and 
correspondingly, ISM was up regulated. These data are very preliminary but point 
to a role of ISM in regulating inflammation. It remains to be understood whether 
up regulated ISM contributes to the asthmatic condition, or whether the asthmatic 
condition leads to up regulated ISM. Using knockout mice, the role of ISM in 
regulating asthma can be studied. Also, the effect of ISM on chemotaxis and 















Abraham, L. A. and E. J. MacKie (1999). "Modulation of osteoblast-like cell 
behavior by activation of protease-activated receptor-1." J Bone Miner 
Res 14(8): 1320-1329. 
Adams, R. H. and K. Alitalo (2007). "Molecular regulation of angiogenesis and 
lymphangiogenesis." Nat Rev Mol Cell Biol 8(6): 464-478. 
Agah, A., T. R. Kyriakides, et al. (2002). "The lack of thrombospondin-1 (TSP1) 
dictates the course of wound healing in double-TSP1/TSP2-null mice." 
Am J Pathol 161(3): 831-839. 
Aiello, L. P., R. L. Avery, et al. (1994). "Vascular endothelial growth factor in 
ocular fluid of patients with diabetic retinopathy and other retinal 
disorders." N Engl J Med 331(22): 1480-1487. 
Alghisi, G. C. and C. Ruegg (2006). "Vascular integrins in tumor angiogenesis: 
mediators and therapeutic targets." Endothelium : journal of 
endothelial cell research 13(2): 113-135. 
Andersen, H., D. L. Greenberg, et al. (1999). "Protease-activated receptor 1 is 
the primary mediator of thrombin-stimulated platelet procoagulant 
activity." Proc Natl Acad Sci U S A 96(20): 11189-11193. 
Andrae, J., R. Gallini, et al. (2008). "Role of platelet-derived growth factors in 
physiology and medicine." Genes Dev 22(10): 1276-1312. 
Asch, A. S., I. Liu, et al. (1993). "Analysis of CD36 binding domains: ligand 
specificity controlled by dephosphorylation of an ectodomain." 
Science 262(5138): 1436-1440. 
Ashton, A. W., J. Dawes, et al. (1995). "Acidic and basic fibroblast growth 
factors have comparable effects on the haemostatic function of 
vascular endothelium." Growth Factors 12(2): 111-120. 
Avraamides, C. J., B. Garmy-Susini, et al. (2008). "Integrins in angiogenesis 
and lymphangiogenesis." Nat Rev Cancer 8(8): 604-617. 
Azzi, S., J. K. Hebda, et al. (2013). "Vascular permeability and drug delivery in 
cancers." Front Oncol 3: 211. 
Baek, H. A., S. Kim do, et al. (2012). "Involvement of endoplasmic reticulum 
stress in myofibroblastic differentiation of lung fibroblasts." Am J 
Respir Cell Mol Biol 46(6): 731-739. 
Banks, R. E., M. A. Forbes, et al. (1998). "Release of the angiogenic cytokine 
vascular endothelial growth factor (VEGF) from platelets: significance 
for VEGF measurements and cancer biology." Br J Cancer 77(6): 956-
964. 
Bao, Z., S. Lim, et al. (2007). "Glycogen synthase kinase-3beta inhibition 
attenuates asthma in mice." Am J Respir Crit Care Med 176(5): 431-
438. 
Becker, S., J. Quay, et al. (1994). "Constitutive and stimulated MCP-1, GRO 
alpha, beta, and gamma expression in human airway epithelium and 
bronchoalveolar macrophages." Am J Physiol 266(3 Pt 1): L278-286. 
Beenken, A. and M. Mohammadi (2009). "The FGF family: biology, 
pathophysiology and therapy." Nat Rev Drug Discov 8(3): 235-253. 
Behzadian, M. A., X. L. Wang, et al. (2001). "TGF-beta increases retinal 
147 
 
endothelial cell permeability by increasing MMP-9: possible role of 
glial cells in endothelial barrier function." Invest Ophthalmol Vis Sci 
42(3): 853-859. 
Bellamy, W. T. (2002). "Vascular endothelial growth factor as a target 
opportunity in hematological malignancies." Current Opinion in 
Oncology 14(6): 649-656. 
Bellini, A., H. Yoshimura, et al. (1993). "Bronchial epithelial cells of patients 
with asthma release chemoattractant factors for T lymphocytes." J 
Allergy Clin Immunol 92(3): 412-424. 
Bellini, M. H., E. L. Coutinho, et al. (2007). "Endostatin expression in the 
murine model of ischaemia/reperfusion-induced acute renal failure." 
Nephrology (Carlton) 12(5): 459-465. 
Bergers, G. and D. Hanahan (2008). "Modes of resistance to anti-angiogenic 
therapy." Nat Rev Cancer 8(8): 592-603. 
Bhattacharjee, G., J. Ahamed, et al. (2005). "Regulation of tissue factor--
mediated initiation of the coagulation cascade by cell surface grp78." 
Arterioscler Thromb Vasc Biol 25(8): 1737-1743. 
Bikfalvi, A. (2004). "Platelet factor 4: an inhibitor of angiogenesis." Semin 
Thromb Hemost 30(3): 379-385. 
Bikfalvi, A., S. Klein, et al. (1997). "Biological roles of fibroblast growth factor-
2." Endocr Rev 18(1): 26-45. 
Birukova, A. A., K. G. Birukov, et al. (2005). "Involvement of microtubules and 
Rho pathway in TGF-beta1-induced lung vascular barrier dysfunction." 
J Cell Physiol 204(3): 934-947. 
Bitto, A., L. Minutoli, et al. (2008). "Angiopoietin-1 gene transfer improves 
impaired wound healing in genetically diabetic mice without 
increasing VEGF expression." Clin Sci (Lond) 114(12): 707-718. 
Bloch, W., K. Huggel, et al. (2000). "The angiogenesis inhibitor endostatin 
impairs blood vessel maturation during wound healing." FASEB J 
14(15): 2373-2376. 
Bocci, G., G. Francia, et al. (2003). "Thrombospondin 1, a mediator of the 
antiangiogenic effects of low-dose metronomic chemotherapy." Proc 
Natl Acad Sci U S A 100(22): 12917-12922. 
Boehm, T., J. Folkman, et al. (1997). "Antiangiogenic therapy of experimental 
cancer does not induce acquired drug resistance." Nature 390(6658): 
404-407. 
Boire, A., L. Covic, et al. (2005). "PAR1 is a matrix metalloprotease-1 receptor 
that promotes invasion and tumorigenesis of breast cancer cells." Cell 
120(3): 303-313. 
Bornstein, P. (2009). "Thrombospondins function as regulators of 
angiogenesis." J Cell Commun Signal 3(3-4): 189-200. 
Bosse, Y., P. D. Pare, et al. (2008). "Airway wall remodeling in asthma: from 
the epithelial layer to the adventitia." Curr Allergy Asthma Rep 8(4): 
357-366. 
Bouck, N. (2002). "PEDF: anti-angiogenic guardian of ocular function." Trends 
Mol Med 8(7): 330-334. 
Brankin, B., M. Campbell, et al. (2005). "Endostatin modulates VEGF-mediated 
148 
 
barrier dysfunction in the retinal microvascular endothelium." Exp Eye 
Res 81(1): 22-31. 
Brem, H. and M. Tomic-Canic (2007). "Cellular and molecular basis of wound 
healing in diabetes." J Clin Invest 117(5): 1219-1222. 
Brigham, K. L. and P. J. Owen (1975). "Increased sheep lung vascular 
permeability caused by histamine." Circulation Research 37(5): 647-
657. 
Brindle, N. P. (1993). "Growth factors in endothelial regeneration." Cardiovasc 
Res 27(7): 1162-1172. 
Bruno, E., R. J. Cooper, et al. (1993). "Basic fibroblast growth factor promotes 
the proliferation of human megakaryocyte progenitor cells." Blood 
82(2): 430-435. 
Buckley, I. K. and G. B. Ryan (1969). "Increased vascular permeability. The 
effect of histamine and serotonin on rat mesenteric blood vessels in 
vivo." Am J Pathol 55(3): 329-347. 
Bull, H. A., P. M. Brickell, et al. (1994). "Src-related protein tyrosine kinases 
are physically associated with the surface antigen CD36 in human 
dermal microvascular endothelial cells." FEBS Lett 351(1): 41-44. 
Burden-Gulley, S. M. and S. M. Brady-Kalnay (1999). "PTPmu regulates N-
cadherin-dependent neurite outgrowth." J Cell Biol 144(6): 1323-
1336. 
Burikhanov, R., Y. Zhao, et al. (2009). "The tumor suppressor Par-4 activates 
an extrinsic pathway for apoptosis." Cell 138(2): 377-388. 
Burri, P. H. and V. Djonov (2002). "Intussusceptive angiogenesis--the 
alternative to capillary sprouting." Mol Aspects Med 23(6S): S1-27. 
Canfield, A. E. and A. M. Schor (1995). "Evidence that tenascin and 
thrombospondin-1 modulate sprouting of endothelial cells." J Cell Sci 
108 ( Pt 2): 797-809. 
Cao, R., J. Farnebo, et al. (1999). "Interleukin-18 acts as an angiogenesis and 
tumor suppressor." FASEB J 13(15): 2195-2202. 
Cao, R., H. L. Wu, et al. (1999). "Suppression of angiogenesis and tumor 
growth by the inhibitor K1-5 generated by plasmin-mediated 
proteolysis." Proc Natl Acad Sci U S A 96(10): 5728-5733. 
Cao, Y., A. Chen, et al. (1997). "Kringle 5 of plasminogen is a novel inhibitor of 
endothelial cell growth." J Biol Chem 272(36): 22924-22928. 
Carlino, A., H. Toledo, et al. (1992). "Interactions of liver Grp78 and 
Escherichia coli recombinant Grp78 with ATP: multiple species and 
disaggregation." Proc Natl Acad Sci U S A 89(6): 2081-2085. 
Carlino, A., H. Toledo, et al. (1994). "BiP is a substrate for src kinase in vitro." 
Biochem Biophys Res Commun 201(3): 1548-1553. 
Carlos, T. M. and J. M. Harlan (1994). "Leukocyte-endothelial adhesion 
molecules." Blood 84(7): 2068-2101. 
Carmeliet, P. (2003). "Angiogenesis in health and disease." Nat Med 9(6): 653-
660. 
Carmeliet, P. (2005). "Angiogenesis in life, disease and medicine." Nature 
438(7070): 932-936. 
Carmeliet, P. and D. Collen (2000). "Molecular basis of angiogenesis. Role of 
149 
 
VEGF and VE-cadherin." Ann N Y Acad Sci 902: 249-262; discussion 
262-244. 
Carmeliet, P., V. Ferreira, et al. (1996). "Abnormal blood vessel development 
and lethality in embryos lacking a single VEGF allele." Nature 
380(6573): 435-439. 
Carmeliet, P. and R. K. Jain (2000). "Angiogenesis in cancer and other 
diseases." Nature 407(6801): 249-257. 
Carmeliet, P. and R. K. Jain (2011). "Molecular mechanisms and clinical 
applications of angiogenesis." Nature 473(7347): 298-307. 
Carmeliet, P., M. G. Lampugnani, et al. (1999). "Targeted deficiency or 
cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-
mediated endothelial survival and angiogenesis." Cell 98(2): 147-157. 
Cebe-Suarez, S., A. Zehnder-Fjallman, et al. (2006). "The role of VEGF 
receptors in angiogenesis; complex partnerships." Cell Mol Life Sci 
63(5): 601-615. 
Chambers, A. F., A. C. Groom, et al. (2002). "Dissemination and growth of 
cancer cells in metastatic sites." Nat Rev Cancer 2(8): 563-572. 
Chang, Y. S., E. di Tomaso, et al. (2000). "Mosaic blood vessels in tumors: 
frequency of cancer cells in contact with flowing blood." Proc Natl 
Acad Sci U S A 97(26): 14608-14613. 
Chaplin, D. J., P. L. Olive, et al. (1987). "Intermittent blood flow in a murine 
tumor: radiobiological effects." Cancer Res 47(2): 597-601. 
Chavakis, T., A. Athanasopoulos, et al. (2005). "Angiostatin is a novel anti-
inflammatory factor by inhibiting leukocyte recruitment." Blood 
105(3): 1036-1043. 
Chen, H., M. E. Herndon, et al. (2000). "The cell biology of thrombospondin-
1." Matrix Biol 19(7): 597-614. 
Chen, M., Y. Zhang, et al. (2014). "Isthmin targets cell-surface GRP78 and 
triggers apoptosis via induction of mitochondrial dysfunction." Cell 
Death Differ. 
Cho, C. H., H. K. Sung, et al. (2006). "COMP-angiopoietin-1 promotes wound 
healing through enhanced angiogenesis, lymphangiogenesis, and 
blood flow in a diabetic mouse model." Proc Natl Acad Sci U S A 
103(13): 4946-4951. 
Chow, L. Q. and S. G. Eckhardt (2007). "Sunitinib: from rational design to 
clinical efficacy." J Clin Oncol 25(7): 884-896. 
Ciccarelli, F. D., T. Doerks, et al. (2002). "AMOP, a protein module alternatively 
spliced in cancer cells." Trends Biochem Sci 27(3): 113-115. 
Claesson-Welsh, L. (2003). "Signal transduction by vascular endothelial 
growth factor receptors." Biochem Soc Trans 31(Pt 1): 20-24. 
Claesson-Welsh, L., M. Welsh, et al. (1998). "Angiostatin induces endothelial 
cell apoptosis and activation of focal adhesion kinase independently 
of the integrin-binding motif RGD." Proc Natl Acad Sci U S A 95(10): 
5579-5583. 
Colorado, P. C., A. Torre, et al. (2000). "Anti-angiogenic cues from vascular 
basement membrane collagen." Cancer Res 60(9): 2520-2526. 
Corvera, C. U., O. Dery, et al. (1999). "Thrombin and mast cell tryptase 
150 
 
regulate guinea-pig myenteric neurons through proteinase-activated 
receptors-1 and -2." J Physiol 517 ( Pt 3): 741-756. 
Cullinan-Bove, K. and R. D. Koos (1993). "Vascular endothelial growth 
factor/vascular permeability factor expression in the rat uterus: rapid 
stimulation by estrogen correlates with estrogen-induced increases in 
uterine capillary permeability and growth." Endocrinology 133(2): 
829-837. 
Dai, Q., J. Huang, et al. (2004). "Engineered zinc finger-activating vascular 
endothelial growth factor transcription factor plasmid DNA induces 
therapeutic angiogenesis in rabbits with hindlimb ischemia." 
Circulation 110(16): 2467-2475. 
Davidson, D. J., C. Haskell, et al. (2005). "Kringle 5 of human plasminogen 
induces apoptosis of endothelial and tumor cells through surface-
expressed glucose-regulated protein 78." Cancer Res 65(11): 4663-
4672. 
Dawson, D. W., S. F. Pearce, et al. (1997). "CD36 mediates the In vitro 
inhibitory effects of thrombospondin-1 on endothelial cells." J Cell Biol 
138(3): 707-717. 
Dawson, D. W., O. V. Volpert, et al. (1999). "Pigment epithelium-derived 
factor: a potent inhibitor of angiogenesis." Science 285(5425): 245-
248. 
de Boer, W. I., A. van Schadewijk, et al. (1998). "Transforming growth factor 
beta1 and recruitment of macrophages and mast cells in airways in 
chronic obstructive pulmonary disease." Am J Respir Crit Care Med 
158(6): 1951-1957. 
Dejana, E. (2004). "Endothelial cell-cell junctions: happy together." Nat Rev 
Mol Cell Biol 5(4): 261-270. 
Dejana, E., F. Orsenigo, et al. (2008). "The role of adherens junctions and VE-
cadherin in the control of vascular permeability." J Cell Sci 121(Pt 13): 
2115-2122. 
Delie, F., P. Petignat, et al. (2012). "GRP78 Protein Expression in Ovarian 
Cancer Patients and Perspectives for a Drug-Targeting Approach." J 
Oncol 2012: 468615. 
Deng, C. X., A. Wynshaw-Boris, et al. (1994). "Murine FGFR-1 is required for 
early postimplantation growth and axial organization." Genes Dev 
8(24): 3045-3057. 
Dentelli, P., L. Del Sorbo, et al. (1999). "Human IL-3 stimulates endothelial cell 
motility and promotes in vivo new vessel formation." J Immunol 
163(4): 2151-2159. 
Desgrosellier, J. S. and D. A. Cheresh (2010). "Integrins in cancer: biological 
implications and therapeutic opportunities." Nat Rev Cancer 10(1): 9-
22. 
Dickens, S., P. Vermeulen, et al. (2008). "Regulable vascular endothelial 
growth factor165 overexpression by ex vivo expanded keratinocyte 
cultures promotes matrix formation, angiogenesis, and healing in 
porcine full-thickness wounds." Tissue Eng Part A 14(1): 19-27. 
DiCosmo, B. F., G. P. Geba, et al. (1994). "Airway epithelial cell expression of 
151 
 
interleukin-6 in transgenic mice. Uncoupling of airway inflammation 
and bronchial hyperreactivity." J Clin Invest 94(5): 2028-2035. 
DiPietro, L. A., N. N. Nissen, et al. (1996). "Thrombospondin 1 synthesis and 
function in wound repair." Am J Pathol 148(6): 1851-1860. 
Dixelius, J., M. Cross, et al. (2002). "Endostatin regulates endothelial cell 
adhesion and cytoskeletal organization." Cancer Res 62(7): 1944-1947. 
Dong, A., J. Shen, et al. (2011). "Vascular cell-adhesion molecule-1 plays a 
central role in the proangiogenic effects of oxidative stress." Proc Natl 
Acad Sci U S A 108(35): 14614-14619. 
Donnini, S. and M. Ziche (2002). "Constitutive and inducible nitric oxide 
synthase: role in angiogenesis." Antioxid Redox Signal 4(5): 817-823. 
Dougher, M. and B. I. Terman (1999). "Autophosphorylation of KDR in the 
kinase domain is required for maximal VEGF-stimulated kinase activity 
and receptor internalization." Oncogene 18(8): 1619-1627. 
Duncan, M. B. and R. Kalluri (2009). "Parstatin, a novel protease-activated 
receptor 1-derived inhibitor of angiogenesis." Mol Interv 9(4): 168-
170. 
Dvorak, H. F., M. Detmar, et al. (1995). "Vascular permeability factor/vascular 
endothelial growth factor: an important mediator of angiogenesis in 
malignancy and inflammation." Int Arch Allergy Immunol 107(1-3): 
233-235. 
Ebos, J. M., C. R. Lee, et al. (2009). "Accelerated metastasis after short-term 
treatment with a potent inhibitor of tumor angiogenesis." Cancer Cell 
15(3): 232-239. 
Eliceiri, B. P. (2001). "Integrin and growth factor receptor crosstalk." 
Circulation Research 89(12): 1104-1110. 
Eliceiri, B. P., R. Paul, et al. (1999). "Selective requirement for Src kinases 
during VEGF-induced angiogenesis and vascular permeability." Mol 
Cell 4(6): 915-924. 
Eliceiri, B. P., X. S. Puente, et al. (2002). "Src-mediated coupling of focal 
adhesion kinase to integrin alpha(v)beta5 in vascular endothelial 
growth factor signaling." J Cell Biol 157(1): 149-160. 
Esser, S., M. G. Lampugnani, et al. (1998). "Vascular endothelial growth factor 
induces VE-cadherin tyrosine phosphorylation in endothelial cells." J 
Cell Sci 111 ( Pt 13): 1853-1865. 
Fagiani, E. and G. Christofori (2013). "Angiopoietins in angiogenesis." Cancer 
Lett 328(1): 18-26. 
Falanga, V. (2005). "Wound healing and its impairment in the diabetic foot." 
Lancet 366(9498): 1736-1743. 
Fan, P., L. He, et al. (2011). "Testicular Sertoli cells influence the proliferation 
and immunogenicity of co-cultured endothelial cells." Biochem 
Biophys Res Commun 404(3): 829-833. 
Ferrara, N. (2001). "Role of vascular endothelial growth factor in regulation of 
physiological angiogenesis." Am J Physiol Cell Physiol 280(6): C1358-
1366. 
Ferrara, N., K. Carver-Moore, et al. (1996). "Heterozygous embryonic lethality 




Ferrara, N. and T. Davis-Smyth (1997). "The biology of vascular endothelial 
growth factor." Endocr Rev 18(1): 4-25. 
Ferrara, N. and W. J. Henzel (1989). "Pituitary follicular cells secrete a novel 
heparin-binding growth factor specific for vascular endothelial cells." 
Biochem Biophys Res Commun 161(2): 851-858. 
Ferrara, N., K. J. Hillan, et al. (2004). "Discovery and development of 
bevacizumab, an anti-VEGF antibody for treating cancer." Nat Rev 
Drug Discov 3(5): 391-400. 
Fidler, I. J. (1991). "Orthotopic implantation of human colon carcinomas into 
nude mice provides a valuable model for the biology and therapy of 
metastasis." Cancer Metastasis Rev 10(3): 229-243. 
Folkman, J. (1971). "Tumor angiogenesis: therapeutic implications." N Engl J 
Med 285(21): 1182-1186. 
Folkman, J. (1995). "Angiogenesis in cancer, vascular, rheumatoid and other 
disease." Nat Med 1(1): 27-31. 
Folkman, J. (2002). "Role of angiogenesis in tumor growth and metastasis." 
Semin Oncol 29(6 Suppl 16): 15-18. 
Folkman, J. and D. Hanahan (1991). "Switch to the angiogenic phenotype 
during tumorigenesis." Princess Takamatsu Symp 22: 339-347. 
Folkman, J., E. Merler, et al. (1971). "Isolation of a tumor factor responsible 
for angiogenesis." J Exp Med 133(2): 275-288. 
Fong, G. H., J. Rossant, et al. (1995). "Role of the Flt-1 receptor tyrosine kinase 
in regulating the assembly of vascular endothelium." Nature 
376(6535): 66-70. 
Fraisl, P., M. Mazzone, et al. (2009). "Regulation of angiogenesis by oxygen 
and metabolism." Dev Cell 16(2): 167-179. 
Fraser, H. M. and S. F. Lunn (2000). "Angiogenesis and its control in the female 
reproductive system." Br Med Bull 56(3): 787-797. 
Frazier, K., S. Williams, et al. (1996). "Stimulation of fibroblast cell growth, 
matrix production, and granulation tissue formation by connective 
tissue growth factor." J Invest Dermatol 107(3): 404-411. 
Freshney, R. I. (1994). Culture of Animal Cells: A Manual of Basic Technique. 
New York, Wiley-Liss. 
Frisch, S. M. and R. A. Screaton (2001). "Anoikis mechanisms." Curr Opin Cell 
Biol 13(5): 555-562. 
Furuse, M. (2006). "[Molecular mechanism behind the barrier function of 
tight junctions]." Seikagaku 78(7): 601-608. 
Futreal, P. A., L. Coin, et al. (2004). "A census of human cancer genes." Nat 
Rev Cancer 4(3): 177-183. 
Gabison, E., J. H. Chang, et al. (2004). "Anti-angiogenic role of angiostatin 
during corneal wound healing." Exp Eye Res 78(3): 579-589. 
Galfione, M., W. Luo, et al. (2003). "Expression and purification of the 
angiogenesis inhibitor 16-kDa prolactin fragment from insect cells." 
Protein Expr Purif 28(2): 252-258. 
Gao, X. and Z. Xu (2008). "Mechanisms of action of angiogenin." Acta Biochim 
Biophys Sin (Shanghai) 40(7): 619-624. 
153 
 
Garcia-Roman, J. and A. Zentella-Dehesa (2013). "Vascular permeability 
changes involved in tumor metastasis." Cancer Lett 335(2): 259-269. 
Garcia, J. G., F. Liu, et al. (2001). "Sphingosine 1-phosphate promotes 
endothelial cell barrier integrity by Edg-dependent cytoskeletal 
rearrangement." J Clin Invest 108(5): 689-701. 
Gardner, T. W., T. Lesher, et al. (1996). "Histamine reduces ZO-1 tight-junction 
protein expression in cultured retinal microvascular endothelial cells." 
Biochem J 320 ( Pt 3): 717-721. 
Garg, P., S. Yang, et al. (2011). "Thrombospondin-1 opens the paracellular 
pathway in pulmonary microvascular endothelia through EGFR/ErbB2 
activation." Am J Physiol Lung Cell Mol Physiol 301(1): L79-90. 
Gately, S., P. Twardowski, et al. (1996). "Human prostate carcinoma cells 
express enzymatic activity that converts human plasminogen to the 
angiogenesis inhibitor, angiostatin." Cancer Res 56(21): 4887-4890. 
Gavard, J. and J. S. Gutkind (2006). "VEGF controls endothelial-cell 
permeability by promoting the beta-arrestin-dependent endocytosis 
of VE-cadherin." Nat Cell Biol 8(11): 1223-1234. 
Gavard, J., V. Patel, et al. (2008). "Angiopoietin-1 prevents VEGF-induced 
endothelial permeability by sequestering Src through mDia." Dev Cell 
14(1): 25-36. 
Glass, C. A., S. J. Harper, et al. (2006). "The anti-angiogenic VEGF isoform 
VEGF165b transiently increases hydraulic conductivity, probably 
through VEGF receptor 1 in vivo." J Physiol 572(Pt 1): 243-257. 
Goldblum, S. E., X. Ding, et al. (1993). "Bacterial lipopolysaccharide induces 
actin reorganization, intercellular gap formation, and endothelial 
barrier dysfunction in pulmonary vascular endothelial cells: 
concurrent F-actin depolymerization and new actin synthesis." J Cell 
Physiol 157(1): 13-23. 
Goldblum, S. E., X. Ding, et al. (1994). "SPARC (secreted protein acidic and rich 
in cysteine) regulates endothelial cell shape and barrier function." 
Proc Natl Acad Sci U S A 91(8): 3448-3452. 
Goldblum, S. E., B. A. Young, et al. (1999). "Thrombospondin-1 induces 
tyrosine phosphorylation of adherens junction proteins and regulates 
an endothelial paracellular pathway." Mol Biol Cell 10(5): 1537-1551. 
Goliath, R., J. Tombran-Tink, et al. (1996). "The gene for PEDF, a retinal growth 
factor is a prime candidate for retinitis pigmentosa and is tightly linked 
to the RP13 locus on chromosome 17p13.3." Mol Vis 2: 5. 
Good, D. J., P. J. Polverini, et al. (1990). "A tumor suppressor-dependent 
inhibitor of angiogenesis is immunologically and functionally 
indistinguishable from a fragment of thrombospondin." Proc Natl 
Acad Sci U S A 87(17): 6624-6628. 
Goumans, M. J., Z. Liu, et al. (2009). "TGF-beta signaling in vascular biology 
and dysfunction." Cell Res 19(1): 116-127. 
Grand, E. K., A. J. Chase, et al. (2004). "Targeting FGFR3 in multiple myeloma: 
inhibition of t(4;14)-positive cells by SU5402 and PD173074." 
Leukemia 18(5): 962-966. 
Greaves, N. S., K. J. Ashcroft, et al. (2013). "Current understanding of 
154 
 
molecular and cellular mechanisms in fibroplasia and angiogenesis 
during acute wound healing." J Dermatol Sci 72(3): 206-217. 
Griswold, M. D. (1988). "Protein secretions of Sertoli cells." Int Rev Cytol 110: 
133-156. 
Gumbiner, B. M. (2005). "Regulation of cadherin-mediated adhesion in 
morphogenesis." Nat Rev Mol Cell Biol 6(8): 622-634. 
Guo, N., H. C. Krutzsch, et al. (1997). "Thrombospondin 1 and type I repeat 
peptides of thrombospondin 1 specifically induce apoptosis of 
endothelial cells." Cancer Res 57(9): 1735-1742. 
Hagedorn, M., L. Zilberberg, et al. (2001). "A short peptide domain of platelet 
factor 4 blocks angiogenic key events induced by FGF-2." FASEB J 
15(3): 550-552. 
Han, G., F. Li, et al. (2012). "The pro-inflammatory role of TGFbeta1: a 
paradox?" Int J Biol Sci 8(2): 228-235. 
Hanahan, D. and J. Folkman (1996). "Patterns and emerging mechanisms of 
the angiogenic switch during tumorigenesis." Cell 86(3): 353-364. 
Hanahan, D. and R. A. Weinberg (2000). "The hallmarks of cancer." Cell 
100(1): 57-70. 
Hanahan, D. and R. A. Weinberg (2011). "Hallmarks of cancer: the next 
generation." Cell 144(5): 646-674. 
Harada, T., H. Saito, et al. (1994). "Murine fibroblast growth factor receptor 1 
gene generates multiple messenger RNAs containing two open 
reading frames via alternative splicing." Biochem Biophys Res 
Commun 205(2): 1057-1063. 
Hayes, A. J., W. Q. Huang, et al. (1999). "Angiopoietin-1 and its receptor Tie-2 
participate in the regulation of capillary-like tubule formation and 
survival of endothelial cells." Microvasc Res 58(3): 224-237. 
Heinke, J., C. Patterson, et al. (2012). "Life is a pattern: vascular assembly 
within the embryo." Front Biosci (Elite Ed) 4: 2269-2288. 
Heishi, T., T. Hosaka, et al. (2010). "Endogenous angiogenesis inhibitor 
vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and 
suppresses lymph node metastasis." Am J Pathol 176(4): 1950-1958. 
Hendershot, L. (2004). "The ER function BiP is a master regulator of ER 
function." The Mount Sinai journal of medicine, New York 71(5): 289-
297. 
Hill, S. J. (1990). "Distribution, properties, and functional characteristics of 
three classes of histamine receptor." Pharmacol Rev 42(1): 45-83. 
Hiraki, Y., H. Inoue, et al. (1997). "Identification of chondromodulin I as a 
novel endothelial cell growth inhibitor. Purification and its localization 
in the avascular zone of epiphyseal cartilage." J Biol Chem 272(51): 
32419-32426. 
Hobbs, S. K., W. L. Monsky, et al. (1998). "Regulation of transport pathways in 
tumor vessels: role of tumor type and microenvironment." Proc Natl 
Acad Sci U S A 95(8): 4607-4612. 
Hong, M., M. Y. Lin, et al. (2005). "Transcriptional regulation of the Grp78 
promoter by endoplasmic reticulum stress: role of TFII-I and its 
tyrosine phosphorylation." J Biol Chem 280(17): 16821-16828. 
155 
 
Hosaka, T., H. Kimura, et al. (2009). "Vasohibin-1 expression in endothelium of 
tumor blood vessels regulates angiogenesis." Am J Pathol 175(1): 430-
439. 
Howdieshell, T. R., D. Callaway, et al. (2001). "Antibody neutralization of 
vascular endothelial growth factor inhibits wound granulation tissue 
formation." J Surg Res 96(2): 173-182. 
Huang, H., P. Vasilakis, et al. (2010). "Parstatin suppresses ocular 
neovascularization and inflammation." Invest Ophthalmol Vis Sci 
51(11): 5825-5832. 
Huang, S. W., K. J. Kao, et al. (1996). "Plasma thrombospondin levels in sheep 
with allergic asthma." Chest 109(6): 1614-1617. 
Hurwitz, H., L. Fehrenbacher, et al. (2004). "Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer." N Engl J 
Med 350(23): 2335-2342. 
Ikenaka, Y., H. Yoshiji, et al. (2003). "Tissue inhibitor of metalloproteinases-1 
(TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 
transgenic mouse model." Int J Cancer 105(3): 340-346. 
Iruela-Arispe, M. L., M. Lombardo, et al. (1999). "Inhibition of angiogenesis by 
thrombospondin-1 is mediated by 2 independent regions within the 
type 1 repeats." Circulation 100(13): 1423-1431. 
Ishida, A., J. Murray, et al. (2001). "Expression of vascular endothelial growth 
factor receptors in smooth muscle cells." J Cell Physiol 188(3): 359-
368. 
Itoh, N. and D. M. Ornitz (2004). "Evolution of the Fgf and Fgfr gene families." 
Trends Genet 20(11): 563-569. 
Ivanov, A. I. (2008). "Pharmacological inhibition of endocytic pathways: is it 
specific enough to be useful?" Methods Mol Biol 440: 15-33. 
Jaffe, E., R. Nachman, et al. (1973). "Culture of human endothelial cells 
derived from umbilical veins. Identification by morphologic and 
immunologic criteria." J Clin Invest 52(11): 2745-2756. 
Jaffe, E. A., J. T. Ruggiero, et al. (1983). "Cultured human fibroblasts synthesize 
and secrete thrombospondin and incorporate it into extracellular 
matrix." Proc Natl Acad Sci U S A 80(4): 998-1002. 
Jimenez, B., O. V. Volpert, et al. (2000). "Signals leading to apoptosis-
dependent inhibition of neovascularization by thrombospondin-1." 
Nat Med 6(1): 41-48. 
Johansson, M. W. (1999). "Cell adhesion molecules in invertebrate immunity." 
Dev Comp Immunol 23(4-5): 303-315. 
Kabrun, N., H. J. Buhring, et al. (1997). "Flk-1 expression defines a population 
of early embryonic hematopoietic precursors." Development 124(10): 
2039-2048. 
Kampfer, H., J. Pfeilschifter, et al. (2001). "Expressional regulation of 
angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases 
during cutaneous wound healing: a comparative study of normal and 
impaired repair." Lab Invest 81(3): 361-373. 
Kamphaus, G. D., P. C. Colorado, et al. (2000). "Canstatin, a novel matrix-




Kanazawa, S., T. Tsunoda, et al. (2001). "VEGF, basic-FGF, and TGF-beta in 
Crohn's disease and ulcerative colitis: a novel mechanism of chronic 
intestinal inflammation." Am J Gastroenterol 96(3): 822-828. 
Karumanchi, S. A., V. Jha, et al. (2001). "Cell surface glypicans are low-affinity 
endostatin receptors." Mol Cell 7(4): 811-822. 
Katanasaka, Y., T. Ishii, et al. (2010). "Cancer antineovascular therapy with 
liposome drug delivery systems targeted to BiP/GRP78." Int J Cancer 
127(11): 2685-2698. 
Kaufmann, R., U. Junker, et al. (2002). "PAR-1- and PAR-3-type thrombin 
receptor expression in primary cultures of human renal cell carcinoma 
cells." Int J Oncol 20(1): 177-180. 
Kelber, J. A., A. D. Panopoulos, et al. (2009). "Blockade of Cripto binding to cell 
surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and 
Smad2/3 pathways." Oncogene 28(24): 2324-2336. 
Keller, M., A. Ruegg, et al. (2008). "Active caspase-1 is a regulator of 
unconventional protein secretion." Cell 132(5): 818-831. 
Kelsen, S. G., X. Duan, et al. (2008). "Cigarette smoke induces an unfolded 
protein response in the human lung: a proteomic approach." Am J 
Respir Cell Mol Biol 38(5): 541-550. 
Kevil, C. G., D. K. Payne, et al. (1998). "Vascular permeability factor/vascular 
endothelial cell growth factor-mediated permeability occurs through 
disorganization of endothelial junctional proteins." J Biol Chem 
273(24): 15099-15103. 
Khanna, C. and K. Hunter (2005). "Modeling metastasis in vivo." 
Carcinogenesis 26(3): 513-523. 
Kimura, H., H. Miyashita, et al. (2009). "Distinctive localization and opposed 
roles of vasohibin-1 and vasohibin-2 in the regulation of 
angiogenesis." Blood 113(19): 4810-4818. 
Kitadai, Y. (2010). "Angiogenesis and lymphangiogenesis of gastric cancer." J 
Oncol 2010: 468725. 
Knight, D. A. and S. T. Holgate (2003). "The airway epithelium: structural and 
functional properties in health and disease." Respirology 8(4): 432-
446. 
Koch, A. E., M. M. Halloran, et al. (1995). "Angiogenesis mediated by soluble 
forms of E-selectin and vascular cell adhesion molecule-1." Nature 
376(6540): 517-519. 
Koh, T. J. and L. A. DiPietro (2011). "Inflammation and wound healing: the role 
of the macrophage." Expert Rev Mol Med 13: e23. 
Kosaka, T., Y. Miyazaki, et al. (2013). "The prognostic significance of vasohibin-
1 expression in patients with prostate cancer." Br J Cancer 108(10): 
2123-2129. 
Krause, W. J., J. Yamada, et al. (1985). "Quantitative distribution of 
enteroendocrine cells in the gastrointestinal tract of the adult 
opossum, Didelphis virginiana." J Anat 140 ( Pt 4): 591-605. 
Ku, D. D., J. K. Zaleski, et al. (1993). "Vascular endothelial growth factor 
induces EDRF-dependent relaxation in coronary arteries." Am J Physiol 
157 
 
265(2 Pt 2): H586-592. 
Kumar, S., N. Rao, et al. (2012). "Emerging Roles of ADAMTSs in Angiogenesis 
and Cancer." Cancers 4(4): 1252-1299. 
Kumar, S., N. Rao, et al. (2009). Endogenous Angiogenesis Inhibitors: Is The 
List Ever Ending? . Advances in medicine and biology. L. V. Berhardt, 
Nova publishers. 38: 1-48. 
Kyriakides, T. R., K. J. Leach, et al. (1999). "Mice that lack the angiogenesis 
inhibitor, thrombospondin 2, mount an altered foreign body reaction 
characterized by increased vascularity." Proc Natl Acad Sci U S A 96(8): 
4449-4454. 
Kyriakides, T. R., J. W. Tam, et al. (1999). "Accelerated wound healing in mice 
with a disruption of the thrombospondin 2 gene." J Invest Dermatol 
113(5): 782-787. 
Lambrecht, B. N. and H. Hammad (2012). "The airway epithelium in asthma." 
Nat Med 18(5): 684-692. 
Lampugnani, M. G. and E. Dejana (2007). "Adherens junctions in endothelial 
cells regulate vessel maintenance and angiogenesis." Thromb Res 120 
Suppl 2: S1-6. 
Lampugnani, M. G. and E. Dejana (2007). "The control of endothelial cell 
functions by adherens junctions." Novartis Found Symp 283: 4-13; 
discussion 13-17, 238-241. 
Lampugnani, M. G., F. Orsenigo, et al. (2006). "Vascular endothelial cadherin 
controls VEGFR-2 internalization and signaling from intracellular 
compartments." J Cell Biol 174(4): 593-604. 
Lampugnani, M. G., M. Resnati, et al. (1992). "A novel endothelial-specific 
membrane protein is a marker of cell-cell contacts." J Cell Biol 118(6): 
1511-1522. 
Lawler, J. and M. Detmar (2004). "Tumor progression: the effects of 
thrombospondin-1 and -2." Int J Biochem Cell Biol 36(6): 1038-1045. 
Lawler, J. W., F. C. Chao, et al. (1977). "Observation of a high molecular weight 
platelet protein released by thrombin." Thromb Haemost 37(2): 355-
357. 
Lawler, J. W., H. S. Slayter, et al. (1978). "Isolation and characterization of a 
high molecular weight glycoprotein from human blood platelets." J 
Biol Chem 253(23): 8609-8616. 
Lee, A. (2005). "The ER chaperone and signaling regulator GRP78/BiP as a 
monitor of endoplasmic reticulum stress." Methods (San Diego, Calif.) 
35(4): 373-381. 
Lee, A. (2007). "GRP78 induction in cancer: therapeutic and prognostic 
implications." Cancer Res 67(8): 3496-3499. 
Lee, C. G., B. Ma, et al. (2011). "Studies of vascular endothelial growth factor 
in asthma and chronic obstructive pulmonary disease." Proc Am 
Thorac Soc 8(6): 512-515. 
Lee, T. Y., S. Muschal, et al. (2009). "Angiostatin regulates the expression of 
antiangiogenic and proapoptotic pathways via targeted inhibition of 
mitochondrial proteins." Blood 114(9): 1987-1998. 
Lee, Y. H., U. S. Kayyali, et al. (2007). "Transforming growth factor-beta1 
158 
 
effects on endothelial monolayer permeability involve focal adhesion 
kinase/Src." Am J Respir Cell Mol Biol 37(4): 485-493. 
Leker, R. R., Z. E. Toth, et al. (2009). "Transforming growth factor alpha 
induces angiogenesis and neurogenesis following stroke." 
Neuroscience 163(1): 233-243. 
Leustek, T., H. Toledo, et al. (1991). "Calcium-dependent autophosphorylation 
of the glucose-regulated protein, Grp78." Arch Biochem Biophys 
289(2): 256-261. 
Li, A., S. Dubey, et al. (2003). "IL-8 directly enhanced endothelial cell survival, 
proliferation, and matrix metalloproteinases production and regulated 
angiogenesis." J Immunol 170(6): 3369-3376. 
Liao, F., Y. Li, et al. (2000). "Monoclonal antibody to vascular endothelial-
cadherin is a potent inhibitor of angiogenesis, tumor growth, and 
metastasis." Cancer Res 60(24): 6805-6810. 
Liebner, S., U. Cavallaro, et al. (2006). "The multiple languages of endothelial 
cell-to-cell communication." Arterioscler Thromb Vasc Biol 26(7): 
1431-1438. 
Liekens, S., E. De Clercq, et al. (2001). "Angiogenesis: regulators and clinical 
applications." Biochem Pharmacol 61(3): 253-270. 
Liu, W., S. A. Ahmad, et al. (2000). "Endothelial cell survival and apoptosis in 
the tumor vasculature." Apoptosis 5(4): 323-328. 
Liu, X. Y., S. B. Qiu, et al. (2005). "Effective gene-virotherapy for complete 
eradication of tumor mediated by the combination of hTRAIL 
(TNFSF10) and plasminogen k5." Mol Ther 11(4): 531-541. 
Lohela, M., M. Bry, et al. (2009). "VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis." Curr Opin Cell Biol 21(2): 
154-165. 
Louissaint, A., Jr., S. Rao, et al. (2002). "Coordinated interaction of 
neurogenesis and angiogenesis in the adult songbird brain." Neuron 
34(6): 945-960. 
Lu, H., M. Dhanabal, et al. (1999). "Kringle 5 causes cell cycle arrest and 
apoptosis of endothelial cells." Biochem Biophys Res Commun 258(3): 
668-673. 
Lu, X., J. Davies, et al. (2006). "The effect of the single substitution of arginine 
within the RGD tripeptide motif of a modified neurotoxin dendroaspin 
on its activity of platelet aggregation and cell adhesion." Cell Commun 
Adhes 13(3): 171-183. 
Lucas, R., L. Holmgren, et al. (1998). "Multiple forms of angiostatin induce 
apoptosis in endothelial cells." Blood 92(12): 4730-4741. 
Ma, C., Y. Rong, et al. (2008). "Extracellular matrix protein betaig-h3/TGFBI 
promotes metastasis of colon cancer by enhancing cell extravasation." 
Genes Dev 22(3): 308-321. 
Machein, M. R., A. Knedla, et al. (2004). "Angiopoietin-1 promotes tumor 
angiogenesis in a rat glioma model." Am J Pathol 165(5): 1557-1570. 
Maeda, H., J. Wu, et al. (2000). "Tumor vascular permeability and the EPR 




Maeshima, Y., P. C. Colorado, et al. (2000). "Two RGD-independent alpha 
vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor 
properties." J Biol Chem 275(31): 23745-23750. 
Maeshima, Y. and H. Makino (2010). "Angiogenesis and chronic kidney 
disease." Fibrogenesis Tissue Repair 3: 13. 
Majno, G., S. M. Shea, et al. (1969). "Endothelial contraction induced by 
histamine-type mediators: an electron microscopic study." J Cell Biol 
42(3): 647-672. 
Malik, A. B., J. J. Lynch, et al. (1989). "Endothelial barrier function." J Invest 
Dermatol 93(2 Suppl): 62S-67S. 
Marrelli, A., P. Cipriani, et al. (2011). "Angiogenesis in rheumatoid arthritis: a 
disease specific process or a common response to chronic 
inflammation?" Autoimmun Rev 10(10): 595-598. 
Martin, K. H., J. K. Slack, et al. (2002). "Integrin connections map: to infinity 
and beyond." Science 296(5573): 1652-1653. 
Martin, S. J., C. P. Reutelingsperger, et al. (1995). "Early redistribution of 
plasma membrane phosphatidylserine is a general feature of 
apoptosis regardless of the initiating stimulus: inhibition by 
overexpression of Bcl-2 and Abl." J Exp Med 182(5): 1545-1556. 
Martinez-Torrecuadrada, J. L., L. H. Cheung, et al. (2008). "Antitumor activity 
of fibroblast growth factor receptor 3-specific immunotoxins in a 
xenograft mouse model of bladder carcinoma is mediated by 
apoptosis." Mol Cancer Ther 7(4): 862-873. 
Masamune, A., K. Kikuta, et al. (2008). "Hypoxia stimulates pancreatic stellate 
cells to induce fibrosis and angiogenesis in pancreatic cancer." Am J 
Physiol Gastrointest Liver Physiol 295(4): G709-717. 
Masamune, A. and T. Shimosegawa (2009). "Signal transduction in pancreatic 
stellate cells." J Gastroenterol 44(4): 249-260. 
Massague, J. (2012). "TGFbeta signalling in context." Nat Rev Mol Cell Biol 
13(10): 616-630. 
McFarland, B. C., J. Stewart, Jr., et al. (2009). "Plasminogen kringle 5 induces 
apoptosis of brain microvessel endothelial cells: sensitization by 
radiation and requirement for GRP78 and LRP1." Cancer Res 69(13): 
5537-5545. 
McPherson, J., H. Sage, et al. (1981). "Isolation and characterization of a 
glycoprotein secreted by aortic endothelial cells in culture. Apparent 
identity with platelet thrombospondin." J Biol Chem 256(21): 11330-
11336. 
Mehta, D. and A. B. Malik (2006). "Signaling mechanisms regulating 
endothelial permeability." Physiol Rev 86(1): 279-367. 
Meyer, A. N., C. W. McAndrew, et al. (2008). "Nordihydroguaiaretic acid 
inhibits an activated fibroblast growth factor receptor 3 mutant and 
blocks downstream signaling in multiple myeloma cells." Cancer Res 
68(18): 7362-7370. 
Miles, A. A. and E. M. Miles (1952). "Vascular reactions to histamine, 
histamine-liberator and leukotaxine in the skin of guinea-pigs." J 
Physiol 118(2): 228-257. 
160 
 
Misra, U., R. Deedwania, et al. (2006). "Activation and cross-talk between Akt, 
NF-kappaB, and unfolded protein response signaling in 1-LN prostate 
cancer cells consequent to ligation of cell surface-associated GRP78." J 
Biol Chem 281(19): 13694-13707. 
Misra, U. K., T. Sharma, et al. (2005). "Ligation of cell surface-associated 
glucose-regulated protein 78 by receptor-recognized forms of alpha 2-
macroglobulin: activation of p21-activated protein kinase-2-
dependent signaling in murine peritoneal macrophages." J Immunol 
175(4): 2525-2533. 
Mizejewski, G. J. (1999). "Role of integrins in cancer: survey of expression 
patterns." Proc Soc Exp Biol Med 222(2): 124-138. 
Monsky, W. L., D. Fukumura, et al. (1999). "Augmentation of transvascular 
transport of macromolecules and nanoparticles in tumors using 
vascular endothelial growth factor." Cancer Res 59(16): 4129-4135. 
Morgan, J. A., G. D. Demetri, et al. (2005). "Patients with imatinib mesylate-
resistant GIST exhibit durable responses to sunitinib malate 
(SU11248)." Ejc Supplements 3(2): 421-421. 
Mori, K., A. Ando, et al. (2001). "Inhibition of choroidal neovascularization by 
intravenous injection of adenoviral vectors expressing secretable 
endostatin." Am J Pathol 159(1): 313-320. 
Moser, T. L., M. S. Stack, et al. (1999). "Angiostatin binds ATP synthase on the 
surface of human endothelial cells." Proc Natl Acad Sci U S A 96(6): 
2811-2816. 
Moses, M. A., D. Wiederschain, et al. (1999). "Troponin I is present in human 
cartilage and inhibits angiogenesis." Proc Natl Acad Sci U S A 96(6): 
2645-2650. 
Mosher, D. F., M. J. Doyle, et al. (1982). "Synthesis and secretion of 
thrombospondin by cultured human endothelial cells." J Cell Biol 
93(2): 343-348. 
Moy, A. B., M. Winter, et al. (2000). "Histamine alters endothelial barrier 
function at cell-cell and cell-matrix sites." Am J Physiol Lung Cell Mol 
Physiol 278(5): L888-898. 
Murata, T., K. Nakagawa, et al. (1996). "The relation between expression of 
vascular endothelial growth factor and breakdown of the blood-retinal 
barrier in diabetic rat retinas." Lab Invest 74(4): 819-825. 
Nagy, J. A., L. Benjamin, et al. (2008). "Vascular permeability, vascular 
hyperpermeability and angiogenesis." Angiogenesis 11(2): 109-119. 
Nagy, J. A., L. F. Brown, et al. (1989). "Pathogenesis of tumor stroma 
generation: a critical role for leaky blood vessels and fibrin 
deposition." Biochim Biophys Acta 948(3): 305-326. 
Nagy, J. A., S. H. Chang, et al. (2010). "Heterogeneity of the tumor 
vasculature." Semin Thromb Hemost 36(3): 321-331. 
Nagy, J. A., A. M. Dvorak, et al. (2012). "Vascular hyperpermeability, 
angiogenesis, and stroma generation." Cold Spring Harb Perspect Med 
2(2): a006544. 
Nakayama, T., L. Yao, et al. (2004). "Mast cell-derived angiopoietin-1 plays a 




Nawroth, R., G. Poell, et al. (2002). "VE-PTP and VE-cadherin ectodomains 
interact to facilitate regulation of phosphorylation and cell contacts." 
EMBO J 21(18): 4885-4895. 
Nemoto, T. and S. Kubota (2011). "Vascular endothelial cadherin is an 
endostatin receptor." Biologia 66(4): 721-726. 
Nermut, M. V., N. M. Green, et al. (1988). "Electron microscopy and structural 
model of human fibronectin receptor." The EMBO journal 7(13): 4093-
4099. 
Nguyen, D. X., P. D. Bos, et al. (2009). "Metastasis: from dissemination to 
organ-specific colonization." Nat Rev Cancer 9(4): 274-284. 
Nguyen, T. M., I. V. Subramanian, et al. (2007). "Kringle 5 of human 
plasminogen, an angiogenesis inhibitor, induces both autophagy and 
apoptotic death in endothelial cells." Blood 109(11): 4793-4802. 
Ni, M., Y. Zhang, et al. (2011). "Beyond the endoplasmic reticulum: atypical 
GRP78 in cell viability, signalling and therapeutic targeting." Biochem J 
434(2): 181-188. 
Nissen, N. N., P. J. Polverini, et al. (1998). "Vascular endothelial growth factor 
mediates angiogenic activity during the proliferative phase of wound 
healing." Am J Pathol 152(6): 1445-1452. 
Noh, Y. H., K. Matsuda, et al. (2003). "An N-terminal 80 kDa recombinant 
fragment of human thrombospondin-2 inhibits vascular endothelial 
growth factor induced endothelial cell migration in vitro and tumor 
growth and angiogenesis in vivo." J Invest Dermatol 121(6): 1536-
1543. 
Nyberg, P., L. Xie, et al. (2005). "Endogenous inhibitors of angiogenesis." 
Cancer Res 65(10): 3967-3979. 
Nykvist, P., K. Tasanen, et al. (2001). "The cell adhesion domain of type XVII 
collagen promotes integrin-mediated cell spreading by a novel 
mechanism." J Biol Chem 276(42): 38673-38679. 
O'Reilly, M. S., T. Boehm, et al. (1997). "Endostatin: an endogenous inhibitor 
of angiogenesis and tumor growth." Cell 88(2): 277-285. 
O'Reilly, M. S., L. Holmgren, et al. (1994). "Angiostatin: a circulating 
endothelial cell inhibitor that suppresses angiogenesis and tumor 
growth." Cold Spring Harb Symp Quant Biol 59: 471-482. 
O'Reilly, M. S., L. Holmgren, et al. (1994). "Angiostatin: a novel angiogenesis 
inhibitor that mediates the suppression of metastases by a Lewis lung 
carcinoma." Cell 79(2): 315-328. 
Ohtani, T., M. Mizuashi, et al. (2007). "Cadexomer as well as cadexomer 
iodine induces the production of proinflammatory cytokines and 
vascular endothelial growth factor by human macrophages." Exp 
Dermatol 16(4): 318-323. 
Oku, N., R. Araki, et al. (1987). "Tumor necrosis factor-induced permeability 
increase of negatively charged phospholipid vesicles." J Biochem 
102(5): 1303-1310. 
Ortega, N., H. Hutchings, et al. (1999). "Signal relays in the VEGF system." 
Front Biosci 4: D141-152. 
162 
 
Ortega, S., M. Ittmann, et al. (1998). "Neuronal defects and delayed wound 
healing in mice lacking fibroblast growth factor 2." Proc Natl Acad Sci 
U S A 95(10): 5672-5677. 
Paez-Ribes, M., E. Allen, et al. (2009). "Antiangiogenic therapy elicits 
malignant progression of tumors to increased local invasion and 
distant metastasis." Cancer Cell 15(3): 220-231. 
Palmer, T. D., A. R. Willhoite, et al. (2000). "Vascular niche for adult 
hippocampal neurogenesis." J Comp Neurol 425(4): 479-494. 
Pastar, I., O. Stojadinovic, et al. (2008). "Role of keratinocytes in healing of 
chronic wounds." Surg Technol Int 17: 105-112. 
Pera, E. M., J. I. Kim, et al. (2002). "Isthmin is a novel secreted protein 
expressed as part of the Fgf-8 synexpression group in the Xenopus 
midbrain-hindbrain organizer." Mech Dev 116(1-2): 169-172. 
Perez-Pinera, P., J. R. Berenson, et al. (2008). "Pleiotrophin, a multifunctional 
angiogenic factor: mechanisms and pathways in normal and 
pathological angiogenesis." Curr Opin Hematol 15(3): 210-214. 
Perri, S. R., J. Nalbantoglu, et al. (2005). "Plasminogen kringle 5-engineered 
glioma cells block migration of tumor-associated macrophages and 
suppress tumor vascularization and progression." Cancer Res 65(18): 
8359-8365. 
Philippova, M., D. Ivanov, et al. (2008). "Identification of proteins associating 
with glycosylphosphatidylinositol- anchored T-cadherin on the surface 
of vascular endothelial cells: role for Grp78/BiP in T-cadherin-
dependent cell survival." Molecular and cellular biology 28(12): 4004-
4017. 
Pike, S. E., L. Yao, et al. (1998). "Vasostatin, a calreticulin fragment, inhibits 
angiogenesis and suppresses tumor growth." J Exp Med 188(12): 
2349-2356. 
Pittet, J. F., M. J. Griffiths, et al. (2001). "TGF-beta is a critical mediator of 
acute lung injury." J Clin Invest 107(12): 1537-1544. 
Potter, M. D., S. Barbero, et al. (2005). "Tyrosine phosphorylation of VE-
cadherin prevents binding of p120- and beta-catenin and maintains 
the cellular mesenchymal state." J Biol Chem 280(36): 31906-31912. 
Presta, L. G., H. Chen, et al. (1997). "Humanization of an anti-vascular 
endothelial growth factor monoclonal antibody for the therapy of 
solid tumors and other disorders." Cancer Res 57(20): 4593-4599. 
Pribluda, V. S., E. R. Gubish, Jr., et al. (2000). "2-Methoxyestradiol: an 
endogenous antiangiogenic and antiproliferative drug candidate." 
Cancer Metastasis Rev 19(1-2): 173-179. 
Provenzale, J. M., S. Mukundan, et al. (2005). "The role of blood-brain barrier 
permeability in brain tumor imaging and therapeutics." AJR Am J 
Roentgenol 185(3): 763-767. 
Providence, K. M. and P. J. Higgins (2004). "PAI-1 expression is required for 
epithelial cell migration in two distinct phases of in vitro wound 
repair." J Cell Physiol 200(2): 297-308. 
Pugh, C. W. and P. J. Ratcliffe (2003). "Regulation of angiogenesis by hypoxia: 
role of the HIF system." Nat Med 9(6): 677-684. 
163 
 
Qi, J. H., Q. Ebrahem, et al. (2003). "A novel function for tissue inhibitor of 
metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage 
of VEGF binding to VEGF receptor-2." Nat Med 9(4): 407-415. 
Quesada Calvo, F., M. Fillet, et al. (2011). "Potential therapeutic target 
discovery by 2D-DIGE proteomic analysis in mouse models of asthma." 
J Proteome Res 10(9): 4291-4301. 
Rastinejad, F., P. J. Polverini, et al. (1989). "Regulation of the activity of a new 
inhibitor of angiogenesis by a cancer suppressor gene." Cell 56(3): 
345-355. 
Raugi, G. J., S. M. Mumby, et al. (1982). "Thrombospondin: synthesis and 
secretion by cells in culture." J Cell Biol 95(1): 351-354. 
Rehn, M., T. Veikkola, et al. (2001). "Interaction of endostatin with integrins 
implicated in angiogenesis." Proc Natl Acad Sci U S A 98(3): 1024-
1029. 
Reynolds, L. E., L. Wyder, et al. (2002). "Enhanced pathological angiogenesis in 
mice lacking beta3 integrin or beta3 and beta5 integrins." Nat Med 
8(1): 27-34. 
Ribatti, D. (2008). "The discovery of the placental growth factor and its role in 
angiogenesis: a historical review." Angiogenesis 11(3): 215-221. 
Ribatti, D. (2009). "Endogenous inhibitors of angiogenesis: a historical 
review." Leukemia research 33(5): 638-644. 
Ribatti, D., D. Leali, et al. (1999). "In vivo angiogenic activity of urokinase: role 
of endogenous fibroblast growth factor-2." J Cell Sci 112 ( Pt 23): 
4213-4221. 
Riewald, M., R. J. Petrovan, et al. (2002). "Activation of endothelial cell 
protease activated receptor 1 by the protein C pathway." Science 
296(5574): 1880-1882. 
Riewald, M. and W. Ruf (2001). "Mechanistic coupling of protease signaling 
and initiation of coagulation by tissue factor." Proc Natl Acad Sci U S A 
98(14): 7742-7747. 
Riley, J. F. (1966). "Mast cells and cancer in the skin of mice." Lancet 2(7479): 
1457-1459. 
Risau, W. (1997). "Mechanisms of angiogenesis." Nature 386(6626): 671-674. 
Rotrosen, D. and J. I. Gallin (1986). "Histamine type I receptor occupancy 
increases endothelial cytosolic calcium, reduces F-actin, and promotes 
albumin diffusion across cultured endothelial monolayers." J Cell Biol 
103(6 Pt 1): 2379-2387. 
Rudroff, C., S. Seibold, et al. (2002). "Expression of the thrombin receptor 
PAR-1 correlates with tumour cell differentiation of pancreatic 
adenocarcinoma in vitro." Clin Exp Metastasis 19(2): 181-189. 
S. T. Holgate, P. M. L., D. E. Davies, W. R. Roche And A. F. Walls (1999). "The 
bronchial epithelium as a key regulator of airway inflammation and 
remodelling in asthma." Clinical and Experimental Allergy 29: 90-95. 
Sage, H., P. Pritzl, et al. (1981). "Secretory phenotypes of endothelial cells in 
culture: comparison of aortic, venous, capillary, and corneal 
endothelium." Arteriosclerosis 1(6): 427-442. 
Sainson, R. C., D. A. Johnston, et al. (2008). "TNF primes endothelial cells for 
164 
 
angiogenic sprouting by inducing a tip cell phenotype." Blood 111(10): 
4997-5007. 
Samson, M., F. V. Peale, Jr., et al. (2004). "Human endocrine gland-derived 
vascular endothelial growth factor: expression early in development 
and in Leydig cell tumors suggests roles in normal and pathological 
testis angiogenesis." J Clin Endocrinol Metab 89(8): 4078-4088. 
Sandler, A., R. Gray, et al. (2006). "Paclitaxel-carboplatin alone or with 
bevacizumab for non-small-cell lung cancer." N Engl J Med 355(24): 
2542-2550. 
Savani, R. C., G. Cao, et al. (2001). "Differential involvement of the hyaluronan 
(HA) receptors CD44 and receptor for HA-mediated motility in 
endothelial cell function and angiogenesis." J Biol Chem 276(39): 
36770-36778. 
Schafer, B. M., K. Maier, et al. (1994). "Plasminogen activation in healing 
human wounds." Am J Pathol 144(6): 1269-1280. 
Schrijvers, B. F., A. Flyvbjerg, et al. (2004). "The role of vascular endothelial 
growth factor (VEGF) in renal pathophysiology." Kidney Int 65(6): 
2003-2017. 
Sellke, F. W., R. J. Laham, et al. (1998). "Therapeutic angiogenesis with basic 
fibroblast growth factor: technique and early results." Ann Thorac 
Surg 65(6): 1540-1544. 
Senger, D. R., S. J. Galli, et al. (1983). "Tumor cells secrete a vascular 
permeability factor that promotes accumulation of ascites fluid." 
Science 219(4587): 983-985. 
Seo, D. W., H. Li, et al. (2003). "TIMP-2 mediated inhibition of angiogenesis: 
an MMP-independent mechanism." Cell 114(2): 171-180. 
Seppinen, L., R. Sormunen, et al. (2008). "Lack of collagen XVIII accelerates 
cutaneous wound healing, while overexpression of its endostatin 
domain leads to delayed healing." Matrix Biol 27(6): 535-546. 
Shaked, Y., D. Cervi, et al. (2005). "The splenic microenvironment is a source 
of proangiogenesis/inflammatory mediators accelerating the 
expansion of murine erythroleukemic cells." Blood 105(11): 4500-
4507. 
Shalaby, F., J. Rossant, et al. (1995). "Failure of blood-island formation and 
vasculogenesis in Flk-1-deficient mice." Nature 376(6535): 62-66. 
Shani, G., W. Fischer, et al. (2008). "GRP78 and Cripto form a complex at the 
cell surface and collaborate to inhibit transforming growth factor beta 
signaling and enhance cell growth." Molecular and cellular biology 
28(2): 666-677. 
Shani, G., W. H. Fischer, et al. (2008). "GRP78 and Cripto form a complex at 
the cell surface and collaborate to inhibit transforming growth factor 
beta signaling and enhance cell growth." Mol Cell Biol 28(2): 666-677. 
Shasby, D. M., D. R. Ries, et al. (2002). "Histamine stimulates phosphorylation 
of adherens junction proteins and alters their link to vimentin." Am J 
Physiol Lung Cell Mol Physiol 282(6): L1330-1338. 
Shen, T. L., A. Y. Park, et al. (2005). "Conditional knockout of focal adhesion 
kinase in endothelial cells reveals its role in angiogenesis and vascular 
165 
 
development in late embryogenesis." J Cell Biol 169(6): 941-952. 
Shen, W., S. Li, et al. (2011). "Tyrosine phosphorylation of VE-cadherin and 
claudin-5 is associated with TGF-beta1-induced permeability of 
centrally derived vascular endothelium." Eur J Cell Biol 90(4): 323-332. 
Shi, H. B., Y. J. Huang, et al. (2007). "Nucleolin is a receptor that mediates 
antiangiogenic and antitumor activity of endostatin." Blood 110(8): 
2899-2906. 
Shibuya, M. (2008). "Vascular endothelial growth factor-dependent and -
independent regulation of angiogenesis." BMB Rep 41(4): 278-286. 
Shim, W. S., I. A. Ho, et al. (2007). "Angiopoietin: a TIE(d) balance in tumor 
angiogenesis." Mol Cancer Res 5(7): 655-665. 
Shimaoka, M. and T. A. Springer (2003). "Therapeutic antagonists and 
conformational regulation of integrin function." Nat Rev Drug Discov 
2(9): 703-716. 
Shing, Y., J. Folkman, et al. (1984). "Heparin affinity: purification of a tumor-
derived capillary endothelial cell growth factor." Science 223(4642): 
1296-1299. 
Sidky, Y. A. and E. C. Borden (1987). "Inhibition of angiogenesis by interferons: 
effects on tumor- and lymphocyte-induced vascular responses." 
Cancer Res 47(19): 5155-5161. 
Silva, R., G. D'Amico, et al. (2008). "Integrins: the keys to unlocking 
angiogenesis." Arterioscler Thromb Vasc Biol 28(10): 1703-1713. 
Silvestre, J. S., Z. Mallat, et al. (2000). "Antiangiogenic effect of interleukin-10 
in ischemia-induced angiogenesis in mice hindlimb." Circulation 
Research 87(6): 448-452. 
Sima, J., S. X. Zhang, et al. (2004). "The effect of angiostatin on vascular 
leakage and VEGF expression in rat retina." FEBS Lett 564(1-2): 19-23. 
Slevin, M., P. Kumar, et al. (2006). "Can angiogenesis be exploited to improve 
stroke outcome? Mechanisms and therapeutic potential." Clin Sci 
(Lond) 111(3): 171-183. 
Smith, J. K., N. M. Mamoon, et al. (2004). "Emerging roles of targeted small 
molecule protein-tyrosine kinase inhibitors in cancer therapy." Oncol 
Res 14(4-5): 175-225. 
Smyth, S. S. and C. Patterson (2002). "Tiny dancers: the integrin-growth factor 
nexus in angiogenic signaling." J Cell Biol 158(1): 17-21. 
Solligard, E., I. S. Juel, et al. (2008). "Gut luminal lactate measured by 
microdialysis mirrors permeability of the intestinal mucosa after 
ischemia." Shock 29(2): 245-251. 
Sorensen, V., T. Nilsen, et al. (2006). "Functional diversity of FGF-2 isoforms by 
intracellular sorting." BioEssays : news and reviews in molecular, 
cellular and developmental biology 28(5): 504-514. 
Sousa, A. R., S. J. Lane, et al. (1994). "Increased expression of the monocyte 
chemoattractant protein-1 in bronchial tissue from asthmatic 
subjects." Am J Respir Cell Mol Biol 10(2): 142-147. 
Sprague, A. H. and R. A. Khalil (2009). "Inflammatory cytokines in vascular 




Spranger, J., H. P. Hammes, et al. (2000). "Release of the angiogenesis 
inhibitor angiostatin in patients with proliferative diabetic retinopathy: 
association with retinal photocoagulation." Diabetologia 43(11): 1404-
1407. 
Steele, F. R., G. J. Chader, et al. (1993). "Pigment epithelium-derived factor: 
neurotrophic activity and identification as a member of the serine 
protease inhibitor gene family." Proc Natl Acad Sci U S A 90(4): 1526-
1530. 
Stellmach, V., S. E. Crawford, et al. (2001). "Prevention of ischemia-induced 
retinopathy by the natural ocular antiangiogenic agent pigment 
epithelium-derived factor." Proc Natl Acad Sci U S A 98(5): 2593-2597. 
Stieger, S. M., C. F. Caskey, et al. (2007). "Enhancement of vascular 
permeability with low-frequency contrast-enhanced ultrasound in the 
chorioallantoic membrane model." Radiology 243(1): 112-121. 
Stitt, A. W., D. Graham, et al. (2004). "Ocular wounding prevents pre-retinal 
neovascularization and upregulates PEDF expression in the inner 
retina." Mol Vis 10: 432-438. 
Stockton, R. A., E. Schaefer, et al. (2004). "p21-activated kinase regulates 
endothelial permeability through modulation of contractility." J Biol 
Chem 279(45): 46621-46630. 
Stoeltzing, O., S. A. Ahmad, et al. (2003). "Angiopoietin-1 inhibits vascular 
permeability, angiogenesis, and growth of hepatic colon cancer 
tumors." Cancer Res 63(12): 3370-3377. 
Storck, J. and E. R. Zimmermann (1996). "Regulation of the thrombin receptor 
response in human endothelial cells." Thromb Res 81(1): 121-131. 
Strande, J. L., M. E. Widlansky, et al. (2009). "Parstatin: a cryptic peptide 
involved in cardioprotection after ischaemia and reperfusion injury." 
Cardiovasc Res 83(2): 325-334. 
Streit, M., P. Velasco, et al. (2000). "Thrombospondin-1 suppresses wound 
healing and granulation tissue formation in the skin of transgenic 
mice." EMBO J 19(13): 3272-3282. 
Stupack, D. G., X. S. Puente, et al. (2001). "Apoptosis of adherent cells by 
recruitment of caspase-8 to unligated integrins." J Cell Biol 155(3): 
459-470. 
Su, G., M. Hodnett, et al. (2007). "Integrin alphavbeta5 regulates lung vascular 
permeability and pulmonary endothelial barrier function." Am J Respir 
Cell Mol Biol 36(3): 377-386. 
Suarez, Y. and W. C. Sessa (2009). "MicroRNAs As Novel Regulators of 
Angiogenesis." Circulation Research 104(4): 442-454. 
Sund, M., Y. Hamano, et al. (2005). "Function of endogenous inhibitors of 
angiogenesis as endothelium-specific tumor suppressors." Proc Natl 
Acad Sci U S A 102(8): 2934-2939. 
Suri, C., P. F. Jones, et al. (1996). "Requisite role of angiopoietin-1, a ligand for 
the TIE2 receptor, during embryonic angiogenesis." Cell 87(7): 1171-
1180. 
Suto, K., Y. Yamazaki, et al. (2005). "Crystal structures of novel vascular 
endothelial growth factors (VEGF) from snake venoms: insight into 
167 
 
selective VEGF binding to kinase insert domain-containing receptor 
but not to fms-like tyrosine kinase-1." J Biol Chem 280(3): 2126-2131. 
Swirski, F. K., M. Nahrendorf, et al. (2009). "Identification of splenic reservoir 
monocytes and their deployment to inflammatory sites." Science 
325(5940): 612-616. 
Takada, Y., X. Ye, et al. (2007). "The integrins." Genome Biol 8(5): 215. 
Takahashi, T., S. Yamaguchi, et al. (2001). "A single autophosphorylation site 
on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-
gamma and DNA synthesis in vascular endothelial cells." EMBO J 
20(11): 2768-2778. 
Tarui, T., L. A. Miles, et al. (2001). "Specific interaction of angiostatin with 
integrin alpha(v)beta(3) in endothelial cells." J Biol Chem 276(43): 
39562-39568. 
Tatler, A. L., A. E. John, et al. (2011). "Integrin alphavbeta5-mediated TGF-beta 
activation by airway smooth muscle cells in asthma." J Immunol 
187(11): 6094-6107. 
Taylor, R. N., J. Yu, et al. (2009). "Mechanistic and therapeutic implications of 
angiogenesis in endometriosis." Reprod Sci 16(2): 140-146. 
Tellez, C. and M. Bar-Eli (2003). "Role and regulation of the thrombin receptor 
(PAR-1) in human melanoma." Oncogene 22(20): 3130-3137. 
Temann, U. A., Y. Laouar, et al. (2007). "IL9 leads to airway inflammation by 
inducing IL13 expression in airway epithelial cells." Int Immunol 19(1): 
1-10. 
ten Dijke, P. and H. M. Arthur (2007). "Extracellular control of TGFbeta 
signalling in vascular development and disease." Nat Rev Mol Cell Biol 
8(11): 857-869. 
Thakar, C. V., K. Zahedi, et al. (2005). "Identification of thrombospondin 1 
(TSP-1) as a novel mediator of cell injury in kidney ischemia." J Clin 
Invest 115(12): 3451-3459. 
Thomas, M. and H. G. Augustin (2009). "The role of the Angiopoietins in 
vascular morphogenesis." Angiogenesis 12(2): 125-137. 
Thurston, G., J. S. Rudge, et al. (2000). "Angiopoietin-1 protects the adult 
vasculature against plasma leakage." Nat Med 6(4): 460-463. 
Thurston, G., C. Suri, et al. (1999). "Leakage-resistant blood vessels in mice 
transgenically overexpressing angiopoietin-1." Science 286(5449): 
2511-2514. 
Tolsma, S. S., O. V. Volpert, et al. (1993). "Peptides derived from two separate 
domains of the matrix protein thrombospondin-1 have anti-
angiogenic activity." J Cell Biol 122(2): 497-511. 
Tombran-Tink, J. and C. J. Barnstable (2003). "Therapeutic prospects for PEDF: 
more than a promising angiogenesis inhibitor." Trends Mol Med 9(6): 
244-250. 
Tombran-Tink, J., K. Mazuruk, et al. (1996). "Organization, evolutionary 
conservation, expression and unusual Alu density of the human gene 
for pigment epithelium-derived factor, a unique neurotrophic serpin." 
Mol Vis 2: 11. 
Tonnesen, M. G., X. Feng, et al. (2000). "Angiogenesis in wound healing." J 
168 
 
Investig Dermatol Symp Proc 5(1): 40-46. 
Toomey, D. P., J. F. Murphy, et al. (2009). "COX-2, VEGF and tumour 
angiogenesis." Surgeon 7(3): 174-180. 
Troyanovsky, B., T. Levchenko, et al. (2001). "Angiomotin: an angiostatin 
binding protein that regulates endothelial cell migration and tube 
formation." J Cell Biol 152(6): 1247-1254. 
Trudel, S., A. K. Stewart, et al. (2006). "The inhibitory anti-FGFR3 antibody, 
PRO-001, is cytotoxic to t(4;14) multiple myeloma cells." Blood 
107(10): 4039-4046. 
Tsopanoglou, N. E. and M. E. Maragoudakis (2007). "Inhibition of 
angiogenesis by small-molecule antagonists of protease-activated 
receptor-1." Semin Thromb Hemost 33(7): 680-687. 
Ukropec, J. A., M. K. Hollinger, et al. (2000). "SHP2 association with VE-
cadherin complexes in human endothelial cells is regulated by 
thrombin." J Biol Chem 275(8): 5983-5986. 
Vaalamo, M., M. Weckroth, et al. (1996). "Patterns of matrix 
metalloproteinase and TIMP-1 expression in chronic and normally 
healing human cutaneous wounds." Br J Dermatol 135(1): 52-59. 
van Cruijsen, H., G. Giaccone, et al. (2005). "Epidermal growth factor receptor 
and angiogenesis: Opportunities for combined anticancer strategies." 
Int J Cancer 117(6): 883-888. 
van Hinsbergh, V. W. and P. Koolwijk (2008). "Endothelial sprouting and 
angiogenesis: matrix metalloproteinases in the lead." Cardiovasc Res 
78(2): 203-212. 
van Nieuw Amerongen, G. P., R. Draijer, et al. (1998). "Transient and 
prolonged increase in endothelial permeability induced by histamine 
and thrombin: role of protein kinases, calcium, and RhoA." Circulation 
Research 83(11): 1115-1123. 
Vincent H.J. van der Velden, A. F. W.-W., Shelley E. Overbeek, Brigitta A.E. 
Naber, Reno Debets, Henk C. Hoogsteden, Huub F.J. Savelkoul, Marjan 
A. Versnel (1998). "Interleukin 4 Receptors On Human Bronchial 
Epithelial Cells. An In Vivo And In Vitro Analysis Of Expression And 
Function." Cytokine 10(10): 803–813. 
Vincent, P. A., K. Xiao, et al. (2004). "VE-cadherin: adhesion at arm's length." 
Am J Physiol Cell Physiol 286(5): C987-997. 
Vlodavsky, I., R. Bar-Shavit, et al. (1991). "Extracellular sequestration and 
release of fibroblast growth factor: a regulatory mechanism?" Trends 
Biochem Sci 16(7): 268-271. 
Volpert, O. V., T. Zaichuk, et al. (2002). "Inducer-stimulated Fas targets 
activated endothelium for destruction by anti-angiogenic 
thrombospondin-1 and pigment epithelium-derived factor." Nat Med 
8(4): 349-357. 
Vu, T. K., D. T. Hung, et al. (1991). "Molecular cloning of a functional thrombin 
receptor reveals a novel proteolytic mechanism of receptor 
activation." Cell 64(6): 1057-1068. 
Wallez, Y., F. Cand, et al. (2007). "Src kinase phosphorylates vascular 
endothelial-cadherin in response to vascular endothelial growth 
169 
 
factor: identification of tyrosine 685 as the unique target site." 
Oncogene 26(7): 1067-1077. 
Walshe, T. E., M. Saint-Geniez, et al. (2009). "TGF-beta is required for vascular 
barrier function, endothelial survival and homeostasis of the adult 
microvasculature." PLoS One 4(4): e5149. 
Waltenberger, J., L. Claesson-Welsh, et al. (1994). "Different signal 
transduction properties of KDR and Flt1, two receptors for vascular 
endothelial growth factor." J Biol Chem 269(43): 26988-26995. 
Wang, Q., Z. He, et al. (2005). "Overexpression of endoplasmic reticulum 
molecular chaperone GRP94 and GRP78 in human lung cancer tissues 
and its significance." Cancer Detect Prev 29(6): 544-551. 
Wang, S., Z. Wu, et al. (2003). "Thrombospondin-1-deficient mice exhibit 
increased vascular density during retinal vascular development and 
are less sensitive to hyperoxia-mediated vessel obliteration." Dev Dyn 
228(4): 630-642. 
Watanabe, K., Y. Hasegawa, et al. (2004). "Vasohibin as an endothelium-
derived negative feedback regulator of angiogenesis." J Clin Invest 
114(7): 898-907. 
Weber, C., L. Fraemohs, et al. (2007). "The role of junctional adhesion 
molecules in vascular inflammation." Nat Rev Immunol 7(6): 467-477. 
Weis, S., S. Shintani, et al. (2004). "Src blockade stabilizes a Flk/cadherin 
complex, reducing edema and tissue injury following myocardial 
infarction." J Clin Invest 113(6): 885-894. 
Weis, S. M. and D. A. Cheresh (2005). "Pathophysiological consequences of 
VEGF-induced vascular permeability." Nature 437(7058): 497-504. 
Weis, S. M. and D. A. Cheresh (2011). "alphaV integrins in angiogenesis and 
cancer." Cold Spring Harb Perspect Med 1(1): a006478. 
Welberg, L. (2011). "Adult neurogenesis: uncoupling the roles of VEGF." Nat 
Rev Neurosci 12(5): 247. 
Welch, D. R. (1997). "Technical considerations for studying cancer metastasis 
in vivo." Clin Exp Metastasis 15(3): 272-306. 
Wilhelm, D. L. (1973). "Mechanisms responsible for increased vascular 
permeability in acute inflammation." Agents Actions 3(5): 297-306. 
Wojciak-Stothard, B., S. Potempa, et al. (2001). "Rho and Rac but not Cdc42 
regulate endothelial cell permeability." J Cell Sci 114(Pt 7): 1343-1355. 
Wu, M. Y. and C. S. Hill (2009). "Tgf-beta superfamily signaling in embryonic 
development and homeostasis." Dev Cell 16(3): 329-343. 
Wu, N. Z. and A. L. Baldwin (1992). "Transient venular permeability increase 
and endothelial gap formation induced by histamine." Am J Physiol 
262(4 Pt 2): H1238-1247. 
Wyckoff, J. B., J. G. Jones, et al. (2000). "A critical step in metastasis: in vivo 
analysis of intravasation at the primary tumor." Cancer Res 60(9): 
2504-2511. 
Xiang, W., Z. Ke, et al. (2009). "Isthmin is a novel secreted angiogenesis 
inhibitor that inhibits tumor growth in mice." J Cell Mol Med. 
Xiang, W., Z. Ke, et al. (2011). "Isthmin is a novel secreted angiogenesis 




Xiang, W., Z. Ke, et al. (2011). "Isthmin is a novel secreted angiogenesis 
inhibitor that inhibits tumour growth in mice." J Cell Mol Med 15(2): 
359-374. 
Xiao, K., J. Garner, et al. (2005). "p120-Catenin regulates clathrin-dependent 
endocytosis of VE-cadherin." Mol Biol Cell 16(11): 5141-5151. 
Xu, M., C. L. Waters, et al. (2007). "Sphingosine 1-phosphate rapidly increases 
endothelial barrier function independently of VE-cadherin but 
requires cell spreading and Rho kinase." Am J Physiol Cell Physiol 
293(4): C1309-1318. 
Xu, X., M. Weinstein, et al. (1998). "Fibroblast growth factor receptor 2 
(FGFR2)-mediated reciprocal regulation loop between FGF8 and 
FGF10 is essential for limb induction." Development 125(4): 753-765. 
Yamaguchi, N., B. Anand-Apte, et al. (1999). "Endostatin inhibits VEGF-
induced endothelial cell migration and tumor growth independently 
of zinc binding." EMBO J 18(16): 4414-4423. 
Yamaguchi, T. P., K. Harpal, et al. (1994). "fgfr-1 is required for embryonic 
growth and mesodermal patterning during mouse gastrulation." 
Genes Dev 8(24): 3032-3044. 
Yang, X. H., X. Y. Man, et al. (2006). "Expression of VEGFR-2 on HaCaT cells is 
regulated by VEGF and plays an active role in mediating VEGF induced 
effects." Biochem Biophys Res Commun 349(1): 31-38. 
Yong Zhang, M. C., Shruthi Venugopal, Yalu Zhou, Wei Xiang, Yu-Hong Li, 
Qingsong Lin, R.Manjunatha Kini, Yap-Seng Chong and Ruowen Ge 
(2011). "Isthmin exerts Pro-Survival And Death-Promoting Effect On 
Endothelial Cells Through Alphavbeta5 Integrin Depending On Its 
Physical State." Cell Death And Disease(In press). 
Young, B. A., X. Sui, et al. (2003). "Protein tyrosine phosphatase activity 
regulates endothelial cell-cell interactions, the paracellular pathway, 
and capillary tube stability." Am J Physiol Lung Cell Mol Physiol 285(1): 
L63-75. 
Yuan, B., R. Xian, et al. (2012). "Isthmin inhibits glioma growth through 
antiangiogenesis in vivo." J Neurooncol 109(2): 245-252. 
Zania, P., D. Gourni, et al. (2009). "Parstatin, the cleaved peptide on 
proteinase-activated receptor 1 activation, is a potent inhibitor of 
angiogenesis." J Pharmacol Exp Ther 328(2): 378-389. 
Zetter, B. R. (1981). "The endothelial cells of large and small blood vessels." 
Diabetes 30(Suppl 2): 24-28. 
Zhai, Y., J. Ni, et al. (1999). "VEGI, a novel cytokine of the tumor necrosis 
factor family, is an angiogenesis inhibitor that suppresses the growth 
of colon carcinomas in vivo." FASEB J 13(1): 181-189. 
Zhang, M., O. Volpert, et al. (2000). "Maspin is an angiogenesis inhibitor." Nat 
Med 6(2): 196-199. 
Zhang, Y., M. Chen, et al. (2011). "Isthmin exerts pro-survival and death-
promoting effect on endothelial cells through alphavbeta5 integrin 
depending on its physical state." Cell Death Dis 2: e153. 
 
